

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2018289581 C1

(54) Title
ROR1 antibody immunoconjugates

(51) International Patent Classification(s)
A61K 47/68 (2017.01) **A61P 35/00** (2006.01)

(21) Application No: **2018289581** (22) Date of Filing: **2018.06.22**

(87) WIPO No: **WO18/237335**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/524,386	2017.06.23	US
62/524,388	2017.06.23	US
62/524,382	2017.06.23	US

(43) Publication Date: **2018.12.27**

(44) Accepted Journal Date: **2024.09.19**

(44) Amended Journal Date: **2025.01.30**

(71) Applicant(s)
Velosbio Inc.

(72) Inventor(s)
Lannutti, Brian;Jessen, Katti;Vo, Thanh-Trang;Watkins, Jeffry Dean

(74) Agent / Attorney
Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU

(56) Related Art
WO 2016/115559 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2018/237335 A1

(43) International Publication Date
27 December 2018 (27.12.2018)

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2018/039112

(22) International Filing Date:

22 June 2018 (22.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/524,382	23 June 2017 (23.06.2017)	US
62/524,386	23 June 2017 (23.06.2017)	US
62/524,388	23 June 2017 (23.06.2017)	US

(71) Applicant: VELOS BIO INC. [US/US]; 3210 Merryfield Row, San Diego, California 92121 (US).

(72) Inventors: LANNUTTI, Brian; c/o VelosBio Inc., 3210 Merryfield Row, San Diego, California 92121 (US). JESSEN, Katti; c/o VelosBio Inc., 3210 Merryfield Row, San Diego, California 92121 (US). VO, Thanh-Trang; c/o VelosBio Inc., 3210 Merryfield Row, San Diego, California 92121 (US). WATKINS, Jeffry Dean; c/o VelosBio Inc., 3210 Merryfield Row, San Diego, California 92121 (US).

(74) Agent: LI, Z. Ying et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, NW, Washington, District of Columbia 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2018/237335 A1

(54) Title: ROR1 ANTIBODY IMMUNOCONJUGATES

(57) Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

ROR1 ANTIBODY IMMUNOCONJUGATES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from U.S. Patent Applications 62/524,382, 62/524,386, and 62/524,388, all of which were filed on June 23, 2017. The disclosures of these priority applications are incorporated by reference herein in their entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on June 21, 2018, is named 024651_WO002_SL.txt and is 58,100 bytes in size.

BACKGROUND OF THE INVENTION

[0003] Cancer is the second leading cause of human death next to coronary artery disease. Receptor tyrosine kinases (RTKs) play a key role in oncogenic transformation, growth and metastases. RTKs regulate cell differentiation, proliferation, migration, angiogenesis, and survival. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an evolutionarily-conserved type I membrane protein that belongs to the ROR subfamily and has extracellular domains that contain immunoglobulin (Ig)-like, Frizzled, and Kringle domains. ROR1-deficient mice display a variety of phenotypic defects within the skeletal and urogenital systems, as well as postnatal growth retardation. ROR1 is expressed during embryogenesis and by a variety of different cancers, but not by normal post-partum tissues, and can be considered an onco-embryonic surface antigen. Functional data suggest that ROR1 may function in non-canonical WNT-signaling to promote the survival of malignant cells.

[0004] ROR1 expression and activation appears to be correlated with features of tumor aggressiveness in models of chronic lymphocytic leukemia (CLL), breast cancer, lung cancer, gastric cancer, and melanoma (Li et al., *PLoS One* 5(7):e11859 (2010); Gentile et al., *Cancer Res.*

71(8):3132-41 (2011); Zhang et al., *PLoS One* 7(3):e31127 (2012); Yamaguchi et al., *Cancer Cell.* 21(3):348-61 (2012); Daneshmanesh et al., *Leukemia* 26(6):1348-55 (2012); Daneshmanesh et al., *Leuk Lymphoma* 54(4):843-50 (2013); O'Connell et al., *Cancer Discov.* 3(12):1378-93 (2013); Hojjat-Farsangi et al., *PLoS One* 8(4):e61167 (2013); Hojjat-Farsangi et al., *PLoS One* 8(10):e78339 (2013); Ida et al., *Cancer Sci.* 107(2):155-61 (2016); and Janovska et al., *Clin Cancer Res.* 22(2):459-69 (2016)). Elevated levels of ROR1 expression in patients and cell lines are associated with genes involved in epithelial-mesenchymal transition (EMT) (Cui et al., *Cancer Res.* 73(12):3649-60 (2013)). In patients with CLL, high levels of ROR1 expression are associated with shorter treatment-free survival and overall survival (OS) (Cui et al., *Blood* 128(25):2931-2940 (2016)). Similarly, in patients with ovarian cancer, high ROR1 expression is associated with poor clinical outcomes (Zhang et al., *Sci Rep.* 4:5811 (2014)).

[0005] In view of the role of ROR1 in cancer, there is a need for new and improved therapies that target ROR1-positive cancer cells.

SUMMARY OF THE INVENTION

[0006] Provided herein is an immunoconjugate having the formula of Ab-((L)m-(D))n, wherein: Ab is an antibody or an antigen-binding fragment thereof that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); L is a linker, and m is 0 or 1; D is a cytotoxic drug moiety; and n is an integer from 1 to 10.

[0007] The cytotoxic drug moiety may be selected from the group consisting of, for example, an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor. In some embodiments, the cytotoxic drug moiety is selected from the group consisting of monomethyl auristatin E (MMAE), azonafide, α -amanitin, duocarmycin TM, pyrrolobenzodiazepine (PBD), PNU-159682, and pharmaceutically acceptable salts, esters, and analogs thereof.

[0008] The linker in the immunoconjugate may comprise a cleavable moiety. It may be cleaved inside a target cell. Alternatively, the linker is not cleavable. The linker can be branched or unbranched. In some embodiments, the linker comprises one or more moieties selected from valine-citrulline (VC), valine-alanine (VA), para-aminobenzylloxycarbonyl (PAB), polyethylene glycol (PEG), diaminopropionic acid (DPR), Phe-C₄, C₂-Gly₃, C₆ alkyl, dimethylethylamine (DMEA), and ethylene diamine (EDA). In certain embodiments, the linker

is covalently bonded to the antibody or antigen-binding fragment at a succinimide, a carbonyl, or a cyclooctene, or a triazole group of the linker.

[0009] In certain embodiments, the antibody or fragment in the immunoconjugate is covalently bonded to the linker by reaction with a moiety selected from the group consisting of 6-maleimidocaproyl (MC)-VC-PAB; 6-MC-C₆; 6-MC-PEG4-VC-PAB-DMEA; 6-MC-PEG4-VA; 6-MC-DPR-VC-PAB; 6-MC-Phe-C₄-VC-PAB; 6-MC-Phe-C₄-VC-PAB-DMEA; 6-MC-C₂-Gly₃-EDA; dibenzylcyclooctyne (DBCO)-(PEG2-VC-PAB)₂; DBCO-PEG4-VC-PAB-DMEA; and N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate-VC-PAB. As used herein, VC represents a valine-citrulline dipeptide; VA represents a valine-alanine dipeptide; PEG represents polyethylene glycol; PAB represents para-amino-benzylloxycarbonyl; DMEA represents dimethylethylamine; Phe represents a benzyl group; and EDA represents ethylene diamine.

[0010] Provided herein also is an immunoconjugate having the formula of Ab-((L)m-(D))n, wherein: Ab is an antibody or an antigen-binding fragment thereof that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); L is a cleavable linker, and m is 0 or 1; D is an auristatin (*e.g.*, MMAE); and n is an integer from 1 to 10.

[0011] In an immunoconjugate of the present disclosure, the linker may comprise, for example, a heterocycle or carbonyl covalently bonded to the antibody or antigen-binding fragment, a spacer group covalently bonded to the heterocycle or carbonyl, and an ester, thioester, amide, carbonate, thiocarbonate or carbamate covalently bonded to the cytotoxic drug moiety. In some embodiments, the spacer group comprises an amino acid, a polyamino acid, or an amino benzyl group, or a combination thereof. In some embodiments, the linker in an immunoconjugate of the present disclosure forms a covalent bond with a cysteine or lysine residue on the antibody or fragment.

[0012] The Ab (antibody or fragment thereof) component of an immunoconjugate of the present disclosure may bind to the same ROR1 epitope as an antibody comprising the heavy chain and light chain amino acid sequences of SEQ ID NOs: 3 and 4, respectively. The antibody or fragment may comprise the heavy chain complementarity-determining region (CDR) 1-3 (HCDR1-3) in SEQ ID NO: 3 and the light chain CDR1-3 (LCDR1-3) in SEQ ID NO: 4. In some embodiments, the antibody or fragment comprises the amino acid sequences of SEQ ID NOs: 7-9, and the light chain of the antibody comprises the amino acid sequences of SEQ ID NOs: 10-12. The antibody or fragment may be humanized. The antibody or fragment may have

one or more of the following properties: a) facilitates ROR1 internalization in a human cell; b) binds to human ROR1 with a K_D of less than 100 nM (e.g., less than 50, 40, 30, 20, or 10 nM); and c) inhibits growth of ROR1⁺ human cancer cells *in vitro* with an EC₅₀ of 500 nM or less (e.g., 400 nM or less, 300 nM or less, 200 nM or less, or 100 nM or less).

[0001] In some embodiments, the heavy chain variable domain (V_H) and light chain variable domain (V_L) of the antibody in the immunoconjugate comprise the amino acid sequences of: a) SEQ ID NOs: 5 and 6, respectively; b) SEQ ID NOs: 5 and 50, respectively; c) SEQ ID NOs: 48 and 6, respectively; or d) SEQ ID NOs: 48 and 50, respectively. The antibody may comprise a human IgG₁ constant region and optionally also a human κ light chain constant region. In further embodiments, the heavy chain and light chain of the antibody comprise the amino acid sequences of: a) SEQ ID NOs: 3 and 4, respectively; b) SEQ ID NOs: 3 and 49, respectively; c) SEQ ID NOs: 47 and 4, respectively; or d) SEQ ID NOs: 47 and 49, respectively.

[0002] In some embodiments, the Ab component of the immunoconjugate is an Fab, F(ab)₂, or scFv, e.g., an Fab, F(ab)₂, or scFv.

[0003] Specific embodiments of the present disclosure include an immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V_H and V_L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively. Examples of such an immunoconjugate are shown in Tables 2 and 3 below, and include Antibody-Drug Conjugates (ADC)-A, E, H, I, J, K, L, M, N, O, P, Q, and R. In further embodiments, the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

[0004] In the immunoconjugate of the present disclosure, the number of the drug moiety to per antibody or fragment, or the ratio of the cytotoxic drug moiety to the antibody or fragment (DAR), may be 1 to 10, for example, 1 to 7, 1 to 6, 1 to 5, 2 to 7, 2 to 6, or 2 to 5.

[0005] Also provided herein are pharmaceutical compositions comprising an immunoconjugate of the present disclosure and a pharmaceutically acceptable excipient. The pharmaceutical compositions may further comprise an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor. For example, the additional therapeutic agent is selected from ibrutinib, acalabrutinib, venetoclax, everolimus, sapanisertib, and idelalisib.

[0006] Also provided herein is a therapy or method for treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an immunoconjugate of the present invention. The cancer may be homogenous or heterogeneous for ROR1 expression and may be, for example, a leukemia, a lymphoma, or a solid tumor. In some embodiments, the cancer is chronic lymphocytic leukemia (CLL), T-cell leukemia (TCL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, multiple myeloma (MM), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), or a non-Hodgkin lymphoma (NHL) that has undergone Richter's transformation. In some embodiments, the cancer is non-small cell lung cancer (NSCLC), hepatocellular carcinoma, pancreatic cancer, osteosarcoma, head and neck cancer, ovarian cancer, breast cancer, or triple negative breast cancer (TNBC).

[0007] The therapy or treatment method of the present disclosure may further comprise administering to the patient an additional anti-cancer therapeutic agent, which may be, for example, a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor. In some embodiments, the additional therapeutic agent is selected from ibrutinib, acalabrutinib, venetoclax, everolimus, sapanisertib, and idelalisib.

[0008] In certain embodiments of the present therapy or treatment method, the cancer is CLL, MCL, or an NHL that has undergone Richter's transformation.

[0009] Provided herein also are immunoconjugates and pharmaceutical compositions as described herein for use in treating cancer in the therapy or treatment methods described herein. For example, provided herein is an immunoconjugate having the formula of Ab-((L)m-(D))n for use in treating cancer in a patient in need thereof, wherein: Ab is an antibody or an antigen-binding fragment thereof that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); L is a linker, and m is 0 or 1; D is a cytotoxic drug moiety; and n is an integer from 1 to 10. Exemplary embodiments of the immunoconjugate and the treatment are described above and will be further described below.

[0010] Provided herein also are the use of an immunoconjugate herein for the manufacture of a medicament for use in treating cancer in a patient in need thereof. For example, provided herein is the use of is an immunoconjugate having the formula of Ab-((L)m-(D))n for the manufacture of a medicament in treating cancer in a patient in need thereof, wherein: Ab is an antibody or an

antigen-binding fragment thereof that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); L is a linker, and m is 0 or 1; D is a cytotoxic drug moiety; and n is an integer from 1 to 10. Exemplary embodiments of the immunoconjugate and the treatment are described above and will be further described below.

[0023] The present disclosure also provides a method of making an immunoconjugate, comprising: providing an antibody or an antigen-binding fragment thereof that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); conjugating to the antibody a cytotoxic drug moiety selected from the group consisting of an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor; wherein the heavy chain of the antibody comprises the amino acid sequences of SEQ ID NOS: 7-9, and the light chain of the antibody comprises the amino acid sequences of SEQ ID NOS: 10-12. Exemplary embodiments of the immunoconjugate are described above and will be further described below.

[0024] Provided herein also are articles of manufacture, such as kits, comprising an immunoconjugate of the present disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

[0025] **FIG. 1** is a schematic diagram illustrating a non-limiting example of an immunoconjugate of the present disclosure.

[0026] **FIGS. 2A and 2B** are graphs illustrating the binding of various concentrations of Ab1 and ADC-A to ROR1-positive cells Jeko-1 (2A) and MDA-MB-231 (2B). The EC₅₀ values for Ab1 and ADC-A are shown below each graph. The similarity between the EC₅₀ values for unconjugated Ab1 and ADC-A demonstrates that drug conjugation had minimal impact on Ab1's binding to the target cells.

[0027] **FIGS. 3A and 3B** are graphs illustrating the binding of Ab1, 4A5, ADC-A and ADC-T (3A) and Ab1, ADC-A, D10 and ADC-S (3B) to Jeko-1 cells. The EC₅₀ values for the antibodies and immunoconjugates are shown below each graph. The similarity between the EC₅₀ values of unconjugated antibodies and the corresponding ADC constructs demonstrates that drug conjugation had minimal impact on the antibodies' binding to the target cells. The difference in EC₅₀ values between Ab1/ADC-A and D10/ADC-S reflect the higher affinity of Ab1 for ROR1 as compared to D10.

[0028] **FIGS. 4A and 4B** are graphs illustrating the internalization of Ab1, ADC-A, and ADC-B into Jeko-1 cells (4A), and the internalization of Ab1 and ADC-A into MDA-MB-231 cells (4B). The addition of linker and payload to Ab1 did not negatively impact its binding or internalization, as demonstrated with ADC-A and ADC-B.

[0029] **FIG. 5** is a graph illustrating the internalization rate of Ab1 in MDA-MB-231 cells. The graph shows an initially rapid rate, and then a slower rate, of cell surface receptor clearance.

[0030] **FIG. 6** is a graph illustrating the cell surface expression of ROR1 during Ab1 internalization into Jeko-1 cells. While Ab1 is rapidly internalized, quantitation of cell surface ROR1 shows a small decrease in the first 10 minutes, with subsequent measurements indicating restoration of ROR1 surface expression to initial or slightly higher levels.

[0031] **FIGS. 7A-C** are graphs illustrating cell surface expression of ROR1 during Ab1 internalization on Jeko-1 cells (7A), MDA-MB-468 cells (7B), and MDA-MB-231 cells (7C).

[0032] **FIGS. 8A-8I** are representative IC₅₀ plots showing ROR1 binding by immunoconjugates of the present disclosure, as well as unconjugated MMAE, in cancer cell lines TMD-8 (8A), HBL-1 (8B), DOHH2 (8C), MDA-MB-468 (8D), Bt549 (8E), TOV112D (8F), JHOM1 (8G), SKOvr3 (8H), and Mino (8I).

[0033] **FIG. 9** is a graph illustrating the inhibition of cell proliferation by 3, 10, or 30 µg/mL of ADC-A in Jeko-1 cells, with or without pre-treatment with 100 µg/mL Ab1. ADC-A inhibited cell proliferation in a dose-dependent manner. Pre-incubation of the cells with Ab1 reduced this activity, demonstrating that ADC-A's inhibitory activity on cell proliferation was mediated by the binding of ADC-A to ROR1.

[0034] **FIG. 10** is a graph illustrating the dose-dependent inhibition of leukemic cell tumor burden in a TCL1-ROR1 chronic lymphocytic leukemia mouse model upon treatment with vehicle, 10 mg/kg Ab1, or 1 mg/kg, 2 mg/kg, or 5 mg/kg ADC-A.

[0035] **FIG. 11** is a graph illustrating tumor growth inhibition in an MCL xenograft model upon treatment with vehicle, 5 mg/kg ADC-A or ADC-Q intravenously (IV) every four days (Q4D), 10 mg/kg Ab1 IV once per week (QW), or 20 mg/kg ibrutinib *per os* (PO) every day (QD). ADC-A treatment caused tumor regression.

[0036] **FIG. 12** is a pair of graphs showing ROR1 expression (left panel) and tumor growth inhibition in a DLBCL-GCB xenograft mouse model upon treatment with control, 10 mg/kg QW Ab1, 50 mg/kg venetoclax QD, Ab1 + venetoclax, or 5 mg/kg ADC-A QW (right panel). ADC-

A treatment resulted in complete tumor regression in all animals treated. Ab1 alone, venetoclax alone, and a combination of Ab1 and venetoclax were ineffective.

[0037] **FIG. 13** is a set of graphs showing ROR1 expression (left panel) and inhibition of tumor growth upon treatment with vehicle, 2.5 or 5 mg/kg ADC-A, or 10 mg/kg Ab1 (right panel), in a chemotherapy-resistant Richter's transformation xenograft mouse model. Although only 20-30% of the intra-tumoral cells were ROR1-positive, complete and sustained tumor regressions were observed with 5 mg/kg ADC-A.

[0038] **FIG. 14** is a graph illustrating tumor growth inhibition upon treatment with vehicle, 1 or 5 mg/kg ADC-A IV QW, 1 or 5 mg/kg ADC-B IV QW, or 10 mg/kg Ab1 IV QW in a MDA-MB-231 triple negative breast cancer (TNBC) mammary fat pad xenograft mouse model.

[0039] **FIG. 15** is a graph illustrating tumor growth inhibition upon treatment with vehicle, 1 or 5 mg/kg ADC-A IV Q4D, or 10 mg/kg Ab1 IV QW in a BR5011 human TNBC xenograft mouse model. Although only 58% of the intra-tumoral cells were ROR1-positive, complete and sustained regressions were observed with 5 mg/kg ADC-A, where tumor regression was maintained for at least 28 days after the last dose.

[0040] **FIG. 16** is a graph illustrating tumor growth inhibition upon treatment with vehicle, 1 or 5 mg/kg ADC-A IV Q4D, or 10 mg/kg Ab1 IV QW in a BR5015 (low ROR1 expression) human TNBC xenograft mouse model. Tumor regression was observed even though only 58% of the intra-tumoral cells were ROR1-positive.

[0041] **FIG. 17** is a graph illustrating tumor growth inhibition in a Jeko-1 human mantle cell lymphoma xenograft mouse model. Mice were treated with vehicle; 1 mg/kg ADC-N, ADC-P, or ADC-R; or 5 mg/kg ADC-A, ADC-L, ADC-M, ADC-S or ADC-T. Vehicle and ADC constructs were administered IV Q4D. Significant tumor regression was observed in animals treated with ADC-A, ADC-L, ADC-M and ADC-S, while inhibition of tumor growth was observed in animals treated with ADC-N, ADC-P, ADC-R and ADC-T.

[0042] **FIGS. 18A and 18B** are graphs illustrating the combination index of treatment with ADC-A and BTK inhibitors ibrutinib (18A) or ACP-196/acalabrutinib (18B) in various cell lines. ADC-A displayed a synergistic effect with both ibrutinib and ACP-196/acalabrutinib on inhibition of cell proliferation.

[0043] **FIGS. 19A and 19B** are graphs illustrating inhibition of Jeko-1 cell proliferation upon treatment with ADC-A, ibrutinib ("Ib"), or a combination of ADC-A and ibrutinib (19A); or

ADC-A, ACP-196/acalabrutinib (“ACP196” or “196”), or a combination of ADC-A and ACP-196/acalabrutinib (19B).

[0044] **FIGS. 20A-C** are graphs illustrating the combination index of treatment with ADC-A and Bcl-2 inhibitor ABT-199/venetoclax (“ABT199”) in various cell lines (20A), or of ADC-A with Bcl-2 inhibitor Bcl-2i-1 or Bcl-2i-2 in Jeko-1 cells (20B) or Mino cells (20C). ADC-A displayed a synergistic effect with ABT-199 on inhibition of both MCL and DLBCL cell proliferation. ADC-A also displayed a synergistic effect with other Bcl-2 inhibitors (Bcl-2i-1 and Bcl-2i-2) on inhibition of Jeko-1 cell proliferation, and displayed an additive effect with both inhibitors on inhibition of Mino cell proliferation.

[0045] **FIG. 21** is a graph illustrating inhibition of Jeko-1 cell proliferation upon treatment with ADC-A, ABT-199, or a combination of ADC-A and ABT-199.

[0046] **FIG. 22** is a graph illustrating the combination index of treatment with ADC-A and mTOR1/2 inhibitor INK128/sapanisertib (“INK128”) in various cell lines. ADC-A displayed a synergistic effect with INK128 on inhibition of both MCL and DLBCL cell proliferation.

[0047] **FIG. 23** is a graph illustrating inhibition of Jeko-1 cell proliferation upon treatment with ADC-A, INK128, or a combination of ADC-A and INK128.

[0048] **FIG. 24** is a graph illustrating the combination index of treatment with ADC-A and PI3K inhibitor CAL-101/idelalisib (“CAL101”) in various cell lines. ADC-A displayed a synergistic effect with CAL101 on inhibition of both MCL and DLBCL cell proliferation.

[0049] **FIGS. 25A and 25B** are graphs illustrating inhibition of cell proliferation upon treatment with ADC-A, PI3K inhibitor CAL-101/idelalisib (“CAL101” or “101”), or a combination of ADC-A and CAL101, in DLBCL-ABC cell line TMD-8 (25A) or in DLBCL-GCB cell line DOHH2 (25B).

DETAILED DESCRIPTION OF THE INVENTION

[0050] The present invention provides immunoconjugates of the formula $Ab-((L)_m-(D))_n$, wherein Ab is an antibody or an antigen-binding fragment thereof that specifically binds to the ROR1 protein; L is a linker; D is a drug moiety that has therapeutic activity in cancer; m is 0 or 1; and n is an integer from 1 to 10. In the formula, the dash “-” denotes a covalent or non-covalent bond. The antibody or fragment includes, but is not limited to, an antibody or antibody fragment that competes with antibody D10 or Ab1 for binding to human ROR1, or binds to the same

epitope as D10 or Ab1. The drug moiety includes, but is not limited to, another antibody or an antigen-binding fragment thereof, a polypeptide, a small molecule compound, a nucleic acid molecule such as a small interfering RNA molecule or an antisense molecule. The immunoconjugates of the present invention may be used to treat a variety of cancers such as ROR1-positive cancers.

1. Immunoconjugates

[0051] An “antibody-drug conjugate,” or “ADC,” or “immunoconjugate” refers to an antibody molecule, or an antigen-binding fragment thereof, that is covalently or non-covalently bonded, with or without a linker, to one or more biologically active molecule(s). The present immunoconjugates comprise antibodies or fragments thereof that are specific for human ROR1 and can thus serve as excellent targeting moieties for delivering the conjugated payloads to ROR1-positive cells. In some embodiments, a ROR1 immunoconjugate provided herein has an equilibrium dissociation constant (K_D) of about 1 μM , 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or less (e.g., 10^{-8} M or less, from 10^{-8} M to 10^{-13} M, or from 10^{-9} M to 10^{-13} M) for human ROR1. K_D can be measured by any suitable assay, such as surface plasmon resonance assays (e.g., using a BIACORE®-2000 or a BIACORE®-3000). In certain embodiments, the K_D of an immunoconjugate of the invention is less than the K_D for the D10 antibody. In certain embodiments, the K_D of an immunoconjugate of the invention for human ROR1 is less than about 50, 40, 30, 20, or 10 nM (e.g., 40 nM). In some embodiments, a ROR1 immunoconjugate provided herein inhibits growth of ROR1⁺ human cancer cells *in vitro* with an EC₅₀ of about 500, 400, 350, 300, or 250 nM or less (e.g., 300 nM or less). As used herein, an antibody is said to bind specifically to an antigen when it binds to the antigen with a K_D of 100 nM or less, such as less than 10 nM or less (e.g., 1-5 nM), as determined by, e.g., surface plasmon resonance or Bio-Layer Interferometry.

[0052] In certain embodiments, the immunoconjugate provided herein is internalized by a ROR1-positive cell primarily through the lysosome/endosome pathway. In particular embodiments, the internalization is independent of the ROR1 expression level on the cell surface.

[0053] Embodiments of the antibody or fragment thereof, the linker, and the drug moiety used in the immunoconjugates are described in further detail below.

1.1. Types and Structures of Antibodies

[0054] The term “antibody” is used herein in the broadest sense and includes polyclonal and monoclonal antibodies, such as intact antibodies and functional (antigen-binding) fragments thereof. The term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multi-specific (e.g., bispecific) antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv, and tandem tri-scFv. Unless otherwise indicated, the term encompasses intact or full-length antibodies, including antibodies of any class or subclass (e.g., IgG and sub-classes thereof such as IgG₁, IgG₂, IgG₃, and IgG₄; IgM; IgE; IgA; and IgD), as well as antibody fragments.

[0055] An antibody may include a heavy chain (or a polypeptide sequence derived therefrom) and a light chain (or a polypeptide sequence derived therefrom). The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in the antibody’s binding to an antigen. The variable domains of the heavy chain and light chain (V_H and V_L, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions and three complementarity-determining regions. A single V_H or V_L domain may sometimes be sufficient to confer all or a majority of the antigen-binding specificity of an antibody. Furthermore, antibodies that bind a particular antigen may be isolated by using a V_H or V_L domain from an antibody that binds the antigen to screen a library of complementary V_L or V_H domains, respectively. *See, e.g., Portolano et al., J. Immunol.* 150:880-887 (1993); Clarkson et al., *Nature* 352:624-628 (1991).

[0056] The terms “complementarity-determining region” and “CDR,” which are synonymous with “hypervariable region” or “HVR,” refer to subregions within the antibody variable domains, which confer the antibody’s specificity and/or affinity for its antigen. In general, there are three CDRs in each heavy chain variable domain (HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variable domain (LCDR1, LCDR2, and LCDR3). “Framework regions” (“FRs”) refer to the non-CDR portions of the variable domains. In general, there are four FRs in each full-length heavy chain variable domain and four FRs in each full-length light chain variable domain. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of several well-known schemes, including those described by Kabat et al., 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (“Kabat”

numbering scheme); Al-Lazikani et al., *JMB* 273,927-948 (1997) (“Chothia” numbering scheme); MacCallum et al., *J. Mol. Biol.* 262:732-745 (1996) (“contact” numbering scheme); Lefranc et al., *Dev Comp Immunol.* 27(1):55-77 (2003) (“IMGT” numbering scheme); and Honegger and Plückthun, *J Mol Biol.* 309(3):657-70 (2001) (“Aho” numbering scheme).

[0057] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on sequence alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a.” The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. Unless indicated otherwise, the CDRs of the antibodies referred to herein may be identified according to any of the Kabat, Chothia, IMGT, and contact methods.

[0058] An antigen-binding fragment of a full-length antibody may be used in making an immunoconjugate of the present invention. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')₂; recombinant IgG (rIgG) fragments; diabodies; linear antibodies; single-chain antibody molecules (*e.g.*, scFv or sFv); single domain antibodies (*e.g.*, sdAb, sdFv, nanobodies); and multi-specific antibodies formed from antibody fragments. In certain embodiments, the fragments are single-chain antibody fragments comprising a variable heavy chain region and/or a variable light chain region, such as scFvs.

1.2 Exemplary ROR1 Antibodies

[0059] An immunoconjugate of the invention comprises an antibody or an antigen-binding fragment thereof that specifically binds to ROR1, *e.g.*, human ROR1. The antibody or fragment binds to an extracellular portion of the ROR1 protein such as an epitope in one or more of the immunoglobulin (Ig)-like, Frizzled, and Kringle domains of the ROR1 protein. In certain embodiments, the ROR1-binding antibody or fragment binds to an amino acid sequence of ROR1 shown in SEQ ID NO: 1 or 2 (not including the terminal cysteine, which is added for convenience of conjugation) and can be internalized by a ROR1⁺ cell; examples of such an antibody are murine antibodies D10 and 99961. *See* U.S. Pats. 9,217,040 and 9,758,591, the

disclosures of which are incorporated by reference herein in their entirety. In certain embodiments, the antibody or fragment competes with D10 or 99961 for binding to human ROR1. Amino acid sequences of exemplary anti-ROR1 antibodies used in the immunoconjugates of the invention are shown in Table 1 below, where Ab1-Ab4 are humanized variants of antibody 99961.

Table 1 SEQ ID NOs of Exemplary Anti-ROR1 Antibodies

Ab	HCDR1	HCDR2	HCDR3	VH	HC	LCDR1	LCDR2	LCDR3	VL	LC
99961	7	8	9	45	--	10	11	12	46	--
Ab1	7	8	9	5	3	10	11	12	6	4
Ab2	7	8	9	5	3	10	11	12	50	49
Ab3	7	8	9	48	47	10	11	12	6	4
Ab4	7	8	9	48	47	10	11	12	50	49
D10	27	28	29	25	--	30	31	32	26	--

[0060] In some embodiments, the antibody or antibody fragment in the immunoconjugate specifically binds human ROR1, and its heavy and light chains respectively comprise:

- a) the heavy chain CDR1-3 (HCDR1-3) amino acid sequences in SEQ ID NO: 3, and the light chain CDR1-3 (LCDR1-3) amino acid sequences in SEQ ID NO: 4;
- b) HCDR1-3 comprising the amino acid sequences of SEQ ID NO: 7-9, respectively, and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 10-12, respectively;
- c) the HCDR1-3 amino acid sequences in SEQ ID NO: 13-15, and the LCDR1-3 amino acid sequences in SEQ ID NOs: 16-18;
- d) HCDR1-3 comprising the amino acid sequences of SEQ ID NO: 27-29, respectively, and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 30-32, respectively;
- e) HCDR1-3 comprising the amino acid sequences of SEQ ID NO: 37-39, respectively, and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs: 40-42, respectively;
- f) HCDR1-3 comprising residues 26-33, 51-58, and 97-105 of SEQ ID NO: 5, respectively, and LCDR1-3 comprising residues 27-32, 50-52, and 89-97 of SEQ ID

NO: 6, respectively;

- g) HCDR1-3 comprising residues 26-32, 52-57, and 99-105 of SEQ ID NO: 5, respectively, and LCDR1-3 comprising residues 24-34, 50-56, and 89-97 of SEQ ID NO: 6, respectively;
- h) HCDR1-3 comprising residues 31-35, 50-66, and 99-105 of SEQ ID NO: 5, respectively, and LCDR1-3 comprising residues 24-34, 50-56, and 89-97 of SEQ ID NO: 6, respectively;
- i) HCDR1-3 comprising residues 26-32, 52-57, and 99-105 of SEQ ID NO: 5, respectively, and LCDR1-3 comprising residues 27-32, 50-52, and 89-97 of SEQ ID NO: 6, respectively; or
- j) HCDR1-3 comprising residues 31-35, 52-57, and 99-105 of SEQ ID NO: 5, respectively, and LCDR1-3 comprising residues 27-32, 50-52, and 89-97 of SEQ ID NO: 6, respectively.

In some embodiments, the antibody or fragment is humanized, or chimeric with human constant regions. In further embodiments, the antibody or fragment may comprise a human IgG₁, IgG₂, IgG₃, or IgG₄ constant region and optionally a human κ constant region.

[0061] In certain embodiments, the immunoconjugate of the invention comprises an anti-ROR1 antibody, or an antigen-binding fragment thereof, wherein the antibody comprises:

- a) a heavy chain variable domain or region (V_H) comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (e.g., at least 90%) identical to that of SEQ ID NO: 5, and a light chain variable domain or region (V_L) comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (e.g., at least 90%) identical to that of SEQ ID NO: 6;
- b) a V_H and a V_L comprising the amino acid sequences of SEQ ID NOs: 5 and 6, respectively;
- c) a heavy chain (HC) comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (e.g., at least 90%) identical to that of SEQ ID NO: 3 and a light chain (LC) comprising an amino acid sequence 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (e.g., at least 90%) identical to that of SEQ ID NO: 4; or

- d) an HC and an LC comprising the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

[0062] In certain embodiments, the V_H and V_L of the antibody respectively comprise the amino acid sequences of:

- a) SEQ ID NOs: 5 and 50;
- b) SEQ ID NOs: 48 and 6; or
- c) SEQ ID NOs: 48 and 50.

In some embodiments, the antibody or fragment comprises a human IgG₁, IgG₂, IgG₃, or IgG₄ constant region and optionally a human κ constant region.

[0063] In certain embodiments, the HC and LC of the antibody respectively comprise the amino acid sequences of:

- a) SEQ ID NOs: 3 and 49;
- b) SEQ ID NOs: 47 and 4; or
- c) SEQ ID NOs: 47 and 49.

[0064] In certain embodiments, the immunoconjugate of the invention comprises an antibody or fragment thereof derived from a murine antibody with the V_H and V_L amino acid sequences of (i) SEQ ID NOs: 25 and 26, respectively; (ii) SEQ ID NOs: 35 and 36, respectively; or (iii) SEQ ID NOs: 45 and 46, respectively. Antibodies derived from these sequences may be, *e.g.*, antibodies that have been humanized or joined to a human Fc region (*e.g.*, chimeric). For example, the antibody or an antigen-binding fragment in the immunoconjugate comprises:

- a) a V_H comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to that of SEQ ID NO: 45 and a V_L comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to that of SEQ ID NO: 46;
- b) a V_H comprising the amino acid sequence of SEQ ID NO: 45 and a V_L comprising the amino acid sequence of SEQ ID NO: 46;
- c) a V_H comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to that of SEQ ID NO: 25 and a V_L comprising an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to that of SEQ ID NO: 26; or
- d) a V_H comprising the amino acid sequence of SEQ ID NO: 25 and a V_L comprising the

amino acid sequence of SEQ ID NO: 26.

[0065] Exemplary coding sequences for the aforementioned antibodies are shown in Table 12 below. For example, the antibody in the immunoconjugate may comprise:

- a) a V_H encoded by (i) nucleotides 73-420 of SEQ ID NO: 21, or (ii) SEQ ID NO: 23; and a V_L encoded by SEQ ID NO: 22 or 24;
- b) a V_H encoded by SEQ ID NO: 52 and a V_L encoded by SEQ ID NO: 54;
- c) a V_H encoded by SEQ ID NO: 33 and a V_L encoded by SEQ ID NO: 34;
- d) an HC encoded by nucleotides 73-1,410 of SEQ ID NO: 19 and an LC encoded by nucleotides 73-714 of SEQ ID NO: 20; or
- e) an HC encoded by SEQ ID NO: 51 and an LC encoded by nucleotides SEQ ID NO: 53.

[0066] In certain embodiments, the immunoconjugate of the invention comprises an antigen-binding fragment of an anti-ROR1 antibody, wherein the antigen-binding fragment comprises the sequence of any one of SEQ ID NOs: 64-68. In certain embodiments, the antigen-binding fragment comprises the V_H and V_L amino acid sequences of:

- a) SEQ ID NOs: 5 and 6;
- b) SEQ ID NOs: 5 and 50;
- c) SEQ ID NOs: 48 and 6;
- d) SEQ ID NOs: 48 and 50;
- e) SEQ ID NOs: 45 and 46; or
- f) SEQ ID NOs: 25 and 26,

wherein the V_H amino acid sequence is optionally linked to the amino acid sequence of SEQ ID NO: 62, and/or the V_L amino acid sequence is optionally linked to the amino acid sequence of SEQ ID NO: 63.

1.3 Antibody Sequence Comparison

[0067] Percent (%) sequence identity with respect to a reference polypeptide sequence refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are

known; for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR). For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0068] In situations where ALIGN-2 is employed for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0069] In some embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. A variant typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants can be naturally occurring or can be synthetically generated, for example, by modifying one or more of the above polypeptide sequences of the invention and evaluating one or more biological activities of the polypeptide as described herein and/or using any of a number of known techniques. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of

deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, *e.g.*, antigen-binding.

[0070] As used herein, the term “substantially identical” refers to two or more sequences having a percentage of sequential units (*e.g.*, amino acid residues) which are the same when compared and aligned for maximum correspondence over a comparison window, or a designated region as measured using comparison algorithms. By way of example, two or more sequences may be “substantially identical” if the sequential units are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, or about 99% identical over a specified region. Such percentages describe the “percent identity” between two sequences.

1.4 Making and Modification of ROR1 Antibodies

[0071] Anti-ROR1 antibodies for use in the immunoconjugates of the present invention can be made by immunizing an animal with human ROR1 or a fragment of human ROR1 protein. Antibodies that bind to the immunizing fragment with high affinity (*e.g.*, with a K_D in the nM or lower range) can be screened by using routine methods such as ELISA.

[0072] If the antibody is a non-human antibody, it can be humanized. A “humanized” antibody is an antibody in which all or substantially all CDR amino acid residues are derived from a non-human (*e.g.*, mouse or rat) antibody and all or substantially all FR amino acid residues are derived from human FRs. A humanized antibody optionally may include at least a portion of a constant region derived from a human antibody. A “humanized form” of a non-human antibody refers to a variant of the non-human antibody that has undergone humanization, typically to reduce immunogenicity to humans, while retaining the antigen-binding specificity and affinity of the parental non-human antibody. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from the cognate non-human antibody to restore or improve the resultant antibody’s antigen-binding specificity and/or affinity.

[0073] ROR1 antibodies or fragments may be manufactured recombinantly in mammalian host cells containing coding sequences for the ROR1 antibodies or fragments, wherein the coding sequences are operably linked to transcription-regulatory elements suitable for expression in the host cells. The coding sequences may be introduced into the host cells on one or more

vectors. Useful mammalian host cells include, *inter alia*, Chinese hamster ovary (CHO) cells, NS0 cells, SP2 cells, HEK-293T cells, 293 Freestyle cells (Invitrogen), NIH-3T3 cells, HeLa cells, baby hamster kidney (BHK) cells, African green monkey kidney cells (COS), human hepatocellular carcinoma cells (*e.g.*, Hep G2), and A549 cells. Cell lines may be selected based on their expression levels. Other cell lines that may be used include insect cell lines, such as Sf9 or Sf21 cells, and yeast cell lines.

[0074] In some embodiments, a parent ROR1 antibody may be engineered by introducing one or more amino acid substitutions to improve the antibody's antigen binding, to decrease immunogenicity (*e.g.*, de-immunize; *see, e.g.*, Jones *et al.*, *Methods Mol Biol.* 525:405-23 (2009)), and/or to improve antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

[0075] In some embodiments, substitutions, insertions, or deletions may be made within one or more CDRs, wherein the mutations do not substantially reduce the antibody's binding to its antigen. For example, conservative substitutions that do not substantially reduce binding affinity may be made.

[0076] Alterations (*e.g.*, substitutions) may be made in CDRs to improve antibody affinity. CDR residues involved in antigen binding may be identified by using, *e.g.*, alanine scanning mutagenesis or computer modeling. HCDR3 and LCDR3 in particular are often targeted. A crystal structure of an antigen-antibody complex may also be used to identify contact points between the antibody and its antigen. Such contact residues and their neighboring residues may be targeted for mutations. Variants may be screened to determine whether they obtain the desired properties. *In vitro* affinity maturation (*e.g.*, using error-prone PCR, chain shuffling, randomization of CDRs, or oligonucleotide-directed mutagenesis) may also be used to improve antibody affinity (*see, e.g.*, Hoogenboom *et al.*, *Methods in Molecular Biology* 178:1-37 (2001)).

[0077] Amino acid sequence insertions and deletions made to an antibody or antibody fragment include amino- and/or carboxyl-terminal fusions ranging in length from one or a few residues to polypeptides containing a hundred or more residues, as well as intra-sequence insertions and deletions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion of the N- or C-terminus of the antibody to an enzyme (*e.g.*, for ADEPT) or a polypeptide that increases the serum half-life of the antibody. Examples

of intra-sequence insertion variants of the antibody molecules include an insertion of 3 amino acids in the light chain. Examples of terminal deletions include an antibody with a deletion of 7 or fewer amino acids at an end of the light chain, and the removal of the C-terminal lysine in the heavy chain.

[0078] In some embodiments, the ROR1 antibodies are altered to increase or decrease their glycosylation (e.g., by altering the amino acid sequence such that one or more glycosylation sites are created or removed). A carbohydrate attached to an Fc region of an antibody may be altered. Native antibodies from mammalian cells typically comprise a branched, biantennary oligosaccharide attached by an N-linkage to Asn₂₉₇ of the CH₂ domain of the Fc region (see, e.g., Wright *et al.*, *TIBTECH* 15:26-32 (1997)). Asn₂₉₇ refers to the asparagine residue located at about position 297 in the Fc region (EU numbering of Fc region residues; see, e.g., Edelman *et al.* *PNAS* 63(1):78-85 (1969)). However, Asn₂₉₇ may also be located about ± 3 amino acids upstream or downstream of position 297, *i.e.*, between positions 294 and 300, due to minor sequence variations in antibodies. The oligosaccharide can be any of various carbohydrates, *e.g.*, mannose, N-acetyl glucosamine (GlcNAc), galactose, sialic acid, or fucose attached to a GlcNAc in the stem of the biantennar oligosaccharide structure. Modifications of the oligosaccharide in an antibody can be made, for example, to create antibody variants with certain improved properties. Antibody glycosylation variants can have improved ADCC and/or CDC function.

[0079] In some embodiments, antibody variants are provided having a carbohydrate structure that has no or a reduced level of fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such an antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn₂₉₇, relative to the sum of all glycostructures attached to Asn₂₉₇ (see, *e.g.*, PCT Patent Publication WO 2008/077546). Such fucosylation variants can have improved ADCC function (see, *e.g.*, Okazaki *et al.*, *J. Mol. Biol.* 336:1239-1249 (2004); and Yamane-Ohnuki *et al.*, *Biotech. Bioeng.* 87:614 (2004)). Cell lines (*e.g.*, knockout cell lines) can be used to produce defucosylated antibodies, *e.g.*, Lec13 CHO cells deficient in protein fucosylation and alpha-1,6-fucosyltransferase gene (FUT8) knockout CHO cells (see, *e.g.*, Ripka *et al.*, *Arch. Biochem. Biophys.* 249:533-545 (1986); Yamane-Ohnuki *et al.*, *Biotech. Bioeng.* 87:614 (2004); and Kanda *et al.*, *Biotechnol. Bioeng.* 94(4):680-688 (2006)). Other antibody glycosylation variants as described in, *e.g.*, U.S. Pat. 6,602,684) may

also be made to the ROR1 antibodies or antibody fragments for use in the present immunoconjugates.

[0080] In some embodiments, one or more amino acid modifications may be introduced into the Fc region of a ROR1 antibody to generate a ROR1 antibody with a variant Fc region that confers new properties to the antibody. A variant Fc region may comprise a human Fc region sequence (e.g., a human IgG₁, IgG₂, IgG₃ or IgG₄ Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions. For example, a ROR1 antibody with a variant Fc region may possess some but not all effector functions, which makes it a desirable candidate for applications in which the half-life of the antibody *in vivo* is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. *In vitro* and/or *in vivo* cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc γ R binding (hence likely lacking ADCC activity), but retains FcRn binding ability. Non-limiting examples of *in vitro* assays to assess ADCC activity of a molecule of interest are described in U.S. Pats. 5,500,362 and 5,821,337. Alternatively, non-radioactive assays methods may be employed (e.g., ACTITM and CytoTox 96® non-radioactive cytotoxicity assays). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs), monocytes, macrophages, and natural killer (NK) cells.

[0081] Antibodies can have increased half-lives and improved binding to the neonatal Fc receptor (FcRn) (see, e.g., U.S. Patent Publication 2005/0014934). Such antibodies can comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn, and include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 and 434 according to the EU numbering system (see, e.g., U.S. Pat. 7,371,826). Other examples of Fc region variants are also contemplated (see, e.g., Duncan & Winter, *Nature* 322:738-40 (1988); U.S. Pats. 5,648,260 and 5,624,821; and PCT Publication WO 94/29351).

[0082] In some embodiments, it may be desirable to create cysteine engineered antibodies, *e.g.*, “thioMAbs,” in which one or more residues of an antibody are substituted with cysteine residues. In some embodiments, the substituted residues occur at accessible sites of the antibody. Reactive thiol groups can be positioned at sites for conjugation to other moieties, such as drug moieties or linker drug moieties, to create an immunoconjugate. Any one or more of the following residues

may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.

[0083] An antibody provided herein may be further modified to include non-proteinaceous moieties. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. The term “polymer,” as used herein, refers to a molecule composed of repeated subunits; such molecules include, but are not limited to, polypeptides, polynucleotides, or polysaccharides, or polyalkylene glycols. Non-limiting examples of water soluble polymers are polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyamino acids (either homopolymers or random copolymers), and dextran or poly(N-vinyl pyrrolidone)-polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if two or more polymers are attached, they can be the same or different molecules.

1.5 Cytotoxic Drug Moieties

[0084] An immunoconjugate of the invention comprises an anti-ROR1 antibody or an antigen-binding fragment thereof conjugated to one or more cytotoxic agents, such as chemotherapeutic agents, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes. The cytotoxic agent(s) can be conjugated to the anti-ROR1 antibody or fragment by a linker covalently bound to an amino acid residue of the antibody. Many drugs that can serve as a cytotoxic moiety in an immunoconjugate are independently too toxic to be used for cancer treatment, and thus are more effective when specifically targeted to the cancer cell by an antibody or antibody fragment.

[0085] The term “cytotoxic drug moiety” or “cytotoxic agent” refers to a compound that can cause harm, disturbances, or death to a cell. Examples of cytotoxic drug moieties that can be used as part of a ROR1 immunoconjugate include, but are not limited to: NCA1, auristatin,

auristatin E, DNA minor groove binding agents, DNA minor groove alkylating agents, enediyne, lexitropsin, duocarmycin, taxane, puromycin, dolastatin, maytansinoid, vinca alkaloid, AFP, MMAF, MMAE, AEB, AEVB, taxoids (e.g., paclitaxel and paclitaxel derivatives (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE® (American Pharmaceutical Partners, Schaumberg, Ill.), as well as docetaxel and docetaxel derivatives), CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, dolastatin-10, echinomycin, combretastatin, calicheamicin, maytansine, DM-1, netropsin, podophyllotoxin (e.g., etoposide and teniposide), baccatin and its derivatives, anti-tubulin agents, cryptophycin, combretastatin, vincristine, vincristine sulfate, vinblastine, vindesine, vinorelbine, VP-16, camptothecin, epothilone A, epothilone B, nocodazole, colchicines, colcimid, estramustine, cemadotin, discodermolide, eleutherobin, mechlorethamine, cyclophosphamide, melphalan, carmustine, lomustine, semustine, streptozocin, chlorozotocin, uracil mustard, chlormethine, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, dacarbazine, temozolomide, ytarabine, cytosine arabinoside, fluorouracil, 5-fluorouracil (5-FU), floxuridine, 6-thioguanine, 6-mercaptopurine, pentostatin, methotrexate, 10-propargyl-5,8-dideazafolate, 5,8-dideazatetrahydrofolic acid, leucovorin, fludarabine phosphate, pentostatine, gemcitabine, Ara-C, deoxycoformycin, mitomycins such as mitomycin-C, L-asparaginase, azathioprine, brequinar, antibiotics (e.g., anthracycline, gentamicin, cefalotin, vancomycin, telavancin, daptomycin, azithromycin, erythromycin, rocidonium, furazolidone, amoxicillin, ampicillin, carbenicillin, flucloxacillin, methicillin, penicillin, ciprofloxacin, moxifloxacin, ofloxacin, doxycycline, minocycline, oxytetracycline, tetracycline, streptomycin, rifabutin, ethambutol, and rifaximin), enediyne antibiotics (e.g., calicheamicin, calicheamicin gammaII and calicheamicin omegaII, and dynemicin, including dynemicin A), antiviral drugs (e.g., abacavir, acyclovir, ampligen, cidofovir, delavirdine, didanosine, efavirenz, entecavir, fosfonet, ganciclovir, ibacicabine, immunovir, idoxuridine, inosine, lopinavir, methisazone, nexavir, nevirapine, oseltamivir, penciclovir, stavudine, trifluridine, truvada, valaciclovir, and zanamivir), daunorubicin hydrochloride, daunorubicin, rubidomycin, cerubidine, idarubicin, doxorubicin, epirubicin and morpholino derivatives, phenoxizone biscyclopeptides (e.g., dactinomycin), basic glycopeptides (e.g., bleomycin), anthraquinone glycosides (e.g., plicamycin and mithramycin), anthracenediones (e.g., mitoxantrone), azirinopyrrolo indolediones (e.g., mitomycin), macrocyclic immunosuppressants (e.g., cyclosporine, FK-506, tacrolimus, prograf, and

rapamycin), navelbene, CPT-11, anastrazole, letrozole, capecitabine, reloxafine, droloxafine, allocolchicine, Halichondrin B, colchicine and colchicine derivatives, rhizoxin, thiocolchicine, trityl cysterin, vinblastine sulfate, hydroxyurea, N-methylhydrazine, epidophyllotoxin, procarbazine, mitoxantrone, leucovorin, and tegafur. "Taxanes" include paclitaxel, as well as any active taxane derivative or pro-drug. Chemotherapeutic agents such as erlotinib (TARCEVA®, Genentech/OSI Pharm.), bortezomib (VELCADE®, Millenium Pharm.), fulvestrant (FASLODEX®, AstraZeneca), sunitinib (Sutent®, Pfizer), letrozole (FEMARA®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), PTK787/ZK 222584 (Novartis), oxaliplatin (Eloxatin®, Sanofi), leucovorin, lapatinib (TYKERB®, GSK572016, GlaxoSmithKline), lonafarnib (SCH 66336), sorafenib (BAY43-9006, Bayer Labs.), and gefitinib (IRESSA®, AstraZeneca), AG1478, AG1571 (SU 5271; Sugen), alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; antifolate antineoplastic such as pemetrexed (ALIMTA® Eli Lilly); aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (such as bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogues adozelesin, carzelesin and bizelesin); cryptophycins (such as cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including its synthetic analogues KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabacin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (ADRIAMYCIN®) (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin,

puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-FU; folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thioguanine, thiamiprine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; niraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, *e.g.*, paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAZAXANE™ Cremophor-free, albumin, nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); mitoxantrone; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, esters, acids, prodrugs, or derivatives of any of the above.

[0086] In some embodiments, a suitable cytotoxic agent for use in the ROR1 immunoconjugate is

- a) an anti-tubulin agent (*e.g.*, an auristatin or dolastatin such as auristatin E, monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF), dimethylvaline-valine-dolaisoleuine-dolaproine-phenylalanine-p-phenylenediamine (AFP), 5-benzoylvaleric

acid-auristatin E ester (AEVB), AEB, a maytansinoid, ansamitocin, mertansine/emtansine (DM1), or ravtansine/soravtansine (DM4)),

- b) a DNA alkylating agent or a DNA minor groove alkylating agent (e.g., duocarmycin),
- c) a DNA cross-linking agent (e.g., pyrrolobenzodiazepine (PBD)),
- d) a DNA intercalating agent (e.g., PNU-159682),
- e) a DNA minor groove binding agent (e.g., CC-1065), or
- f) an RNA polymerase II inhibitor (e.g., amanitin, such as α -amanitin).

As used herein, the term “intercalating agent” refers to a chemical that can insert into the intramolecular space of a molecule or the intermolecular space between molecules. By way of example, a DNA intercalating agent may be a molecule that inserts into the stacked bases of the DNA double helix.

[0087] In some embodiments, the cytotoxic agent used in the ROR1 immunoconjugate is selected from the group consisting of an enediyne, a lexitropsin, a duocarmycin, a taxane, a puromycin, a podophyllotoxin, a baccatin derivative, a cryptophysin, a combrestatin, a dolastatin, a maytansinoid, a vinca alkaloid, paclitaxel, docetaxel, ansamitocin, CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, dolastatin-10, echinomycin, combretatstatin, chalicheamicin, vincristine, vinblastine, vindesine, vinorelbine, VP-16, camptothecin, epothilone A, epothilone B, nocodazole, colchicines, colcimid, estramustine, cemadotin, discodermolide maytansine, eleutherobin, and netropsin.

[0088] In some embodiments, the cytotoxic drug moiety in the immunoconjugate is a prodrug. The term “prodrug” or “pharmaceutically acceptable prodrug,” as used herein, refers to an agent that is converted into the parent drug *in vivo* or *in vitro* and is relatively nontoxic. That is, the immunoconjugate may be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. Prodrugs are generally drug precursors that, following administration to a subject and subsequent absorption, are converted to an active or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug, the active drug is generated. Prodrugs may be converted into active drug within the body through enzymatic or non-enzymatic reactions. Prodrugs may provide improved physiochemical

properties over their parent drugs such as better solubility, enhanced delivery characteristics (e.g., targeting a particular cell, tissue, organ or ligand), and improved therapeutic value of the drug. The benefits of such prodrugs may include, but are not limited to, (i) ease of administration compared with the parent drug; (ii) the prodrug may be bioavailable by oral administration where the parent is not; and (iii) the prodrug may have improved solubility in pharmaceutical compositions compared with the parent drug. A prodrug includes a pharmacologically inactive or less active derivative of a drug. Prodrugs may be designed to modulate the amount of a drug or biologically active molecule that reaches a desired site of action through the manipulation of the properties of a drug, such as physiochemical, biopharmaceutical, or pharmacokinetic properties.

[0089] In some embodiments, the average number of the drug moiety to the antibody in the immunoconjugate (i.e., drug-to-antibody ratio or DAR) is 1; or at least 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 6, 7, 8, 9, or 10. Exemplary methods for measuring DAR are described in the Examples below.

1.6 Linkers

[0090] In certain embodiments of an immunoconjugate of the invention, the antibody can be conjugated directly to the cytotoxic agent, or can be conjugated via a linker. Suitable linkers include, for example, cleavable and non-cleavable linkers. In some embodiments, the linker is a cleavable linker. A cleavable linker refers to a linker that comprises a cleavable moiety and is typically susceptible to cleavage under intracellular conditions. Suitable cleavable linkers include, for example, peptide linkers cleavable by an intracellular protease (such as a lysosomal protease or an endosomal protease), and acid-cleavable linkers. In exemplary embodiments, the linker can be a dipeptide, such as a valine-citrulline (val-cit or VC) or a phenylalanine-lysine (phe-lys) linker. The linker may also be a tripeptide or a polypeptide having four or more amino acid residues. Other suitable linkers include linkers hydrolyzable at a pH of less than 5.5, such as a hydrazone linker. Additional suitable cleavable linkers include disulfide linkers. In some embodiments, the linker is a non-polymeric linker. In some cases, the linker is a non-peptide linker or a linker that does not contain an amino acid residue.

[0091] In some embodiments, the linker includes a C₁-C₆ alkyl group (e.g., a C₅, C₄, C₃, C₂, or

C_1 alkyl group). As used herein the term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation. C_1-C_x includes C_1-C_2 , C_1-C_3 , ..., C_1-C_x , where x is an integer. C_1-C_x refers to the number of carbon atoms in the designated group. In some embodiments, an alkyl comprises one to eight carbon atoms (C_{1-8} alkyl). In some embodiments, an alkyl comprises two to six carbon atoms (C_{2-6} alkyl).

[0092] As used herein, a linker prior to the chemical reaction to link the Ab (antibody or fragment) and D (payload) components of the immunoconjugate is also called a "linker precursor." It will be apparent to the skilled person in the ADC art whether a certain chemical entity disclosed herein is a linker precursor based on its reactive capabilities, or a linker component in the final immunoconjugate product.

[0093] In some embodiments, the linkage between the Ab and D components of the immunoconjugate may be formed through reaction of the components with a homobifunctional linker. Exemplary homobifunctional linkers include, but are not limited to, Lomant's reagent dithiobis (succinimidylpropionate) DSP, 3'3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo DST), ethylene glycobis(succinimidylsuccinate) (EGS), disuccinimidyl glutarate (DSG), N,N'-disuccinimidyl carbonate (DSC), dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS), dimethyl-3,3'-dithiobispropionimidate (DTBP), 1,4-di-3'-(2'-pyridyldithio)propionamido)butane (DPDPB), bismaleimidohexane (BMH), aryl halide-containing compound (DFDNB), such as, *e.g.* 1,5-difluoro-2,4-dinitrobenzene or 1,3-difluoro-4,6-dinitrobenzene, 4,4'-difluoro-3,3'-dinitrophenylsulfone (DFDNPS), bis-[β -(4-azidosalicylamido)ethyl]disulfide (BASED), formaldehyde, glutaraldehyde, 1,4-butanediol diglycidyl ether, adipic acid dihydrazide, carbohydrazide, o-toluidine, 3,3'-dimethylbenzidine, benzidine, α,α' -p-diaminodiphenyl, diiodo-p-xylene sulfonic acid, N,N'-ethylene-bis(iodoacetamide), and N,N'-hexamethylene-bis(iodoacetamide).

[0094] In some embodiments, the linkage between the Ab and D components of the immunoconjugate may be formed through reaction of the components with a heterobifunctional linker. Exemplary heterobifunctional linkers include, but are not limited to, amine-reactive and sulphydryl cross-linkers such as N-succinimidyl 3-(2-pyridyldithio)propionate (sPDP), long-

chain N-succinimidyl 3-(2-pyridyldithio)propionate (LC-sPDP), water-soluble-long-chain N-succinimidyl 3-(2-pyridyldithio) propionate (sulfo-LC-sPDP), succinimidylloxycarbonyl- α -methyl- α -(2-pyridyldithio)toluene (sMPT), sulfosuccinimidyl-6-[α -methyl- α -(2-pyridyldithio)toluamido]hexanoate (sulfo-LC-sMPT), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-sMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBs), m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBs), N-succinimidyl(4-iodoacteyl)aminobenzoate (sIAB), sulfosuccinimidyl(4-iodoacteyl)aminobenzoate (sulfo-sIAB), succinimidyl-4-(p-maleimidophenyl)butyrate (sMPB), sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate (sulfo-sMPB), N-(γ -maleimidobutyryloxy)succinimide ester (GMBs), N-(γ -maleimidobutyryloxy)sulfosuccinimide ester (sulfo-GMBs), succinimidyl 6-((iodoacetyl)amino)hexanoate (sIAX), succinimidyl 6-[6-((iodoacetyl)amino)hexanoyl]amino]hexanoate (sIAXX), succinimidyl 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate (sIAC), succinimidyl 6-(((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino) hexanoate (sIACX), p-nitrophenyl iodoacetate (NPIA), carbonyl-reactive and sulfhydryl-reactive cross-linkers such as 4-(4-N-maleimidophenyl)butyric acid hydrazide (MPBH), 4-(N-maleimidomethyl)cyclohexane-1-carboxyl-hydrazide-8 (M₂C₂H), 3-(2-pyridyldithio)propionyl hydrazide (PDPH), amine-reactive and photoreactive cross-linkers such as N-hydroxysuccinimidyl-4-azidosalicylic acid (NHs-AsA), N-hydroxysulfosuccinimidyl-4-azidosalicylic acid (sulfo-NHs-AsA), sulfosuccinimidyl-(4-azidosalicylamido)hexanoate (sulfo-NHs-LC-AsA), sulfosuccinimidyl-2-(p-azidosalicylamido)ethyl-1,3'-dithiopropionate (sAsD), N-hydroxysuccinimidyl-4-azidobenzoate (HsAB), N-hydroxysulfosuccinimidyl-4-azidobenzoate (sulfo-HsAB), N-succinimidyl-6-(4'-azido-2'-nitrophenylamino)hexanoate (sANPAH), sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino)hexanoate (sulfo-sANPAH), N-5-azido-2-nitrobenzoyloxysuccinimide (ANB-NOs), sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3'-dithiopropionate (sAND), N-succinimidyl-4(4-azidophenyl)1,3'-dithiopropionate (sADP), N-sulfosuccinimidyl(4-azidophenyl)-1,3'-dithiopropionate (sulfo-sADP), sulfosuccinimidyl 4-(p-azidophenyl)butyrate (sulfo-sAPB), sulfosuccinimidyl 2-(7-azido-4-methylcoumarin-3-acetamide)ethyl-1,3'-dithiopropionate (sAED), sulfosuccinimidyl 7-azido-4-methylcoumain-3-acetate (sulfo-sAMCA), p-nitrophenyl diazopyruvate (pNPDP), p-nitrophenyl-2-diazo-3,3-trifluoropropionate (PNP-).

DTP), sulphydryl-reactive and photoreactive cross-linkers such as 1-(p-Azidosalicylamido)-4-(iodoacetamido)butane (AsIB), N-[4-(p-azidosalicylamido)butyl]-3'-(2'-pyridyldithio)propionamide (APDP), benzophenone-4-iodoacetamide, benzophenone-4-maleimide carbonyl-reactive and photoreactive cross-linkers such as p-azidobenzoyl hydrazide (ABH), carboxylate-reactive and photoreactive cross-linkers such as 4-(p-azidosalicylamido)butylamine (AsBA), and arginine-reactive and photoreactive cross-linkers such as p-azidophenyl glyoxal (APG).

[0095] In some embodiments, the linkage between the Ab and D components of the immunoconjugate may be formed through reaction of the components with a linker having a reactive functional group that may comprise, e.g., a nucleophilic group that is reactive to an electrophilic group present on a binding moiety. Exemplary electrophilic groups include carbonyl groups such as aldehydes, ketones, carboxylic acids, esters, amides, enones, acyl halides, and acid anhydrides. In particular embodiments, the reactive functional group is an aldehyde. Exemplary nucleophilic groups include hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.

[0096] In some embodiments, the conjugation of the linker/payload to the antibody or fragment may be formed through reaction with a maleimide group (which may also be referred to as a maleimide spacer). In certain embodiments, the maleimide group is maleimidocaproyl (mc); thus, the linker/payload is conjugated to the antibody or fragment through reaction between a residue on the antibody or fragment and the mc group in the linker precursor. In some embodiments, the maleimide group comprises a maleimidomethyl group, such as succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) or sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), as described herein.

[0097] In some embodiments, the maleimide group is a self-stabilizing maleimide. In some embodiments, the self-stabilizing maleimide utilizes diaminopropionic acid (DPR) to incorporate a basic amino group adjacent to the maleimide to provide intramolecular catalysis of thiosuccinimide ring hydrolysis, thereby decreasing the ability of the maleimide to undergo an elimination reaction through a retro-Michael reaction. In some embodiments, the self-stabilizing maleimide is a maleimide group described in Lyon *et al.*, *Nat. Biotechnol.* 32(10):1059-1062 (2014). In certain embodiments, the linker precursor comprises a self-stabilizing maleimide. In certain embodiments, the linker precursor is a self-stabilizing maleimide.

[0098] In some embodiments, the linker may include a peptide moiety. In some embodiments, the peptide moiety comprises at least 2, 3, 4, 5, 6, 7, 8, or more amino acid residues. In some embodiments, the peptide moiety is cleavable (e.g., either enzymatically or chemically). In some embodiments, the peptide moiety is non-cleavable. In some embodiments, the peptide moiety comprises Val-Cit (valine-citrulline), Gly-Gly-Phe-Gly (SEQ ID NO: 55), Phe-Lys, Val-Lys, Gly-Phe-Lys, Phe-Phe-Lys, Ala-Lys, Val-Arg, Phe-Cit, Phe-Arg, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Ala, Ala-Leu-Ala-Leu (SEQ ID NO: 56), or Gly-Phe-Leu-Gly (SEQ ID NO: 57). In certain embodiments, the linker comprises Val-Cit (VC). In certain embodiments, the linker is Val-Cit (VC).

[0099] In some embodiments, the linker may include a benzoic acid or benzyloxy group, or a derivative thereof. For example, the linker may comprise para-amino-benzoic acid (PABA). In some embodiments, the linker includes a para-amino-benzyloxycarbonyl (PAB) group. In some embodiments, the linker comprises gamma-amino-butyric acid (GABA).

[0100] In some embodiments, the linkage between the Ab and D components of the immunoconjugate may be formed through reaction of the components with a linker comprising a maleimide group, a peptide moiety, and/or a benzoic acid (e.g., PABA) or benzyloxycarbonyl group, in any combination. In certain embodiments, the maleimide group is maleimidocaproyl (mc). In certain embodiments, the peptide group is Val-Cit (VC). In certain embodiments, the linker comprises a Val-Cit-PABA group. In certain embodiments, the conjugation of the linker to the antibody or fragment may be formed from an mc-Val-Cit-PABA group. In certain embodiments, the conjugation of the linker to the antibody or fragment may be formed from an mc-Val-Cit group. In certain embodiments, the linkage between the antibody or fragment and the drug moiety may be formed from an mc-Val-Cit-PAB group.

[0101] In some embodiments, the linker is a self-immolative linker or a self-elimination linker (e.g., a cyclization self-elimination linker). In some embodiments, the linker may be a linker described in U.S. Pat. 9,089,614 or PCT Publication WO 2015/038426.

[0102] In some embodiments, the linker is a dendritic type linker. In certain embodiments, the dendritic type linker comprises a branching, multifunctional linker moiety. The dendritic linker can have two or more branches. In certain embodiments, the dendritic type linker is used to increase the molar ratio of the drug moiety to the antibody or fragment. In certain embodiments, the dendritic type linker comprises PAMAM dendrimers.

[0103] In some embodiments, the linker is a traceless linker or a linker which after cleavage does not leave behind a linker moiety (e.g., an atom or a linker group). Exemplary traceless linkers include, but are not limited to, germanium linkers, silicium linkers, sulfur linkers, selenium linkers, nitrogen linkers, phosphorus linkers, boron linkers, chromium linkers, and phenylhydrazide linkers. In some embodiments, the linker is a traceless aryl-triazene linker as described in Hejesen *et al.*, *Org Biomol Chem* 11(15):2493-2497 (2013). In some embodiments, the linker is a traceless linker described in Blaney *et al.*, *Chem. Rev.* 102:2607-2024 (2002). In some embodiments, a linker is a traceless linker as described in U.S. Pat. 6,821,783.

[0104] In some embodiments, the linker comprises a functional group that exerts steric hindrance at the site of bonding between the linker and a conjugating moiety (e.g., any of ADC-A, B, C, E, F, and H-T described herein). In some embodiments, the steric hindrance is a steric hindrance around a disulfide bond. An exemplary linker that exhibits steric hindrance may be, e.g., a heterobifunctional linker (e.g., as described herein). In some embodiments, a linker that exhibits steric hindrance comprises SMCC and SPDB.

[0105] In some embodiments, the linker is an acid cleavable linker. In some embodiments, the acid cleavable linker comprises a hydrazone linkage, which is susceptible to hydrolytic cleavage. In some embodiments the acid cleavable linker comprises a thiomaleamic acid linker. In some embodiments, the acid cleavable linker is a thiomaleamic acid linker as described in Castaneda *et al.*, *Chem. Commun.* 49:8187-8189 (2013).

[0106] In some embodiments, the linker is a linker described in any of U.S. Pats. 6,884,869, 7,498,298, 8,288,352, 8,609,105, and 8,697,688; any of U.S. Patent Publications 2014/0127239, 2013/028919, 2014/286970, 2013/0309256, 2015/037360; and 2014/0294851; or any of PCT Publications WO 2015/057699, WO 2014/080251, WO 2014/197854, WO 2014/145090, and WO 2014/177042.

[0107] Suitable linkers for use in the immunoconjugates of the invention may include, e.g., linkers that are intracellularly cleavable with high extracellular stability. In certain embodiments, the linker comprises a functional group that allows for attachment of the linker to any of the antibodies or fragments described herein (e.g., a maleimide derivative). In certain embodiments, the linker (or precursor) comprises 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (VC), alanine-phenylalanine (AP), p-aminobenzylloxycarbonyl (PAB), N-succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl)

cyclohexane-1-carboxylate (SMCC), N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB), 6-maleimidocaproyl-valine-citrulline (MC-VC), 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB), N-succinimidyl-1-carboxylate-valine-citrulline-p-aminobenzylloxycarbonyl (SC-VC-PAB), 6-maleimidocaproyl-polyethylene glycol-valine-citrulline (MC-PEG4-VC), 6-maleimidocaproyl-polyethylene glycol-valine-alanine (MC-PEG4-VA), or MC-PEG8-VC-PAB. In some embodiments, the linker prior to conjugation reaction (aka linker precursor) is 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB), or N-succinimidyl-1-carboxylate-valine-citrulline-p-aminobenzylloxycarbonyl (SC-VC-PAB). In some embodiments, the linker is a 6-maleimidocaproyl (MC) linker. In some embodiments, the linker is a maleimidopropanoyl (MP) linker. In some embodiments, the linker is a valine-citrulline (VC) linker. In some embodiments, the linker is an alanine-phenylalanine (AP) linker. In some embodiments, the linker is a *p*-aminobenzylloxycarbonyl (PAB) linker. In some embodiments, the linker is an N-succinimidyl 4-(2-pyridylthio) pentanoate (SPP) linker. In some embodiments, the linker is an N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker. In some embodiments, the linker is an N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB) linker. In some embodiments, the linker is a 6-maleimidocaproyl-valine-citrulline (MC-VC) linker. In some embodiments, the linker is a 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB) linker. In some embodiments, the linker is an N-succinimidyl-1-carboxylate-valine-citrulline-p-aminobenzylloxycarbonyl (SC-VC-PAB) linker. In some embodiments, the linker further comprises a spacer between the linker and the cytotoxic moiety. In some embodiments, the spacer is a heteroatom. In some embodiments, the spacer is an alkyl chain. In some embodiments, the spacer is an alkyl chain comprising one or more heteroatoms. In some embodiments, the spacer is a carbonyl group. In some embodiments, the linker is a homobifunctional linker or a heterobifunctional linker.

[0108] In some embodiments, the linkers described herein may be attached to the antibodies or antigen-binding fragments described herein at a naturally occurring amino acid residue such as a lysine or a reduced cysteine. In some embodiments, the linkers can be attached to a non-natural amino acid (*e.g.*, azidophenylalanine, *p*-acetylphenylalanine, or *p*-azidomethylphenylalanine) by way of an alkyne/azide “click” reaction, carbonyl condensations, Michael-type additions, and Mizoroki-Heck substitutions. Additional linker sites can be added genetically and may comprise a polypeptide motif that allows enzymatic addition of the linker. Such polypeptide motifs can

comprise, *e.g.*, a glutamine tag (*e.g.*, LLQGA (SEQ ID NO: 58)), an aldehyde tag (*e.g.*, CxPxR, where x is any amino acid), a sortase motif (*e.g.*, LPxTG (SEQ ID NO: 59, where x is any amino acid), NPQTN (SEQ ID NO: 60)), or a BirA tag (*e.g.*, GFEIDKVVYDLDA (SEQ ID NO: 61)). Attaching linkers to a glutamine tag may be achieved by using a bacterial transglutaminase. Attaching linkers to an aldehyde tag is achieved by using formylglycine-generating enzyme (FGE), which oxidizes the cysteine residue of the consensus sequence, creating an aldehyde; this aldehyde can be reacted with an aminoxy group on a linker to form a stable oxime. Attaching linkers to a sortase motif can be achieved by using a bacterial transpeptidase that recognizes a C-terminal LPxTG sequence (SEQ ID NO: 59) or NPQTN sequence (SEQ ID NO: 60), cleaves the TG or TN bond, and facilitates—via a thioacyl enzyme-threonine intermediate—the nucleophilic attack of the incoming protein alpha amine on the threonine. The attacking residue can be a glycine dimer or trimer of a linker or added to a linker. Attaching linkers to a sortase motif or a BirA tag can be achieved by using a biotin ligase. In certain embodiments, the linker is not attached at a lysine residue. In certain embodiments, the linker is only attached to a cysteine residue. In certain embodiments, the cysteine residue has been engineered into the antibody by converting one or more non-cysteine residues on the light chain and/or heavy chain to a cysteine. In certain embodiments, cysteine conversion does not interfere with antigen binding. In certain embodiments, selenocysteine is incorporated into the antibody by genetic modification. *See, e.g.*, Sochaj *et al.*, *Biotechnology Advances* 33:775-784 (2015).

[0109] In some embodiments, the linker is conjugated to the anti-ROR1 antibody or fragment by a chemical ligation process. In some embodiments, the linker is conjugated to the anti-ROR1 antibody or fragment by a native ligation. In some embodiments, the conjugation is as described in Dawson *et al.*, *Science* 266:776-779 (1994); Dawson *et al.*, *J. Am. Chem. Soc.* 119:4325-4329 (1997); Hackeng *et al.*, *PNAS* 96:10068-10073 (1999); or Wu *et al.*, *Angew. Chem. Int. Ed.* 45:4116-4125 (2006). In some embodiments, the conjugation is as described in U.S. Pat. 8,936,910. In some embodiments, the linker is conjugated to the anti-ROR1 antibody or fragment either site-specifically or non-specifically via native ligation chemistry.

[0110] In some embodiments, the linker is conjugated to the anti-ROR1 antibody or antigen-binding fragment by a site-directed method utilizing a “traceless” coupling technology (Philochem). In some embodiments, the “traceless” coupling technology utilizes an N-terminal 1,2-aminothiol group on the binding moiety which is then conjugated with the antibody or

fragment thereof containing an aldehyde group. *See, e.g., Casi et al., JACS 134(13):5887-5892 (2012).* In some embodiments, the linker is conjugated to the anti-ROR1 antibody or fragment by a site-directed method utilizing an unnatural amino acid incorporated into the binding moiety. In some embodiments, the unnatural amino acid comprises p-acetylphenylalanine (pAcPhe). In some embodiments, the keto group of pAcPhe is selectively coupled to an alkoxy-amine derivatized conjugating moiety to form an oxime bond. *See, e.g., Axup et al., PNAS 109(40):16101-16106 (2012).*


[0111] In some embodiments, the linker is conjugated to the anti-ROR1 antibody or antigen-binding fragment by a sis conjugated to the anti-ROR1 antibody by a site-directed method utilizing an enzyme-catalyzed process. In some embodiments, the site-directed method utilizes SMARTag™ technology (Redwood). In some embodiments, the SMARTag™ technology comprises generation of a formylglycine (FGly) residue from cysteine by formylglycine-generating enzyme (FGE) through an oxidation process under the presence of an aldehyde tag and the subsequent conjugation of FGly to an alkylhydrazine-functionalized amino acid molecule via hydrazino-Pictet-Spengler (HIPS) ligation. *See, e.g., Wu et al., PNAS 106(9):3000-3005 (2009) and Agarwal et al., PNAS 110(1):46-51 (2013)).*

[0112] In some embodiments, the enzyme-catalyzed process comprises microbial transglutaminase (mTG). In certain embodiments, the linker is conjugated to the anti-ROR1 antibody or fragment by utilizing a microbial transglutaminase catalyzed process. In some embodiments, mTG catalyzes the formation of a covalent bond between the amide side chain of a glutamine within the recognition sequence and a primary amine of a functionalized amino acid molecule. In some embodiments, mTG is produced from *Streptomyces mobarensis*. *See, e.g., Strop et al., Chemistry and Biology 20(2):161-167 (2013).* In some embodiments, the linker is conjugated to the anti-ROR1 antibody by a carbohydrate-based chemical reaction. In the strategy of carbohydrate-based conjugation, the first step is usually to introduce new bioorthogonal functionalities to facilitate conjugation of the antibody to a drug. Strategies that can be used to introduce bioorthogonal functionalities onto the carbohydrate moiety for bioconjugation (glyco-conjugation) include but are not limited to chemical oxidation of glycans; enzymatic and chemo-enzymatic modification of glycans; and metabolic engineering of the carbohydrate moiety. Chemical approaches may use sodium periodate (NaIO4) to oxidize *cis*-glycol groups of *e.g.*, galactose or sialic acid to generate aldehydes, which then can be coupled

with hydrazide- or primary amine functionalized molecules to create acid-labeled hydrazones or with aminoxy groups to form oximes. Enzymatic and chemo-enzymatic approaches treat the sugar residue with neuraminidase (Neu) and galactose oxidase (Gal Oxi) to formate aldehyde functionalities. Continuous treatment of the antibody with β 1,4-galactosyltransferase (Gal T)/ α 2,6-sialyltransferase (Sial T) can yield homogeneously sialylated antibodies. The resulting antibodies then can be selectively oxidized to the corresponding aldehyde functionalities, and if sialic acid derivatives are used, these antibodies can be used as selective bioorthogonal handles. Similarity, the antibody may be treated with β -galactosidase (Gal) and a mutant Gal T to mediate the attachment of bioorthogonal azide- or keto-galactoses to generate homogeneous G2 glycan patterns which possess non-natural functionalities. Another method makes non-canonical thio-fucose derivatives that can be incorporated into the glycan of antibodies by feeding the cells with the bioorthogonal sugar generating expressed antibodies that display thiol functionalities.

[0113] Linkers can be conjugated to the anti-ROR1 antibodies and antigen-binding fragments of the current disclosure in multiple ways. Generally a linker and a cytotoxic moiety are synthesized and conjugated before attachment to an antibody. One method of attaching a linker-drug conjugate to an antibody involves reduction of solvent-exposed disulfides with dithiothreitol (DTT) or tris (2-carboxyethyl)phosphine (TCEP), followed by modification of the resulting thiols with maleimide-containing linker-drug moieties (e.g., 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB)). A native antibody contains 4 inter-chain disulfide bonds and 12 intra-chain disulfide bonds, as well as unpaired cysteines. Thus, antibodies modified in this way can comprise greater than one linker-drug moiety per antibody. In certain embodiments, the immunoconjugates described herein comprise at least 1, 2, 3, 4, 5, 6, 7, or 8, 9, or 10 linker/drug moieties. In certain embodiments, the immunoconjugates described herein comprise 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, linker/drug moieties, or 1 linker/drug moiety. In cases where the linker is branched and can each attach to multiple drug moieties, the ratio of the drug moiety to the antibody will be higher than using an unbranched linker.

[0114] In some embodiments, the linker is of the formula:




wherein

X is C₂₋₈ alkyl;

Y is -(CH₂CH₂O)_qCH₂CH₂-;

W is an amino acid unit;



n is 0 or 1;

p is 0 or 1;

q is an integer from 0 to 12;


u is an integer from 0 to 5; and

v is 0 or 1; wherein ** indicates the point of attachment to the drug moiety (D); and

* indicates the point of attachment to the antibody or fragment (Ab).

[0115] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 1 and X is -(CH₂)₂- . In some embodiments, p is 1 and X is -(CH₂)₃- . In some embodiments, p is 1 and X is -(CH₂)₄- . In some embodiments, p is 1 and X is -(CH₂)₅- . In some embodiments, p is 1 and X is -(CH₂)₆- . In some embodiments, q is an integer from 1 to 12. In some embodiments, q is an integer from 4 to 12. In some embodiments, q is an integer from 4 to 8. In some embodiments, q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In some embodiments, W is an amino acid unit comprising naturally occurring amino acid residues, as well as minor amino acids and non-naturally occurring amino acid analogs. In some embodiments, W is selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, lysine protected or not with acetyl or formyl, arginine, arginine protected or not with tosyl or nitro groups, histidine, ornithine, ornithine protected with acetyl or formyl, and citrulline. In some embodiments, u is 1, 2, 3, 4, or 5. In some embodiments, u is 0. In some embodiments, v is 0. In some embodiments, v is 1.

[0116] In some embodiments, the linker is of the formula:




wherein

X is C₂₋₈ alkyl;

Y is -(CH₂CH₂O)_qCH₂CH₂-;

W is an amino acid unit;



Z is

n is 0 or 1;

p is 0 or 1;

q is an integer from 0 to 12;

u is an integer from 0 to 5; and

v is 0 or 1; wherein ** indicates the point of attachment to the drug moiety (D); and

* indicates the point of attachment to the antibody or fragment (Ab).

[0117] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, X is -(CH₂)₂- . In some embodiments, X is -(CH₂)₃- . In some embodiments, X is -(CH₂)₄- . In some embodiments, X is -(CH₂)₅- . In some embodiments, X is -(CH₂)₆- . In some embodiments, W is an amino acid unit comprising naturally occurring amino acid residues, as well as minor amino acids and non-naturally occurring amino acid analogs. In some embodiments, W is selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, lysine protected or not with acetyl or formyl, arginine, arginine protected or not with tosyl or nitro groups, histidine, ornithine, ornithine protected with acetyl or formyl, and citrulline. In some embodiments, w is 1, 2, 3, 4, or 5. In some embodiments, w is 0. In some embodiments, v is 0. In some embodiments, v is 1.

[0118] In some embodiments, the immunoconjugate optionally further comprises an endosomolytic moiety. In some cases, the endosomolytic moiety is a cellular compartmental release component, such as a compound capable of releasing from any of the cellular compartments known in the art, such as the endosome, lysosome, endoplasmic reticulum (ER), Golgi apparatus, microtubule, peroxisome, or other vesicular bodies with the cell. In some cases, the endosomolytic moiety comprises an endosomolytic polypeptide, an endosomolytic polymer, an endosomolytic lipid, or an endosomolytic small molecule. In some cases, the endosomolytic moiety comprises an endosomolytic polypeptide. In other cases, the endosomolytic moiety


comprises an endosomolytic polymer. In some embodiments, an endosomolytic polymer described herein is a pH-responsive endosomolytic polymer. A pH-responsive polymer comprises a polymer that increases in size (swells) or collapses depending on the pH of the environment. Polyacrylic acid and chitosan are examples of pH-responsive polymers. In some embodiments, an endosomolytic moiety described herein is a membrane-disruptive polymer. In some cases, the membrane-disruptive polymer comprises a cationic polymer, a neutral or hydrophobic polymer, or an anionic polymer. In some embodiments, the membrane-disruptive polymer is a hydrophilic polymer. In some embodiments, p(alkylacrylic acids) include poly(propylacrylic acid) (polyPAA), poly(methacrylic acid) (PMAA), poly(ethylacrylic acid) (PEAA), and poly(propyl acrylic acid) (PPAA). In some embodiments, a p(alkylacrylic acid) described herein may be a p(alkylacrylic acid) described in Jones, et al., *Biochemistry Journal* 372:65-75 (2003). In some embodiments, a pH-responsive membrane-disruptive polymer comprises p(butyl acrylate-co-methacrylic acid). *See, e.g.*, Bulmus, et al., *Journal of Controlled Release* 93:105-120 (2003); and Yessine et al., *Biochimica et Biophysica Acta* 1613:28-38 (2003). In some embodiments, a pH-responsive membrane-disruptive polymer comprises p(styrene-alt-maleic anhydride). *See, e.g.*, Henry et al., *Biomacromolecules* 7:2407-2414 (2006). In some embodiments, a pH-responsive membrane-disruptive polymer comprises a pyridyldisulfide acrylate (PDSA) polymer such as poly(MAA-co-PDSA), poly(EAA-co-PDSA), poly(PAA-co-PDSA), poly(MAA-co-BA-co-PDSA), poly(EAA-co-BA-co-PDSA), or poly(PAA-co-BA-co-PDSA) polymer. *See, e.g.*, El-Sayed et al., *Journal of Controlled Release* 104:417-427 (2005); or Flanary et al., *Bioconjugate Chem.* 20:241-248 (2009). In some embodiments, the endosomolytic moiety is a lipid (*e.g.*, a fusogenic lipid). In some embodiments, a molecule of Formula (I): A-X-B-Y-C is further conjugated with an endosomolytic lipid (*e.g.*, fusogenic lipid). Exemplary fusogenic lipids include 1,2-dileoyl-sn-3-phosphoethanolamine (DOPE), phosphatidylethanolamine (POPE), palmitoyloleoylphosphatidylcholine (POPC), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol (Di-Lin), N-methyl(2,2-di((9Z,12Z)-octadeca-9,12-dienyl)-1,3-dioxolan-4-yl)methanamine (DLin-k-DMA) and N-methyl-2-(2,2-di((9Z,12Z)-octadeca-9,12-dienyl)-1,3-dioxolan-4-yl)ethanamine (XTC). Exemplary small molecules suitable as endosomolytic moieties include, but are not limited to, quinine, chloroquine, hydroxychloroquines, amodiaquins (carnoquines), amopyroquines, primaquines, mefloquines, nivaquines, halofantrines, quinone imines, or any

combination thereof.


[0119] The term “linkage,” as used herein, refer to a bond or chemical moiety formed from a chemical reaction between the functional group of one molecular entity and another molecule entity. Such bonds may include, but are not limited to, covalent and non-covalent bonds, while such chemical moieties may include, but are not limited to, esters, carbonates, carbamates, imines phosphate esters, hydrazones, acetals, orthoesters, peptide linkages, and oligonucleotide linkages. Hydrolytically stable linkage means that the linkage is substantially stable in water and does not react with water at useful pH values, including but not limited to under physiological conditions, for an extended period of time, perhaps even indefinitely. Hydrolytically unstable or degradable linkage means that the linkage is degradable in water or in aqueous solutions, including, for example, blood. Enzymatically unstable or degradable linkage means that the linkage can be degraded by one or more enzymes. By way of example only, PEG and related polymers may include degradable linkages in the polymer backbone or in the linker group between the polymer backbone and one or more of the terminal functional groups of the polymer molecule. Such degradable linkages include, but are not limited to, ester linkages formed by the reaction of PEG carboxylic acids or activated PEG carboxylic acids with alcohol groups on a biologically active agent, wherein such ester groups generally hydrolyze under physiological conditions to release the biologically active agent. Other hydrolytically degradable linkages include but are not limited to carbonate linkages; imine linkages resulted from reaction of an amine and an aldehyde; phosphate ester linkages formed by reacting an alcohol with a phosphate group; hydrazone linkages which are reaction product of a hydrazide and an aldehyde; acetal linkages that are the reaction product of an aldehyde and an alcohol; orthoester linkages that are the reaction product of a formate and an alcohol; peptide linkages formed by an amine group, including but not limited to, at an end of a polymer such as PEG, and a carboxyl group of a peptide; and oligonucleotide linkages formed by a phosphoramidite group, including but not limited to, at the end of a polymer, and a 5' hydroxyl group of an oligonucleotide.

1.7 Exemplary ROR1 Immunoconjugates


[0120] In some embodiments, the ADC of the present invention has the structure:




wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is monomethyl auristatin E (MMAE). In some embodiments, the ADC has the structure:



wherein Ab is an antibody. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is mertansine (also called DM1). In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0121] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is mertansine. In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0122] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is a dimeric pyrrolobenzodiazepine (PBD). In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0123] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is mertansine. In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0124] In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is MMAE. In some embodiments, the ADC has the structure:



wherein Ab is an antibody. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is mertansine. In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0125] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is a duocarmycin. In some embodiments, the ADC has the structure:




wherein Ab is an antibody.


[0126] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is an amanitin, such as α -amanitin. In some embodiments, the ADC has the structure:




wherein Ab is an antibody.

[0127] In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:




wherein Ab is an antibody and D is PNU159682. In some embodiments, the ADC has the

structure:




wherein Ab is an antibody.


[0128] In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is a drug moiety. In some embodiments, the ADC has the structure:



wherein Ab is an antibody and D is PBD. In some embodiments, the ADC has the structure:



wherein Ab is an antibody.

[0129] Exemplary immunoconjugates of the present invention are shown in the table below:

Table 2 Exemplary Immunoconjugates

Construct ID	mAb	Conjugation	Linker Components			Payload
ADC-A	Ab1	MAL (mc)		VC	PAB	MMAE
ADC-E	Ab1	SC		VC	PAB	MMAE
ADC-B	Ab1	SMCC				DM1
ADC-C	Ab1	MAL		VC	PAB	DM1
ADC-F	Ab1	SC		VC	PAB	DM1
ADC-H	Ab1	MAL		VC	PAB	azonafide
ADC-I	Ab1	MAL (mc)			C6	α -amanitin
ADC-J	Ab1	MAL	PEG4	VC	PAB	Duocarmycin TM
ADC-K	Ab1	MAL	PEG4	VA		PBD
ADC-L	Ab1	MAL	DPR	VC	PAB	MMAE
ADC-M	Ab1	MAL	Phe-C4	VC	PAB	MMAE
ADC-N	Ab1	MAL	PEG4	VC	PAB	DMEA
ADC-O	Ab1	MAL	C2-Gly3		EDA	PNU-159682
ADC-P	Ab1	MAL	Phe-C4	VC	PAB	DMEA
ADC-Q [#]	Ab1*	DBCO	(PEG2	VC	PAB	MMAE)2
ADC-R	Ab1*	DBCO	PEG4	VC	PAB	DMEA
ADC-S	D10	MAL		VC	PAB	MMAE
ADC-T	4A5	MAL		VC	PAB	MMAE




[#]Branched linker-payload.

*Site-specific conjugation using microbial transglutaminase.


[0130] In the above table, the abbreviations are used as follows: maleimide chemistry (MAL); maleimidocaproyl (mc); succinimide chemistry (SC); succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC); dibenzylcyclooctyne (DBCO); diaminopropionic acid (DPR); benzyl (Phe); polyethylene glycol (PEG); valine-citrulline (VC); valine-alanine (VA); para-amino-benzylloxycarbonyl (self immolative moiety) (PAB); dimethylethylamine (DMEA); ethylene diamine (EDA); monomethyl auristatin E (MMAE); N2'-Deacetyl-N2' -(3-mercaptop1-oxopropyl)maytansine (DM1); and pyrrolobenzodiazepine (PBD), [1,2]Diazepino[3,4-e]indole. For ADC-Q and ADC-R, site-specific conjugation of the payload may be made by using microbial transglutaminase.

[0131] The chemical structures of immunoconjugates in Table 2 are shown in the table below:


Table 3 Chemical Structures of Exemplary Immunoconjugates

ADC	Structure
A	
E	
B	


C






F






H



I	
J	
K	
L	
M	

	
N	
O	
P	
Q	


	
R	
S	




2. Synthesis of Immunoconjugates

[0132] In some embodiments, the immunoconjugates described herein are prepared as shown in Schemes 1 and 2. MMAE is prepared in 12 steps starting from L-isoleucine as outlined in Scheme 1. As shown in Scheme 2, MMAE prepared in Scheme 1 is coupled with the 4-nitrophenyl carbonate of a FMOC protected valine-citrulline-p-aminobenzylloxycarbonyl (VC-PAB) linker. Deprotection of the FMOC group gives the VC-PAB-MMAE linker-MMAE construct.

Scheme 1



Scheme 2



[0133] Exemplary synthesis methods for the ADCs shown in Table 3 are illustrated in

Example 1 below. In ADC-A, C, H through P, S and T, the antibody is covalently bonded to the linker/payload moiety via cysteine residues. In ADC-B, E, and F, the antibody is covalently bonded to the linker/payload moiety (or to the payload for B) via lysine residues. In ADC-Q and R, the antibody is covalently bonded to the linker/payload via glutamine residues.

3. Immunoconjugate Therapy

[0134] The immunoconjugates described herein are useful for treating a variety of cancers. ROR1 has been shown to express across many types of tumors, including lymphomas and solid tumors. High proportions of human cancers express ROR1. For example, Zhang et al. showed that 54% ovarian cancers, 57% colon cancers, 77% lung cancers, 90% lymphomas, 89% skin cancers, 83% pancreatic cancers, 73% testicular cancers, 43% bladder cancers, 96% uterus cancers, 90% prostate cancers, and 83% adrenal cancers that they examined had moderate-to-strong staining with the anti-ROR1 antibody 4A5 (Zhang et al., *Am J Pathol.* 181(6):1903-10 (2012)). Daneshmanesh et al. similarly found near universal expression of ROR1 in CLL and hairy cell leukemia (HCL) and varying degrees of expression in other lymphoid cancers such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL)/marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic myeloid leukemia (CML), acute myeloid lymphoma (AML), and myeloma (Daneshmanesh et al., *Leuk Lymphoma* 54(4):843-50 (2013)). Our own studies similarly have shown that substantial proportions of patients with hepatocellular cancers (HCC) or non-small-cell lung cancer (NSCLC) are ROR1-positive. This broad tumor expression pattern of ROR1 renders the immunoconjugates of the present invention useful in treating many hematological cancers and solid tumors, such as those aforementioned. Further, it has been shown that ROR1 expression increases in aggressive cancers and correlates with poor prognosis; thus, immunoconjugates of the present invention are particularly well suited to treat aggressive or advanced cancers. In some embodiments, the immunoconjugates of the invention lead to partial or complete tumor regression. In particular embodiments, the partial or complete tumor regression may be sustained beyond the final dose of immunoconjugate treatment.

[0135] The ROR1 immunoconjugates of the invention, such as those made with an antibody that binds to a ROR1 epitope set forth in SEQ ID NO:1 or 2 (e.g., Ab1, Ab2, Ab3, or Ab4), are effective in treating cancers such as solid tumors that are heterogeneous in ROR1 expression. Tumors having as little as 20% of their cells expressing ROR1 can be treated effectively by the

ROR1 immunoconjugates; for example, the tumors may have 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, or 70% or more of their cells expressing ROR1. Without wishing to be bound by theory, it is contemplated that the ROR1 immunoconjugates of the invention may cause cell death in ROR1-negative tumor cells through bystander toxicity effect (*i.e.*, the payload released from a dead tumor cell causes cytotoxicity to a neighboring tumor cell), or by enhancing the anti-tumor immunity of the immune system, or both.

[0136] “Treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a biological disorder and/or at least one of its attendant symptoms. As used herein, to “alleviate” a disease, disorder or condition means reducing the severity and/or occurrence frequency of the symptoms of the disease, disorder, or condition. Further, references herein to “treatment” include references to curative, palliative and prophylactic treatment. Treatment of cancer encompasses inhibiting cancer growth (including causing partial or complete cancer regression), inhibiting cancer progression or metastasis, preventing cancer recurrence or residual disease, and/or prolonging the patient’s survival.

[0137] In some embodiments, the cancer treatable by the immunoconjugates described herein is a ROR1-expressing cancer. The ROR1-expressing cancer can be determined by any suitable method of determining gene or protein expression, for example, by histology, flow cytometry, RT-PCR, or RNA-Seq. The cancer cells used for the determination may be obtained through tumor biopsy or through collection of circulating tumor cells. In certain embodiments, if an antibody-based assay such as flow cytometry or immunohistochemistry is used, ROR1-expressing cancers are any cancers with cells that show anti-ROR1 antibody reactivity greater than that of an isotype control antibody. In certain embodiments, if an RNA-based assay is used, ROR1-expressing cancers are those that show an elevated level of ROR1 RNA compared to a negative control cell or cancer that does not express ROR1.

[0138] In certain embodiments, the antibodies and immunoconjugates are for use in treating hematological malignancies. In certain embodiments, the antibodies and immunoconjugates are for use in treating solid tumors. The cancer to be treated may be selected from, *e.g.*, lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, marginal cell B-cell lymphoma, Burkitt's lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, a non-Hodgkin lymphoma that has undergone Richter's transformation, chronic lymphocytic leukemia, T cell leukemia, osteosarcoma, renal cell carcinoma, hepatocellular carcinoma, colon cancer, colorectal

cancer, breast cancer, epithelial squamous cell cancer, melanoma, myeloma, multiple myeloma, stomach cancer, brain cancer, lung cancer, non-small cell lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, and head and neck cancer. In certain embodiments, the cancer to be treated can be a cancer that is refractory to other therapeutics (for example, triple negative breast cancer).

[0139] In certain embodiments, the methods for treating cancer described herein comprise treatment with an immunoconjugate of the invention and treatment with an additional therapeutic agent or biologically active molecule. Examples of biologically active molecules include, but are not limited to, peptides, proteins, enzymes, small molecule drugs, prodrugs, carbohydrates, imaging agents, lipids, nucleosides, radionuclides, oligonucleotides, toxins, cells, antibiotics, fungicides, anti-viral agents, anti-inflammatory agents, anti-tumor agents, cardiovascular agents, anti-anxiety agents, hormones, growth factors, steroid agents, microbially derived toxins, and the like. Further examples of biologically active molecules are those listed above under the heading “Cytotoxic drug moieties.”

[0140] In certain embodiments, the immunoconjugate and the additional therapeutic agent or biologically active molecule are administered at the same time, *e.g.*, in the same formulation. In certain embodiments, they are administered separately, on the same or different dosing schedules. In some embodiments, the additional therapeutic agent is a vascular endothelial growth factor (VEGF) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, an inhibitor of the mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase (PI3K) inhibitor, a Janus kinase/signal transducers and activators of transcription (Jak/STAT) signaling inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a spleen tyrosine kinase (SYK) inhibitor, a microtubule inhibitor, an epithelial growth factor receptor (EGFR) inhibitor, a poly ADP ribose polymerase (PARP) inhibitor, an anaplastic lymphoma kinase (ALK) inhibitor, a DNA-repair inhibitor, a DNA cross-linker, a nucleoside analog, or an immunomodulatory agent.

[0141] In some embodiments, the additional therapeutic agent is

- a) an antibody such as rituximab (anti-CD20) or bevacizumab (anti-VEGF);
- b) a Bruton's tyrosine kinase inhibitor such as acalabrutinib or ibrutinib;
- c) an mTOR inhibitor such as sapanisertib, everolimus or BEZ235;
- d) a PI3K inhibitor such as idelalisib or buparlisib;
- e) a Jak/STAT signaling inhibitor such as ruxolitinib;

- f) a Bcl-2 inhibitor such as ABT-199/venetoclax, Bcl-2i-1, or Bcl-2i-2;
- g) a SYK inhibitor such as fostamatinib;
- h) a microtubule inhibitor such as paclitaxel or vincristine;
- i) an EGFR inhibitor such as erlotinib;
- j) a PARP inhibitor such as olaparib;
- k) an ALK inhibitor such as crizotinib;
- l) a DNA-repair inhibitor such as carboplatin;
- m) a DNA cross-linker such as oxaliplatin/cisplatin;
- n) a nucleoside analog such as gemcitabine; or
- o) an immunomodulatory drug (IMiD) such as lenalidomide or pomalidomide.

In a specific embodiment, the additional therapeutic agent is venetoclax.

[0142] In certain embodiments, an immunoconjugate of the invention and an additional therapeutic agent or biologically active molecule are used in combination to treat CLL, MCL, or a non-Hodgkin lymphoma that has undergone Richter's transformation. In particular embodiments, the additional therapeutic agent or biologically active molecule is, *e.g.*, ibrutinib, acalabrutinib, venetoclax, Bcl-2i-1, Bcl-2i-2, everolimus, sapanisertib, or idelalisib.

[0143] Additional examples of the additional therapeutic agent are pacritinib, buparlisib, BEZ235, ruxolitinib, fostamatinib, rituximab, lenalidomide, pomalidomide, paclitaxel, vincristine, erlotinib, crizotinib, carboplatin, oxaliplatin/cisplatin, bevacizumab, and gemcitabine.

[0144] In certain embodiments, an immunoconjugate of the invention is used in combination with an immune checkpoint modulator that enhances the patient's immune system. For example, the conjugate is used with an immune checkpoint inhibitor such as an antibody or antibody derivative, an antisense oligonucleotide, a small interfering RNA, an aptamer, or a peptide, targeting programmed death-ligand 1 (PD-L1, also known as B7-H1, CD274), programmed death 1 (PD-1), CTLA-4, PD-L2 (B7-DC, CD273), LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS (inducible T cell costimulator), KIR, LAIR1, LIGHT, MARCO (macrophage receptor with collagenous structure), PS (phosphatidylserine), OX-40, SLAM, TIGHT, VISTA, VTCN1, or any combination thereof.

[0145] It is understood that the immunoconjugates of the invention may be used in a method of treatment as described herein, may be for use in a treatment as described herein, and/or may be

for use in the manufacture of a medicament for a treatment as described herein. The invention also provides kits and articles of manufacture comprising the immunoconjugates of the invention as described herein.

4. Pharmaceutical Compositions

[0146] In some embodiments, the immunoconjugate of the invention may be comprised in a pharmaceutical composition further comprising one or more pharmaceutically acceptable excipients, carriers, and diluents. For example, the antibodies and immunoconjugates of the invention may be administered suspended in a sterile solution (e.g., a solution comprising 0.9% NaCl). In certain embodiments, the solution further comprises one or more of the following: buffers (e.g., acetate, citrate, histidine, succinate, phosphate, bicarbonate and hydroxymethylaminomethane (Tris) buffers); surfactants (e.g., polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), and poloxamer 188); polyols/disaccharide/polysaccharides (e.g., glucose, dextrose, mannose, mannitol, sorbitol, sucrose, trehalose, and dextran 40); amino acids (e.g., glycine and arginine); antioxidants (e.g., ascorbic acid and methionine); and/or chelating agents (e.g., EDTA and EGTA). Any combination of these excipients is also contemplated. In certain embodiments, the immunoconjugates of the invention are shipped/stored lyophilized and reconstituted before administration. In certain embodiments, lyophilized antibody or immunoconjugate formulations comprise a bulking agent such as mannitol, sorbitol, sucrose, trehalose, and/or dextran 40. The lyophilized formulation can be contained in a vial, such as a glass vial. The immunoconjugates, when formulated, whether reconstituted or not, can be buffered at a certain pH, e.g., less than 7.0 (such as a pH between 4.5 and 6.5, between 4.5 and 6.0, between 4.5 and 5.5, between 4.5 and 5.0, or between 5.0 and 6.0).

[0147] The immunoconjugates of the invention, as used herein, encompass pharmaceutically acceptable salts or esters of the conjugates. The pharmaceutically acceptable salts may be formed when an acidic proton present in the polypeptides either is replaced by a metal ion, by way of example an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. In addition, the salt forms of the immunoconjugates can be prepared using salts of the starting materials or intermediates. The immunoconjugates described herein may be prepared as pharmaceutically acceptable acid addition salts (which are a type of a pharmaceutically acceptable salt) by reacting the free base form of the polypeptides described

herein with a pharmaceutically acceptable inorganic or organic acid. Alternatively, the immunoconjugates described herein may be prepared as pharmaceutically acceptable base addition salts (which are a type of a pharmaceutically acceptable salt) by reacting the free acid form of amino acids in polypeptides described herein with a pharmaceutically acceptable inorganic or organic base.

[0148] Pharmaceutically acceptable salts include, but are not limited to: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; and (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, *e.g.*, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. The corresponding counterions of the pharmaceutically acceptable salts may be analyzed and identified using various methods including, but not limited to, ion exchange chromatography, ion chromatography, capillary electrophoresis, inductively coupled plasma, atomic absorption spectroscopy, mass spectrometry, or any combination thereof.

[0149] In some embodiments, a pharmaceutical composition of the invention includes multiparticulate formulations. In some embodiments, the pharmaceutical composition includes nanoparticle formulations. In some embodiments, nanoparticles comprise cMAP, cyclodextrin, and/or lipids. In some cases, nanoparticles comprise solid lipid nanoparticles, polymeric nanoparticles, self-emulsifying nanoparticles, liposomes, microemulsions, and/or micellar solutions. Additional exemplary nanoparticles include, but are not limited to, paramagnetic

nanoparticles, superparamagnetic nanoparticles, metal nanoparticles, fullerene-like materials, inorganic nanotubes, dendrimers (such as with covalently attached metal chelates), nanofibers, nanohorns, nano-onions, nanorods, nanoropes and/or quantum dots. In some embodiments, a nanoparticle is a metal nanoparticle, *e.g.*, a nanoparticle of scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, yttrium, zirconium, niobium, molybdenum, ruthenium, rhodium, palladium, silver, cadmium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, platinum, gold, gadolinium, aluminum, gallium, indium, tin, thallium, lead, bismuth, magnesium, calcium, strontium, barium, lithium, sodium, potassium, boron, silicon, phosphorus, germanium, arsenic, antimony, and combinations, alloys or oxides thereof.

[0150] Any method for administering immunoconjugates accepted in the art may be employed. The pharmaceutical compositions of the invention are typically suitable for parenteral administration. As used herein, “parenteral administration” of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue, thus generally resulting in the direct administration into the blood stream, into muscle, or into an internal organ. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intraperitoneal, intramuscular, intrasternal, intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intracranial, intratumoral, and intrasynovial injection or infusions; and kidney dialytic infusion techniques. Regional perfusion is also contemplated. Particular embodiments include the intravenous and subcutaneous routes.

5. Articles of Manufacture and Kits


[0151] The present invention also provides articles of manufacture, *e.g.*, kits, comprising a container (*e.g.*, a single-use or multi-use container) containing a pharmaceutical composition of the present immunoconjugate, optionally an additional biologically active molecule (*e.g.*, another therapeutic agent), and instructions for use. The immunoconjugate and additional biologically active molecule can be packaged separately in suitable packing such as a vial or ampule made from non-reactive glass or plastic. In certain embodiments, the vial or ampule

holds lyophilized powder comprising the immunoconjugate or additional therapeutic agent or biologically active molecule. In certain embodiments, the vial or ampule holds a concentrated stock (e.g., 2x, 5x, 10x or more) of the immunoconjugate or biologically active molecule. In certain embodiments, the articles of manufacture such as kits include a medical device for administering the immunoconjugate and/or biologically active molecule (e.g., a syringe and a needle); and/or an appropriate diluent (e.g., sterile water and normal saline). The present invention also includes methods for manufacturing said articles.

6. Certain Embodiments

[0152] Certain embodiments of the invention are further illustrative below.

1. An immunoconjugate of the formula:



or a pharmaceutically acceptable salt thereof,

wherein:

- i. Ab is an antibody or antigen binding fragment thereof which binds the ROR1 protein;
- ii. L is a linker;
- iii. D is a drug moiety selected from an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor;
- iv. m is 0 or 1; and
- v. n is an integer from 1 to 10.

2. An immunoconjugate of the formula:



or a pharmaceutically acceptable salt thereof,

wherein:

- i. Ab is an antibody or antigen binding fragment thereof which binds the ROR1 protein;
- ii. L is a cleavable linker;
- iii. D is a drug moiety selected from an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor;
- iv. m is 0 or 1; and
- v. n is an integer from 1 to 10

3. An immunoconjugate of the formula:

Ab-((L)_m-(D))_n

or a pharmaceutically acceptable salt thereof,

wherein:

- i. Ab is an antibody or antigen binding fragment thereof which binds the ROR1 protein;
- ii. L is a linker, wherein the linker is not attached to a lysine amino acid residue;
- iii. D is a drug moiety selected from an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, and an RNA polymerase II inhibitor;
- iv. m is 0 or 1; and
- v. n is an integer from 1 to 10.

4. The immunoconjugate of any one of embodiments 1-3, wherein D is an anti-tubulin agent.
5. The immunoconjugate of embodiment 4, wherein the anti-tubulin agent comprises an auristatin, a dolastatin, or analog thereof.
6. The immunoconjugate of embodiment 5, wherein the auristatin or dolastatin comprises auristatin E, monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF), dimethylvaline-valine-dolaisoleuine-dolaproine-phenylalanine-p-phenylenediamine (AFP), 5-benzoylvaleric acid-auristatin E ester (AEVB), or (AEB).
7. The immunoconjugate of embodiment 6, wherein the auristatin comprises monomethyl auristatin E (MMAE).
8. The immunoconjugate of embodiment 4, wherein the anti-tubulin agent comprises a maytansine, maytansinoid, or analog thereof.
9. The immunoconjugate of embodiment 8, wherein the maytansinoid comprises ansamitocin, mertansine/emtansine (DM1), or ravidansine/soravtansine (DM4).
10. The immunoconjugate of embodiment 9, wherein the maytansinoid comprises mertansine/emtansine (DM1).
11. The immunoconjugate of embodiment 9, wherein the maytansinoid comprises ravidansine/soravtansine (DM4).
12. The immunoconjugate of embodiment 1, wherein D is a DNA alkylating agent.
13. The immunoconjugate of embodiment 12, wherein the DNA alkylating agent comprises duocarmycin.
14. The immunoconjugate of embodiment 1, wherein D is a DNA cross-linking agent.

15. The immunoconjugate of embodiment 14, wherein the DNA cross-linking agent comprises pyrrolobenzodiazepine (PBD).
16. The immunoconjugate of embodiment 1, wherein D is a DNA intercalating agent.
17. The immunoconjugate of embodiment 16, wherein the DNA intercalating agent comprises PNU-159682.
18. The immunoconjugate of embodiment 1, wherein D is an RNA polymerase II inhibitor.
19. The immunoconjugate of embodiment 18, wherein the RNA polymerase II inhibitor comprises α -amanitin.
20. The immunoconjugate of embodiment 1, wherein D is two different drug moieties covalently linked.
21. The immunoconjugate of embodiment 20, wherein D is any two or more of a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, an RNA polymerase II inhibitor, or an anti-tubulin agent covalently linked to one another.
22. The immunoconjugate of any one of embodiments 1 to 21, wherein the antibody or antigen binding fragment thereof comprises a chimeric, humanized, deimmunized, or human antibody, or antigen binding fragment thereof.
23. The immunoconjugate of any one of embodiments 1 to 22, wherein the antibody or antigen binding fragment comprises a Fab, F(ab)₂, or scFv.
24. The immunoconjugate of any one of embodiments 1 to 23, wherein the immunoconjugate further comprises a second antibody or antigen binding fragment thereof, wherein the second antibody or antigen binding fragment thereof specifically binds to an epitope distinct from the antibody or antigen binding fragment.
25. The immunoconjugate of any one of embodiments 1 to 24, wherein the antibody or antigen binding fragment thereof comprises:
 - a. a heavy chain CDR1 (HCDR1) amino acid sequence set forth in SEQ ID NO: 7, a heavy chain CDR2 (HCDR2) amino acid sequence set forth in SEQ ID NO: 8, a heavy chain CDR3 (HCDR3) amino acid sequence set forth in SEQ ID NO: 9, a light chain CDR1 (LCDR1) amino acid sequence set forth in SEQ ID NO: 10, a light chain CDR2 (LCDR2) amino acid sequence set forth in SEQ ID NO: 11, and a light chain CDR3 (LCDR3) amino acid sequence set forth in SEQ ID NO: 12;

- b. a HCDR1 amino acid sequence set forth in SEQ ID NO: 27, a HCDR2 amino acid sequence set forth in SEQ ID NO: 28, a HCDR3 amino acid sequence set forth in SEQ ID NO: 29, a LCDR1 amino acid sequence set forth in SEQ ID NO: 30, a LCDR2 amino acid sequence set forth in SEQ ID NO: 31, and a LCDR3 amino acid sequence set forth in SEQ ID NO: 32; or
- c. a HCDR1 amino acid sequence set forth in SEQ ID NO: 37, a HCDR2 amino acid sequence set forth in SEQ ID NO: 38, a HCDR3 amino acid sequence set forth in SEQ ID NO: 39, a LCDR1 amino acid sequence set forth in SEQ ID NO: 40, a LCDR2 amino acid sequence set forth in SEQ ID NO: 41, and a LCDR3 amino acid sequence set forth in SEQ ID NO: 42.

26. The immunoconjugate of any one of embodiments 1 to 24, wherein the antibody or antigen binding fragment thereof comprises: a heavy chain variable region comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 6, and a light chain variable region comprising an amino acid sequence at least 80% identical to that set forth in SEQ ID NO: 5.

27. The immunoconjugate of any one of embodiments 1 to 26, wherein the antibody binds ROR1 with a K_D of less than about 40 nM.

28. The immunoconjugate of any one of embodiments 1 to 26, wherein the antibody binds ROR1 with a K_D of less than about 1 nM.

29. The immunoconjugate of any one of embodiments 1 to 26, wherein the antibody binds ROR1 with an affinity greater than about 10 times that of antibody D10, wherein antibody D10 comprises an immunoglobulin light chain amino acid sequence set forth in SEQ ID NO: 25, and an immunoglobulin heavy chain amino acid sequence set forth in SEQ ID NO: 26.

30. The immunoconjugate of any one of embodiments 1 to 26, wherein the antibody binds ROR1 with an affinity greater than about 50 times that of antibody D10, wherein antibody D10 comprises an immunoglobulin light chain amino acid sequence set forth in SEQ ID NO: 25, and an immunoglobulin heavy chain amino acid sequence set forth in SEQ ID NO: 26.

31. The immunoconjugate of any one of embodiments 1 to 30, wherein L is selected from a cleavable linker, a non-cleavable linker, a hydrophilic linker, a procharged linker, and a dicarboxylic acid based linker.

32. The immunoconjugate of any one of embodiments 1 to 31, wherein L is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (VC), alanine-phenylalanine (AP), p-aminobenzylloxycarbonyl (PAB), N-succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB), 6-maleimidocaproyl-valine-citrulline (MC-VC), 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB), and N-succinimidyl-1-carboxylate-valine-citrulline-p-aminobenzylloxycarbonyl (SC-VC-PAB).


33. The immunoconjugate of any one of embodiments 1 to 31, wherein L is 6-maleimidocaproyl-valine-citrulline-p-aminobenzylloxycarbonyl (MC-VC-PAB).

34. The immunoconjugate of any one of embodiments 1 to 31, wherein L is N-succinimidyl-1-carboxylate-valine-citrulline-p-aminobenzylloxycarbonyl (SC-VC-PAB).

35. The immunoconjugate of any one of embodiments 1 to 31, wherein L is 6-maleimidocaproyl-valine-citrulline (MC-VC).

36. The immunoconjugate of any one of embodiments 1 to 31, wherein L is N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).

37. The immunoconjugate of any one of embodiments 1 to 31, wherein L is a linker of the formula:




wherein

X is C₂-8alkyl;

Y is -(CH₂CH₂O)_qCH₂CH₂-;

W is an amino acid unit;



n is 0 or 1;

p is 0 or 1;

q is an integer from 0 to 12;

u is an integer from 0 to 5; and

v is 0 or 1; wherein ** indicates the point of attachment to D; and

* indicates the point of attachment to Ab.

38. The immunoconjugate of embodiment 37, wherein X is $-(CH_2)_2-$.
39. The immunoconjugate of embodiment 37, wherein X is $-(CH_2)_3-$.
40. The immunoconjugate of embodiment 37, wherein X is $-(CH_2)_4-$.
41. The immunoconjugate of embodiment 37, wherein X is $-(CH_2)_5-$.
42. The immunoconjugate of any one of embodiments 37 to 41, wherein p is 0.
43. The immunoconjugate of any one of embodiments 37 to 41, wherein p is 1.
44. The immunoconjugate of any one of embodiments 37 to 43, wherein q is an integer from 4 to 8.
45. The immunoconjugate of any one of embodiments 37 to 43, wherein q is 4.
46. The immunoconjugate of any one of embodiments 37 to 43, wherein q is 8.
47. The immunoconjugate of any one of embodiments 37 to 46, wherein n is 0.
48. The immunoconjugate of any one of embodiments 37 to 46, wherein n is 1.
49. The immunoconjugate of any one of embodiments 37 to 48, wherein v is 0.
50. The immunoconjugate of any one of embodiments 37 to 48, wherein v is 1.
51. The immunoconjugate of any one of embodiments 37 to 50, wherein u is an integer from 2 to 4.
52. The immunoconjugate of any one of embodiments 37 to 51, wherein W is selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, lysine protected or not with acetyl or formyl, arginine, arginine protected or not with tosyl or nitro groups, histidine, ornithine, ornithine protected with acetyl or formyl, and citrulline.
53. The immunoconjugate of any one of embodiments 37 to 52, wherein u is 0.
54. The immunoconjugate of any one of embodiments 1 to 53, further comprising a spacer between L and D.
55. The immunoconjugate of any one of embodiments 1 to 54, wherein the immunoconjugate further comprises at least one additional linker-drug moiety of the formula- $(((L)_m-(D))_n)_x$ wherein:
L is a linker;

D is a drug moiety selected from an anti-tubulin agent, a DNA alkylating agent, a DNA cross-linking agent, a DNA intercalating agent, or an RNA polymerase II inhibitor; m is 0 or 1;

n is an integer from 1 to 10; and

x is an integer from 1 to 10.

56. A pharmaceutical composition comprising the immunoconjugate of any one of embodiments 1 to 55 and a pharmaceutically acceptable excipient, diluent, or carrier.
57. The pharmaceutical composition of embodiment 56, wherein the pharmaceutical composition is formulated for intravenous administration.
58. The pharmaceutical composition of embodiment 56, wherein the pharmaceutical composition is formulated for subcutaneous administration.
59. A method of treating cancer comprising administering to an individual in need thereof a therapeutic dose of the immunoconjugate of any one of embodiments 1 to 55 or the pharmaceutical composition of any one of embodiments 56 to 58.
60. Use of the immunoconjugate of any one of embodiments 1 to 55 or the pharmaceutical composition of any one of embodiments 56 to 58 for treating cancer.
61. The method of embodiment 59 or the use of embodiment 60, wherein the cancer expresses ROR1.
62. The method or use of embodiment 61, wherein the cancer is selected from lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal cell B-cell lymphoma, Burkett's lymphoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, epithelial squamous cell cancer, melanoma, myeloma, stomach cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, and head and neck cancer
63. A method of treating an individual with cancer, the method comprising administering to the individual:
 - a. the immunoconjugate of any one of embodiments 1 to 55; and
 - b. an additional therapeutic agent.
64. The method of embodiment 63, wherein the additional therapeutic agent comprises acalabrutinib, idelalisib, sapanisertib, pacritinib, ABT-199, buparlisib, everolimus, BEZ235,

ruxolitinib, fostamatinib, rituximab, lenalidomide, paclitaxel, vincristine, ibrutinib, erlotinib, crizotinib, carboplatin, oxaliplatin/cisplatin, bevacizumab, or gemcitabine.

65. The method of embodiment 63 or 64, wherein the cancer expresses ROR1.
66. The method of embodiment 65, wherein the cancer comprises lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal cell B-cell lymphoma, Burkett's lymphoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, epithelial squamous cell cancer, melanoma, myeloma, stomach cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, and head and neck cancer.
67. The method of any one of embodiments 63 to 66, wherein the immunoconjugate and the additional therapeutic agent are administered separately to the individual with cancer.
68. A pharmaceutical composition comprising the immunoconjugate as described in any one of embodiments 1 to 55 and the additional therapeutic agent as described in embodiment 64.
69. The pharmaceutical composition of embodiment 68, for use in a method of any one of embodiments 63 to 67.
70. A kit comprising the immunoconjugate as described in any one of embodiments 1 to 55 and the additional therapeutic agent as described in embodiment 64, wherein said immunoconjugate and additional therapeutic agent are in suitable packaging.
71. The kit of embodiment 70, for use in a method of any one of embodiments 63 to 67.

[0153] Unless the context requires otherwise, throughout the specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising,” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. As used herein the term “about” refers to a numerical range that is 10%, 5%, or 1% plus or minus from a stated numerical value within the context of the particular usage. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.

[0154] All publications and patents mentioned herein are incorporated herein by reference in

their entirety for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications, which might be used in connection with the presently described inventions. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors of the subject invention are not entitled to antedate such disclosure by virtue of prior invention or for any other reason.

[0155] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the inventions described herein belong. Any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the inventions described herein.

EXAMPLES

[0156] The following examples illustrate representative embodiments of the present invention and are not meant to be limiting in any way.

Example 1: Synthesis of Exemplary Immunoconjugates

1. Conjugation of Ab1 cysteines in ADC-A, C, and H through P

[0157] Conjugation of Ab1 with MC-VC-PAB-MMAE (ADC-A) was performed at multiple scales (2 mg, 30 mg, and 350 mg) with similar results. For the smallest scale, 2 mg Ab1 (10 mg/mL in PBS, pH 6.5) was treated with 2.50 equivalents (eq) of tris(2-carboxyethyl)phosphine (TCEP, 5 mM) in conjugation buffer solution in a water bath at 37°C for 2 hours. The PBS buffer contained 15.75 mM Na₂HPO₄, 34.25 mM NaH₂PO₄, 2 mM EDTA, and 50 mM NaCl, at pH 6.5. Subsequently, the reaction was cooled to 4°C. Next, 7 eq MC-VC-PAB-MMAE in N,N-dimethylacetamide (DMA) was added and the mixture was left at 4°C for an additional 1 hour. The buffer was exchanged with 20 mM histidine, pH 5.5 (MMAE buffer) by using a spin desalting column (40 kD, 0.5 mL). The number of MMAE drug molecules linked per antibody molecule (DAR) was determined using HIC-HPLC, SEC-HPLC, RP-HPLC, and UV/Vis and is summarized in Table 4. Consistent results were obtained at all scales, with DAR ranging from 3.89 to 5.09 on average, depending on the methodology used.

Table 4 Characterization of ADC-A

Scale (mg)	Aggregate (%)	Recovery (%)	D0* (%)	DAR			
				UV	SEC	HIC	RP
2	3.47	85.6	6.06	4.33	4.81	3.95	3.89
30	3.50	86.1	4.75	4.44	5.09	4.21	4.09
350	3.51	90.2	5.12	4.40	4.96	4.12	3.99

* D0: unconjugated antibody.

[0158] Other linkers and payloads (ADC-C, and ADC-H through ADC-P) were conjugated to Ab1 in a similar fashion, and the resulting DARs are summarized in Table 5.

Table 5 Average DAR for Additional ADC Constructs

Construct	DAR	Methodology
ADC-C	6.33	UV
	6.62	SEC
	3.97	HIC
	4.15	RP
	4.24	MS
ADC-H	1.98	UV
	1.93	SEC
ADC-I	4.1	SEC/UV
ADC-J	2.1	HIC
ADC-K	1.9	PLRP
ADC-L	3.9	HIC
ADC-M	4.1	HIC
ADC-N	4.1, 1.9	PLRP
ADC-O	1.8	SEC
ADC-P	1.9	PLRP

2. Conjugation of Ab1 lysines in ADC-B, E, and F

[0159] Ab1 in PBS (pH 6.5) was combined with SC-VC-PAB-MMAE (ADC-E) or SC-VC-PAB-DM1 (ADC-F) in DMA and placed on a rotating platform at 10 rpm at 22°C for 2-4 hours. For ADC-B, Ab1 in PBS (pH 7.0) was combined with SMCC-DM1 and placed on a rotating platform at 10 rpm at 22°C for 2-4 hours. Unreacted payload was removed through buffer exchange, using Amicon ultrafiltration (50 kDa, 0.5 mL). ADC-B was exchanged into 20 mM succinic acid (pH 5.0). DAR values were determined using SEC-HPLC, MS, and UV/Vis and are summarized in Table 6. When linker-payload was used at ~11 eq, the DARs approached 4.0 following 4 hours incubation.

Table 6 Characterization of ADC-B, ADC-E and ADC-F

Construct	Scale (mg)	Aggregate (%)	Recovery (%)	D0 (%)	DAR		
					UV	SEC	MS
ADC-B	80	2.93	-	5.86	3.18	3.20	3.0
ADC-E	60	3.94	82.1	1.85	5.08	6.14	4.2
ADC-F	75	2.92	59.0	7.44	5.51	5.72	3.0

3. Site-specific conjugation of Ab1 in ADC-Q and R

[0160] ADC-Q and ADC-R were synthesized using site-specific conjugation technology

(Dennler et al., *Bioconjugate Chemistry*, 25(3):569-578 (2014) and U.S. Patent Publication 2016/0022833). Ab1 was first deglycosylated by incubation with 6 U/mg protein of N-glycosidase F (PNGase F) overnight at 37°C. The deglycosylated antibody was purified by Protein A chromatography and formulated for the bacterial transglutaminase modification reaction. Next, 10-40 eq of 11-azido-3,6,9-trioxaundecan-1-amine (azido-PEG3-amine) per glutamine was added to 1-5 mg/ml of Ab1 in PBS (pH 7.4) and the reaction was initiated by the addition of 2-6 U/mL of microbial transglutaminase and incubated overnight at 37°C. Subsequently, excess azido-PEG3-amine was removed by Protein A chromatography. Finally, 50-200 μM dibenzylcyclooctyne (DBCO)-containing drug payload (1.25 to 5 mol equiv. per azide group) was added to 20 μM azide-activated Ab1 and incubated at room temperature for 0.5-6 hours, forming Ab1-payload conjugates linked via a triazole moiety. Excess DBCO-containing payload was removed. Characterization of ADCs synthesized in this manner demonstrated DARs of 4.4 for ADC-Q and 2.1 for ADC-R (Table 7).

Table 7 Average DAR for Additional ADC Constructs

Construct	DAR	Methodology
ADC-Q	4.4	HIC
ADC-R	2.1	PLRP

Example 2: Antibody and Immunoconjugate Binding to ROR1-Positive Cells

[0161] The binding to tumor cells by antibodies Ab1 and 4A5, as well as ADC constructs derived from those antibodies (ADC-A and ADC-T), was evaluated. First, the binding of Ab1 to two ROR1-positive human tumor cell lines representing different cancer types was tested. The Jeko-1 cell line, from mantle cell lymphoma, is a suspension cell line, while the MDA-MB-231 cell line, from triple negative breast cancer, is an adherent cell line. The cell lines have different levels of ROR1 expression, with Jeko-1 cells displaying about 13507 cell surface copies and the MDA-MB-231 cells displaying about 21015 cell surface copies. The Jeko-1 (ATCC Cat. No. CRL-3006) and MDA-MB-231 (ATCC Cat. No. CCL-227) cell lines were purchased from the American Type Culture Collection and were maintained according to the ATCC recommendations.

[0162] Jeko-1 cells (**FIG. 2A**) or MDA-MB-231 cells (**FIG. 2B**) were incubated with 0, 1, 10, 100, or 1000 ng/mL of Ab1 for 20 minutes on ice. After washing off unbound antibody, the cells

were incubated with secondary anti-human IgG antibody labeled with phycoerythrin (PE) for an additional 20 minutes. The amount of PE fluorescence was measured using the BD FACS Verse analyzer and FlowJo V10 software. The PE signal for the highest concentration was used as the maximal binding signal to calculate the % maximal binding. EC₅₀ was calculated using GraphPad Prism 7. The receptor binding assay resulted in EC₅₀ values of 13.6 ng/ml in Jeko-1 cells and 32.8 ng/ml in MDA-MB-231 cells.

[0163] Next, the binding of Ab1 was compared to ADC-A (**FIGS. 2A** and **2B**). Binding was compared on both Jeko-1 and MDA-MB-231 cell lines. The binding of ADC-A to Jeko-1 cells (**FIG. 2A**, squares) and MDA-MB-231 cells (**FIG. 2B**, squares) was very similar to the binding of the unconjugated, parental antibody Ab1 (**FIG. 2A**, 17 ng/mL vs. 13.6 ng/mL and **FIG. 2B**, 48.5 ng/mL vs. 32.8 ng/mL). The similarity between the EC₅₀ values of unconjugated Ab1 and ADC-A demonstrates that drug conjugation had minimal impact on Ab1's binding to the target cells.

[0164] The binding of Ab1 was compared to 4A5, an antibody that binds an epitope on ROR1 distinct from Ab1's epitope (**FIG. 3A**). Ab1 (EC₅₀ = 16.39 ng/mL; **FIG. 3A**, open circles) bound Jeko-1 cells with a higher affinity/avidity than did 4A5 (EC₅₀ = 120.6 ng/mL; **FIG. 3A**, open squares). The binding of the ADC constructs was compared to the corresponding unconjugated parental antibodies (Ab1 versus ADC-A and 4A5 versus ADC-T). ADC-A bound with an EC₅₀ of 21.57 ng/mL while ADC-T bound with an EC₅₀ of 192.7 ng/mL. The similarity between the EC₅₀ values of unconjugated antibodies and the corresponding ADC constructs demonstrates again that drug conjugation had minimal impact on the antibodies' binding to the target cells.

[0165] In a different experiment, the binding of Ab1 to Jeko-1 cells was also compared to the binding of D10, a lower affinity antibody that binds the same epitope as Ab1 (**FIG. 3B**). Ab1 (EC₅₀ = 16.5 ng/mL; **FIG. 3B**, open circles) bound Jeko-1 cells with a higher affinity/avidity than did D10 (EC₅₀ = 250 ng/mL; **FIG. 3B**, open triangles). In addition, the binding of the ADC constructs was compared to that of the corresponding unconjugated parental antibodies (Ab1 versus ADC-A and D10 versus ADC-S). ADC-A bound with an EC₅₀ of 22.1 ng/mL (**FIG. 3B**, closed circles) while ADC-S bound with an EC₅₀ of 150 ng/mL (**FIG. 3B**, closed triangles). The similarity between the EC₅₀ values of unconjugated antibodies and the corresponding ADC constructs demonstrates again that drug conjugation had minimal impact on the antibodies'

binding to the target cells.

[0166] In a similar fashion, the binding of all other ADC constructs to ROR1-positive cells was evaluated. All constructs described herein were found to bind ROR1-positive cells.

Example 3: Internalization of ROR1 Antibody and Immunoconjugates

[0167] Multiple methods were used to determine antibody internalization. In one approach, internalization was measured using a pulse-chase methodology that quantitates non-internalized, cell surface antibody at 15, 30, 60, 120, and 240 minutes using flow cytometry. Jeko-1 cells were grown and harvested prior to confluence, washed with cold PBS and resuspended at 1×10^7 in cold FACS buffer (PBS+2% FBS - Fisher/Gibco Cat. No. 16140071). 1×10^6 cells were added to microcentrifuge tubes or wells. Internalization of Ab1 and ADC constructs by the cells was determined at saturating antibody concentrations, using 30 $\mu\text{g}/\text{ml}$ for Jeko-1 cells and 100 $\mu\text{g}/\text{mL}$ for MDA-MB-231 cells. 10X stock solutions of ADC constructs or Ab1 were prepared (300 $\mu\text{g}/\text{ml}$ for use with Jeko-1 cells or 1 mg/ml for use with MDA-MB-231 cells) and 10 μL of sample or buffer control was added to the following (adding additional tubes for each time point):

- a) Unstained
- b) Secondary antibody only
- c) Negative Control hIgG mAb at 30 $\mu\text{g}/\text{ml}$ – time 0
- d) Positive Control ADC construct or Ab1 at 30 $\mu\text{g}/\text{ml}$ – time 0
- e) ADC construct or Ab1 – time point 1
- f) ADC construct or Ab1 – time point 2, etc.

[0168] Cells and antibody were incubated on ice for 20 minutes, spun at 300 x g for 4 minutes, washed twice with 200 μL of FACS buffer, and resuspended in 100 μL of FACS buffer. The samples were incubated at 37°C for 15, 30, 60, 120, and 240 minutes, as indicated above. Internalization was terminated by transferring the samples to ice. A time course for antibody internalization was generated for each test article as described above, after which antibody remaining on the cell surface was detected using a PE-labeled secondary antibody. Cells were spun at 250 x g, washed twice with FACS buffer and resuspended in 100 μL of FACS buffer. The secondary antibody (goat anti-human IgG-PE, Fc-gamma specific - eBiosciences, Cat. No. 12-4998) was diluted 1:2000 (10X stock) in FACS buffer and 10 μL /tube was added to the

appropriate tubes. Cells were incubated on ice for 20 minutes, washed twice with FACS buffer and resuspended in 100 μ L of fix buffer (4% paraformaldehyde in PBS). Subsequently, FACS analysis was performed. The median fluorescent intensity (MFI) was quantitated and the degree of receptor internalization was determined using the amount of the antibody or ADC present at each time point when compared to the amount present at time = 0. The dashed line represents background staining (secondary antibody only).

[0169] Ab1 bound to and was rapidly internalized by both Jeko-1 (**FIG. 4A**) and MDA-MB-231 (**FIG. 4B**) cells. Internalization of 80-90% of the bound antibody was observed in less than 60 minutes for MDA-MB-231 or 120 minutes for Jeko-1. Notably, the addition of linker and payload to Ab1 did not negatively impact binding or internalization, as demonstrated with ADC-A and ADC-B (**FIG. 4A**, compare ADC-A and ADC-B with Ab1, and **FIG. 4B**, compare ADC-A with Ab1).

[0170] In a similar fashion, the internalization characteristics of other ADC constructs with different linkers and payloads were evaluated using Jeko-1 cells. All of the constructs displayed similar kinetics of internalization compared to Ab1, consistent with the above observation that the linkers and payloads used did not impact the antibody characteristics (data not shown).

[0171] We also evaluated the internalization properties of an ADC construct (ADC-T) utilizing a ROR1 antibody (4A5) that recognizes an epitope distinct from Ab1, but with linker and payload chemistries identical to those of ADC-A. ADC-T bound Jeko-1 cells but was internalized at a slower rate and to a lesser extent than did ADC-A (data not shown). These data demonstrate the importance of the antibody and its epitope in determining the internalization properties of the ADC construct.

[0172] Internalization of Ab1 was also characterized using conventional immunofluorescent staining methods and MDA-MB-231 cells. In this approach, Ab1 was loaded at the cell surface and the cells were subsequently fixed and surface Ab1 was quantitated. In addition, a second sample of the cells was permeabilized and total Ab1 (surface and intracellular) was quantitated. In this protocol, the primary antibody was allowed to incubate without a secondary antibody, eliminating the possibility that the secondary antibody might influence internalization. Surface staining was observed. After permeabilization, clear and distinct punctate intracellular staining of Ab1 was observed. Furthermore, by utilizing a lysosome-specific tracker, it was demonstrated that internalized Ab1 co-localized with the lysosomal pathway. This finding is consistent with a

mode of antibody internalization that primarily occurs by the lysosome/endosome pathway. Finally, the rate of internalization was quantitated. When cells were subjected to continuous exposure to Ab1, the initial rate was approximately twice the average rate, and the terminal rate was approximately half the average rate (FIG. 5). This indicates that there is an initial rapid phase of clearing the cell surface receptor followed by a slower process of binding and internalizing receptor that is newly expressed on the cell surface. The newly expressed cell surface receptor may be recycled, expressed from intracellular stores, and/or newly synthesized. The extent and character of co-localization of Ab1 was similar to EGFR, showing substantially lysosomal co-localization after 4 hours.

Example 4: Measurement of Cell Surface ROR1 Expression

[0173] Internalization of antibodies was measured using pulse-chase approaches that detected non-internalized, cell surface antibody at various time points (2, 5, 10, 15, 20, 30, 60, 120 and 240 minutes). In this study, in addition to measuring non-internalized cell surface antibody, the expression of ROR1 on the cell surface was quantitated either by (1) re-staining with Ab1 and a secondary antibody or (2) by using a second, labeled anti-ROR1 antibody that recognizes an epitope distinct from that of Ab1.

[0174] For the first approach, internalization of Ab1 on Jeko-1 cells was performed as described in Example 3 (one sample was processed at each time point to quantitate antibody remaining on the cell surface). Additionally, a second sample at each time point was rapidly re-stained using saturating levels of Ab1 (30 µg/mL) while maintaining the cells on ice. Subsequently, the cells were washed and surface antibody was quantitated using the same secondary antibody used for internalization measurements. As shown previously, Ab1 was rapidly internalized (FIG. 6, squares). By contrast, while quantitation of cell surface ROR1 initially showed a small decrease in the first 10 minutes, subsequent measurements indicated ROR1 surface expression was restored to initial or slightly higher levels (FIG. 6, circles). These data are consistent with recycling of ROR1 to the cell surface dissociated from antibody, or with rapid upregulation of ROR1 through *de novo* synthesis or trafficking of intracellular stores. This experiment was repeated using Jeko-1 (FIG. 7A), MDA-MB-468 (FIG. 7B), and MDA-MB-231 (FIG. 7C) cells, with similar results.

[0175] An alternative approach to measuring cell surface ROR1 expression in conjunction with Ab1 internalization studies was tested. Specifically, cell surface ROR1 expression was quantitated at 0, 0.5, 1, 2, and 4 hours by staining cells directly with a labeled anti-ROR1 antibody that binds an epitope distinct from that of Ab1. ROR1 surface expression on Jeko-1 cells treated with ADC-A, M, N, and P was assessed. Consistent with the results obtained using the previously described approach, ROR1 expression was maintained, or slightly increased, while cells were being treated with Ab1-based ADC constructs (data not shown).

[0176] These data indicate that Ab1 and its immunoconjugates may be internalized effectively by ROR1-positive cells. Further, the persistent expression of ROR1 on the cell surface demonstrates that ROR1 is an excellent target for delivering cytotoxic agents to cancer cells through an ADC of the present invention.

Example 5: Potency of Immunoconjugates *in vitro*

[0177] The ADC-A, B, C, E, and F immunoconjugates, which had different cytotoxic moieties and linker chemistry, were analyzed for this Example. ROR1 binding by these conjugates was tested in cell culture to define the potency of various linker-cytotoxic agent combinations. Three different types of cancer cell lines were tested: B-lymphoma cell-lines TMD-8, HBL-1, and DOHH2; triple negative breast cancer cell lines HCC1187, MDA-MB-468, Bt549; and ovarian cancer cell lines A2008, TOV112D, JHOM1, and SKOvr3.

[0178] Cells were cultured in log phase growth and distributed into 96-well plates. Each cell line was plated at a slightly different cell density, ranging from 5×10^3 to 50×10^3 cells/well. Cells in duplicate were incubated with 3-fold serial dilution of a particular immunoconjugate (10, 3.33, 1.11, 0.37, 0.12, 0.041, 0.014, and 0.0045 μ M) for 72 hours at 37° C and 5% CO₂. After treatment, cells were incubated with an equal volume of CellTiter-Glo® reagent (Promega Inc.) for 15 minutes at room temperature and viability was determined by a luminometer. Curves and EC₅₀ values were generated in GraphPad Prism using a sigmoidal dose response non-linear regression fit. The data from these experiments are summarized in Table 8. **FIGS. 8A-8I** show representative IC₅₀ plots for all five immunoconjugates tested against the indicated cell lines.

Table 8 Cytotoxicity of Exemplary Immunoconjugates *in vitro**

Cancer Type	Cell line	ADC-A	ADC-B	ADC-C	ADC-E	ADC-F
B-cell lymphoma	TMD-8	122	50	>1000	94.3	>1000
	HBL-1	118	70.1	>1000	147	>1000
	DOHH2	129	78.3	>1000	89.6	>1000
Triple negative breast cancer	HCC1187	6.8	6.2	>1000		>1000
	MDA-MB-468	23.5	18.8	>1000	80.1	>1000
	Bt549	13.5	20.2	>1000	74.4	>1000
Ovarian cancer	A2008	125	49	>1000		>1000
	TOV112D	62.4	34.2	>1000	57.8	>1000
	JHOM1	15.6	24.3	>1000	32.9	>1000
	SKOvr3	62.6	78.7	>1000	200.6	>1000

*Data represented as IC₅₀ in nM. Empty cells: not done.

Example 6: Additional Data on Potency of Immunoconjugates *in vitro*

[0179] This Example presented additional data on the potency of the various ADCs in inducing cell death of a variety of cancer cell lines. Cells were grown and distributed into 96-well plates as described in Example 5. Cells in duplicate were incubated with 3-fold serial dilution of a particular immunoconjugate (660, 220, 73.3, 24.4, 8.14, 2.71, 0.91, and 0.3 nM) for 72 hours at 37°C and 5% CO₂. In some experiments, cells were incubated with an immunoconjugate for 96 hours instead of 72 hours (values highlighted with “*”). After treatment, cell viability was determined as described in Example 5. The data from these experiments is summarized in Tables 9.1 through 9.17 below. Cell surface ROR1 expression was assessed by quantitative flow cytometry and ROR1 expression was characterized as MFI>30 or MFI<30 (MFI: mean fluorescent intensity). The data demonstrate that payload-sensitive cancer cells expressing ROR1 responded to a number of the tested ADCs in the cell death assays described herein. While many of the ADC-responsive cancer cells expressed high levels of ROR1 (MFI>30), some cells expressing lower levels of ROR1 (MFI<30) were also sensitive to certain ADCs.

[0180] The MEC1 cell line, which is derived from B-chronic lymphocytic leukemia in prolymphocytoid transformation, was transfected with either an expression vector encoding human ROR1 or a control vector, and stable cell lines were created using selection media containing G418. ROR1-transfected MEC1 cells had significantly greater proportions of cells in S/G2/M phase than did control-transfected cells 16 hours after being transferred from serum-free medium to complete growth medium, implying that expression of ROR1 increased the relative

proportions of cells undergoing cell division. Consistent with this, ROR1⁺ MEC1 cells had significantly greater numbers of cells \geq 48 hours after being transferred from serum-free medium than did comparably seeded cultures of MEC1 cells that did not express ROR1. Increased levels of p-AKT and p-CREB were also observed in MEC1 cells made to express ROR1 relative to MEC1 cells transfected with control vector.

Table 9.1 Cytotoxicity of ADC-A *in vitro*

Cell Line	Cancer Type	ADC-A Binding K _D (nM)	ADC-A EC ₅₀ (nM)	MMAE EC ₅₀ (nM)	ROR1 Expression
Mec-vector	CLL		558	0.5	MFI<30
Mec-ROR	CLL		208	0.6	MFI>30
Jeko-1	MCL	0.10	22.4*, 40.4*, 186.7	<0.0001	MFI>30
Mino	MCL		19.5, 27.7*	<0.0001	MFI>30
TMD-8	DLBCL		122*	<0.0001	MFI<30
HBL-1	DLBCL		118*	<0.0001	MFI>30
DOHH2	DLBCL		129, 48.3*	0.007	MFI>30
OCI-Ly18	DLBCL		95	0.003	MFI>30
U2932	DLBCL		176	0.006	MFI<30
OCI-Ly19	DLBCL		199		
WSU-DLCL	DLBCL		68	0.06	MFI>30
KMS-PE	MM		43.3, 89		
RPMI-8229	MM		174		
OPM2	MM		123		
L363	MM		244		
NCI-H929	MM		179		
HCC1187	TNBC		2.3*, 6.8	<0.0001	MFI>30
HCC1806	TNBC		13.4*, 38.1	<0.0001	MFI>30
MDA-MB-468	TNBC		23.4, 21.7*, 82.5, 23.5*	<0.0001	MFI>30
MDA-MB-231	TNBC	0.32	58.4*, 106, 46.7*	<0.0001	MFI>30
Bt549	TNBC		13.5	0.047	MFI>30
Hs578T	TNBC		22.9	<0.0001	
DU4475	TNBC		248	2.5	MFI>30
HCC1937	TNBC		>1,000	>1,000	MFI>30
MCF-7	Breast		198.4*, 289.0, >1000*	<0.0001	MFI<30
H1975	NSCLC		9.7	<0.0001	MFI>30
H460	NSCLC		61.5	<0.0001	MFI>30
A549	NSCLC		53.4	0.06	MFI>30
Hep-G2	HCC		>1,000	>1,000	
A4573	EWS		15.3	<0.0001	MFI>30
SKES	EWS		15.3	0.03	MFI>30
U2OS	OS		223	1.2	MFI>30
HOS	OS		126, 148	0.06	MFI>30
SAOS	OS		15.6, 26.3	0.05	MFI>30
FaDu	HN		>1,000	>1,000	

Cell Line	Cancer Type	ADC-A Binding K _D (nM)	ADC-A EC ₅₀ (nM)	MMAE EC ₅₀ (nM)	ROR1 Expression
A2008	Ovarian		125	0.03	
OvCar4	Ovarian		283	24.2	MFI>30
TOV112D	Ovarian		62.4	0.04	MFI>30
JHOM1	Ovarian		15.6	0.01	MFI>30
SKOvr3	Ovarian		62.6	0.01	MFI>30
ES2	Ovarian		170	1.1	MFI>30
A2780	Ovarian		64	0.08	MFI>30
Bx-PC3	Pancreatic		47.4	0.04	MFI>30
As-PC1	Pancreatic		>1,000	0.04	MFI>30
Ramos	Burkitt's		649.8	<0.0001	MFI<30

Table 9.2 Cytotoxicity of ADC-E *in vitro*

Cell Line	Cancer Type	ADC-E EC ₅₀ (nM)	MMAE EC ₅₀ (nM)
TMD-8	DLBCL	94.3	<0.0001
HBL-1	DLBCL	147	<0.0001
DOHH2	DLBCL	89.6	0.007
HCC1187	TNBC		<0.0001
MDA-MB-468	TNBC	80.1	<0.0001
Bt549	TNBC	74.4	0.047
A2008	Ovarian		0.03
TOV112D	Ovarian	57.8	0.04
JHOM1	Ovarian	32.9	0.01
SKOvr3	Ovarian	200.6	0.01

Table 9.3 Cytotoxicity of ADC-B *in vitro*

Cell Line	Cancer Type	ADC-B EC ₅₀ (nM)	DM1 EC ₅₀ (nM)
TMD-8	DLBCL	50	1.4
HBL-1	DLBCL	70.1	9.3
DOHH2	DLBCL	78.3	1.78
OCI-Ly18	DLBCL	40	
U2932	DLBCL	53.9	
OCI-Ly19	DLBCL	40	
WSU-DLCL	DLBCL	>1,000	
KMS-12PE	MM	72	
RPMI-8229	MM	91	
OPM2	MM	108	
L363	MM	177	
NCI-H929	MM	90	

Cell Line	Cancer Type	ADC-B EC ₅₀ (nM)	DM1 EC ₅₀ (nM)
HCC1187	TNBC	6,225.1	3.9
HCC1806	TNBC	23.1	
MDA-MB-468	TNBC	18.8, 70.1	15.2
MDA-MB-231	TNBC	67.5	
Bt549	TNBC	20.2	0.047
Hs578T	TNBC	11.7	
DU4475	TNBC	105	
HCC1937	TNBC	>1,000	
MCF-7	ER+/PR+/HER2- Breast	>1,000	
A2008	Ovarian	49	
OvCar4	Ovarian	291	>1,000
TOV112D	Ovarian	34.2	2.4
JHOM1	Ovarian	24.3	0.01
SKOvr3	Ovarian	78.7	9.1
ES2	Ovarian	117	
A2780	Ovarian	36	

Table 9.4 Cytotoxicity of ADC-C *in vitro*

Cell Line	Cancer Type	ADC-C EC ₅₀ (nM)	DM1 EC ₅₀ (nM)
TMD-8	DLBCL	>1,000	1.4
HBL-1	DLBCL	>1,000	9.3
DOHH2	DLBCL	>1,000	1.78
HCC1187	TNBC	>1,000	3.9
MDA-MB-468	TNBC	>1,000	15.2
Bt549	TNBC	>1,000	0.047
A2008	Ovarian	>1,000	
TOV112D	Ovarian	>1,000	2.4
JHOM1	Ovarian	>1,000	0.01
SKOvr3	Ovarian	>1,000	9.1

Table 9.5 Cytotoxicity of ADC-F *in vitro*

Cell Line	Cancer Type	ADC-F EC ₅₀ (nM)	DM1 EC ₅₀ (nM)
TMD-8	DLBCL	>1,000	1.4
HBL-1	DLBCL	>1,000	9.3
DOHH2	DLBCL	>1,000	1.78
HCC1187	TNBC	>1,000	3.9
MDA-MB-468	TNBC	>1,000	15.2
Bt549	TNBC	>1,000	0.047
A2008	Ovarian	>1,000	
TOV112D	Ovarian	>1,000	2.4

Cell Line	Cancer Type	ADC-F EC ₅₀ (nM)	DM1 EC ₅₀ (nM)
JHOM1	Ovarian	>1,000	0.01
SKOvr3	Ovarian	>1,000	9.1

Table 9.6 Cytotoxicity of ADC-H *in vitro*

Cell Line	Cancer Type	ADC-H EC ₅₀ (nM)	Azonafide EC ₅₀ (nM)
Jeko	MCL	170	
MDA-MB-231	TNBC	>1,000	
A549	NSCLC	>1,000	>1,000
Hep-3B	HCC	>1,000	>1,000

Table 9.7 Cytotoxicity of ADC-I *in vitro*

Cell Line	Cancer Type	ADC-I EC ₅₀ (nM)
Jeko	MCL	>1000
DOHH2	DLBCL	>1000
KMS-PE	MM	266
MDA-MB-468	TNBC	>1000
MDA-MB-231	TNBC	>1000
MCF-7	ER+/PR+/HER2- Breast	>1,000
A549	NSCLC	>1,000
Hep-G2	HCC	>1,000
U2OS	OS	>1,000
FaDu	HN	>1,000

Table 9.8 Cytotoxicity of ADC-J *in vitro*

Cell Line	Cancer Type	ADC-J EC ₅₀ (nM)
Jeko	MCL	59.35
DOHH2	DLBCL	5.975
KMS-PE	MM	362
MDA-MB-468	TNBC	146
MDA-MB-231	TNBC	>1000
MCF-7	ER+/PR+/HER2- Breast	268
A549	NSCLC	>1,000
Hep-G2	HCC	>1,000
U2OS	OS	>1,000
FaDu	HN	658.5

Table 9.9 Cytotoxicity of ADC-K *in vitro*

Cell Line	Cancer Type	ADC-K EC ₅₀ (nM)
Jeko	MCL	761.5
DOHH2	DLBCL	247
KMS-PE	MM	1,000
MDA-MB-468	TNBC	>1000
MDA-MB-231	TNBC	>1000
MCF-7	ER+/PR+/HER2- Breast	363
A549	NSCLC	>1,000
Hep-G2	HCC	>1,000
U2OS	OS	>1,000
FaDu	HN	>1,000

Table 9.10 Cytotoxicity of ADC-L *in vitro*

Cell Line	Cancer Type	ADC-L Binding K _D (nM)	ADC-L EC ₅₀ (nM)	MMAE EC ₅₀ (nM)
Mec-vector	CLL		535	0.5
Mec-ROR	CLL		192	0.6
Jeko	MCL	0.15	81.1	<0.0001
Mino	MCL		20.5	<0.0001
MDA-MB-468	TNBC		141.5	<0.0001
MCF-7	ER+/PR+/HER2- Breast		232.5*	<0.0001

Table 9.11 Cytotoxicity of ADC-M *in vitro*

Cell Line	Cancer Type	ADC-M Binding K _D (nM)	ADC-M EC ₅₀ (nM)	MMAE EC ₅₀ (nM)
Mec-vector	CLL		569	0.5
Mec-ROR	CLL		170	0.6
Jeko	MCL	0.12	112.3	<0.0001
Mino	MCL		15.8	<0.0001
MDA-MB-468	TNBC		53.1	<0.0001
MCF-7	ER+/PR+/HER2- Breast		164.1	<0.0001

Table 9.12 Cytotoxicity of ADC-N *in vitro*

Cell Line	Cancer Type	ADC-N Binding K _D (nM)	ADC-N EC ₅₀ (nM)	PNU-159682 EC ₅₀ (nM)
Mec-vector	CLL		772	
Mec-ROR	CLL		262	
Jeko	MCL	0.13	31.7, 20.3	
Mino	MCL		7.7	
DOHH2	DLBCL		3.8	
KMS-PE	MM		26.75	
MDA-MB-468	TNBC		4.1, 29.4	
MDA-MB-231	TNBC		71.	0.005
MCF-7	ER+/PR+/HER2- Breast		78.6	
H460	NSCLC		84.4	0.001
A549	NSCLC		30.7	
Hep-G2	HCC		20.8	
U2OS	OS		11.25	
FaDu	HN		27.05	

Table 9.13 Cytotoxicity of ADC-O *in vitro*

Cell Line	Cancer Type	ADC-O Binding K _D (nM)	ADC-O EC ₅₀ (nM)	PNU-159682 EC ₅₀ (nM)
Mec-vector	CLL		296	
Mec-ROR	CLL		116	
Jeko	MCL	0.12	71.7	
Mino	MCL		28	
MDA-MB-468	TNBC		85.8	
MDA-MB-231	TNBC		782	0.005
MCF-7	ER+/PR+/HER2- Breast		12.65	
H460	NSCLC		365	0.002

Table 9.14 Cytotoxicity of ADC-P *in vitro*

Cell Line	Cancer Type	ADC-P Binding K _D (nM)	ADC-P EC ₅₀ (nM)	PNU-159682 EC ₅₀ (nM)
Mec-vector	CLL		30.3	
Mec-ROR	CLL		10.4	
Jeko	MCL	0.11	2.4	
Mino	MCL		1.2	
MDA-MB-468	TNBC		10.4	
MDA-MB-231	TNBC		24.7	0.005
MCF-7	ER+/PR+/HER2- Breast		30.9	

Cell Line	Cancer Type	ADC-P Binding K _D (nM)	ADC-P EC ₅₀ (nM)	PNU-159682 EC ₅₀ (nM)
H460	NSCLC		39.6	0.001

Table 9.15 Cytotoxicity of ADC-Q *in vitro*

Cell Line	Cancer Type	ADC-Q Binding K _D (nM)	ADC-Q EC ₅₀ (nM)	MMAE EC ₅₀ (nM)
Jeko	MCL	0.23	265*	<0.0001
Mino	MCL		139*	<0.0001
HCC1187	TNBC		5.3*	<0.0001
HCC1806	TNBC		56.1*	<0.0001
MDA-MB-468	TNBC		79.7*	<0.0001
MDA-MB-231	TNBC		167.8*	<0.0001
HCC1937	TNBC		>1,000*	>1,000
MCF-7	ER+/PR+/HER2- Breast		>1,000*	<0.0001
H1975	NSCLC		26.8*	<0.0001
H460	NSCLC		180.1*	<0.0001
Bx-PC3	Pancreatic		45.6*	0.04

Table 9.16 Cytotoxicity of ADC-R *in vitro*

Cell Line	Cancer Type	ADC-R Binding K _D (nM)	ADC-R EC ₅₀ (nM)	PNU- 159682 EC ₅₀ (nM)
Mec-vector	CLL		183	
Mec-ROR	CLL		44.6	
Jeko	MCL	0.25	53.3	
Mino	MCL		15	
MDA-MB-468	TNBC		44.3	
MDA-MB-231	TNBC		203	0.005
MCF-7	ER+/PR+/HER2- Breast		167*	
H460	NSCLC		191	0.001

Table 9.17 Cytotoxicity of ADC-S *in vitro*

Cell Line	Cancer Type	ADC-S EC ₅₀ (nM)	MMAE EC ₅₀ (nM)
Mino	MCL	83.3	<0.0001

[0181] The data in the tables demonstrate that the tested ADCs are effective against a variety of cancer cell lines with different ROR1 expression levels and different sensitivities to the

various payloads.

Example 7: Antigen Dependency of Anti-Proliferative Effects of Exemplary ADCs

[0182] The studies described in this Example evaluated the dependency of the tested ADCs on ROR1 for their anti-proliferative effects. Jeko-1 cells were cultured in log phase growth prior to experiment setup. For competition experiments, 5×10^4 cells were incubated with 100 $\mu\text{g}/\text{ml}$ of Ab1 or vehicle control for 2 hours at 37°C and 5% CO₂. Subsequently, 3, 10, and 30 $\mu\text{g}/\text{ml}$ of ADC-A was added and the cells were incubated for an additional 72 hours at 37°C and 5% CO₂. Each condition was tested in duplicate. Cell viability was determined as described in Example 5.

[0183] The data show that ADC-A inhibited cell proliferation in a dose-dependent manner (**FIG. 9**, black bars). Pre-incubation of the cells with the non-conjugated parental antibody Ab1 inhibited this anti-proliferative activity at all ADC-A concentrations tested (**FIG. 9**, gray bars), demonstrating that the cell killing was mediated by the binding of ADC-A to its target, ROR1.

Example 8: Anti-Tumor Activities of Exemplary Immunoconjugates *in vivo*

1. Efficacy of ADC-A in a TCL1 x ROR1 CLL mouse model

[0184] It has been demonstrated that ROR1 interacts with the T-cell leukemia 1 oncogene (TCL1) and enhances leukemogenesis in Em-TCL1 transgenic mice, and treatment with an anti-ROR1 antibody can impair the engraftment of ROR1 x TCL1 leukemia cells (Widhopf et al., *PNAS* 111: 793-798 (2014)). This study evaluated the activity of ADC-A as compared to vehicle and unconjugated Ab1 in the TCL1 x ROR1 CLL mouse model. In the study, ROR1 x TCL1 leukemia cells were engrafted into mice via tail vein injection, and the injected mice were randomized into five groups, 8 mice/group. The groups were vehicle control, 10 mg/kg Ab1, and 1, 2, and 5 mg/kg ADC-A. The mice were dosed IV weekly for a total of four doses. The results of this study are shown in Table 10 below.

2. Efficacy of ADC-A and ADC-Q in a MCL xenograft mouse model

[0185] Jeko-1 (MCL) cells were engrafted subcutaneously into mice, and the engrafted mice were randomized into five groups, 9 mice/group. The groups were vehicle control, 10 mg/kg Ab1, 20 mg/kg ibrutinib, 5 mg/kg ADC-A, and 5 mg/kg ADC-Q. The mice were dosed IV q4d. The results of this study are shown in Table 10 below.

3. Efficacy of ADC-A in a DLBCL-GCB PDX mouse model

[0186] Germinal center B-cell like diffuse large B-cell lymphoma (DLBCL-GCB) cells were engrafted subcutaneously into mice, and the engrafted mice were randomized into five groups, 6 mice/group. The groups were vehicle control, 10 mg/kg Ab1, 50 mg/kg venetoclax, 10 mg/kg Ab1 plus 50 mg/kg venetoclax, and 5 mg/kg ADC-A. Ab1 and ADC-A were administered IV, qw and venetoclax was administered PO qd. The results of this study are shown in Table 10 below.

4. Efficacy of ADC-A in a ROR1-positive Richter's syndrome PDX mouse model

[0187] NSG mice were subcutaneously injected in both flank areas with RS9373 cells (patient-derived xenograft or PDX) in a cell suspension in matrigel. When palpable tumors were observed (at approximately 50 mm³), the animals were randomized into three groups, 4 mice/group. The treatment groups were vehicle control, 2.5 mg/kg ADC-A IV q4d, and 5 mg/kg ADC-A IV q4d. The mice received 3 total treatments and tumors were harvested 24 hours after the last treatment. Mean tumor growth inhibition (TGI) was calculated utilizing the following formula:

$$TGI = \left[1 - \frac{\left(\bar{X}_{Treated(Final)} - \bar{X}_{Treated(Day 1)} \right)}{\left(\bar{X}_{Control(Final)} - \bar{X}_{Control(Day 1)} \right)} \right] \times 100\%$$

[0188] With most tumor types, heterogenous ROR1 expression is observed at the intra-tumoral level. Nonetheless, tumor regression was observed in the ADC-A treated groups. In the RS101 PDX model of Richter lymphoma, 20-30% of the cells were ROR1-positive, but complete and sustained regressions were observed (FIG. 13). The results of this study are shown in Table 10 below.

5. Efficacy of ADC-A in a ROR1-positive human TNBC xenograft model

[0189] NCR mice were subcutaneously injected in the mammary fat pad with MDA-MB-231 cells (ROR1-positive human triple negative breast cancer (TNBC) cells) in a cell suspension in matrigel. When palpable tumors were observed (at approximately 250 mm³), the animals were randomized into three different groups, 9 mice/group: vehicle control, 1 mg/kg ADC-A IV qw, and 5 mg/kg ADC-A IV qw. The mice received 5 total treatments and tumors were harvested 24 h after the last treatment. Mean tumor growth inhibition (TGI) was calculated utilizing the above formula. The results of this study are shown in Table 10 below.

6. Efficacy of ADC-A in two ROR1-positive human TNBC PDX models

[0190] Two PDX models displaying different levels of ROR1 expression were selected for this study. ROR1 expression was based on the level of ROR1 staining via IHC of a tissue microarray representing triplicate cores of TNBC PDX models. The mean level of ROR1 expression as assessed by % ROR1-positive cells were 58% and 38% for human TNBC cells BR5011 and BR5015, respectively.

[0191] NOD/SCID nude mice were subcutaneously injected with BR5011 or BR5015 cells in the mammary fat pad. When palpable tumors were observed (mean tumor volume approximately 150 mm³ for BR5011 and approximately 250 mm³ for BR5015), animals were randomized into three groups. The groups for the BR5011 PDX model were vehicle control, 1 mg/kg ADC-A IV q4d, and 5 mg/kg ADC-A IV q4d. The groups for the BR5015 PDX model were vehicle control, 1 mg/kg ADC-A IV qw, and 5 mg/kg ADC-A IV qw. Mean TGI was calculated as described above.

[0192] Tumor inhibition and/or regression was observed in the ADC-A treated groups. For example, in the BR5011 TNBC PDX model, which showed ROR1 expression in 58% of the cancer cells, complete and sustained regressions were observed (FIG. 15). The results of this study are shown in Table 10 below.

7. Efficacy of ADC-A, L, M, N, P, R, S and T in a Jeko-1 human MCL xenograft model

[0193] Jeko-1 (MCL) cells were engrafted subcutaneously into mice. When tumor size reached 100 mm³, the mice were randomized into nine groups, 9 mice/group. The groups were vehicle control; 1 mg/kg ADC-N, ADC-P or ADC-R; or 5 mg/kg ADC-A, ADC-L, ADC-M, ADC-S, or ADC-T. The mice were dosed IV q4d. The interim results of this study are shown in Table 10 below.

Table 10 Results of *in vivo* Studies with Exemplary Immunoconjugates

Study	ADC	Animal Model	Duration	Results	FIG.
1	ADC-A	TCL1 x ROR1 leukemia cells	1 month	ADC-A inhibited leukemic cell tumor burden in a dose-dependent manner (1, 2, and 5 mg/kg).	10
2	ADC-A ADC-Q	Jeko-1 MCL xenograft	3 weeks	ADC-A caused tumor regression while ADC-Q caused	11

Study	ADC	Animal Model	Duration	Results	FIG.
				tumor growth delay.	
3	ADC-A	DLBCL-GCB PDX	24 days	ADC-A caused tumor regression (104%) with complete regressions in all animals. Ab1 (unconjugated) alone, venetoclax alone, or Ab1 (unconjugated) + venetoclax were ineffective.	12
4	ADC-A	Chemotherapy-resistant PDX model of Richter transformation	48 days	20-30% of the intra-tumoral cells were ROR1-positive, but complete and sustained regressions were observed. ADC-A mean TGI: 78% at 2.5 mg/kg; 90% at 5mg/kg.	13
5	ADC-A ADC-B	MDA-MB-231 xenograft	47 days	ADC-A mean TGI: 56.4% at 1 mg/kg; 94.2% at 5mg/kg.	14
6	ADC-A	Human TNBC PDX model, BR5011	56 days dosing; 84 days observation (5 mg/kg group)	58% of the intra-tumoral cells were ROR1-positive, but complete and sustained regressions were observed at 5 mg/kg ADC-A. ADC-A mean TGI: 40.1% at 1 mg/kg, complete regression at 5mg/kg. The 5 mg/kg group was monitored for 28 days post last dose and tumor regression was maintained throughout the observation period.	15
		Human TNBC PDX, BR5015 (low ROR1 expression)	17 days	ADC-A mean TGI: 22% at 1 mg/kg; 75.6% at 5 mg/kg.	16

Study	ADC	Animal Model	Duration	Results	FIG.
7	ADC-A ADC-L ADC-M ADC-N ADC-P ADC-R ADC-S ADC-T	Jeko-1 MCL xenograft	Interim results 14 days	Interim analysis at days at 11 and 14 shows that all ADC constructs inhibited tumor growth and all ADC-treated animals demonstrated a reduction in average tumor size at day 14 compared to day 11. This suggests that regression may be observed in all treatment groups by the end of the study (beyond day 14). Animals treated with ADC-A, L, M, and S all displayed significant tumor regression, as shown by the reduction in average tumor size at day 14 compared to pre-treatment at day 0.	17

[0194] *In vivo* studies 1-7 here show that despite the heterogeneity of ROR1 expression within a tumor and varying levels of ROR1 expression across cancer types, treatment with ADC-A resulted in tumor growth inhibition and even sustained, complete regression in a variety of cancers. For example, in the TNBC PDX model that showed expression of ROR1 in 58% of the tumor cells, complete and sustained regressions were observed in all tumors (**FIG. 15**). Similarly, in the RS101 PDX model of Richter lymphoma, 20-30% of the cells were ROR1-positive, but complete and sustained regressions were observed in all tumors (**FIG. 13**). These results suggest that the anti-ROR1 immunoconjugates eradicate cancer by not only cytotoxicity to the bound cancer cells, but also bystander toxicity on neighboring cancer cells in the tumor microenvironment, or by upregulating the immune system's anti-cancer effect, or by a combination of these mechanisms. This finding is significant because it indicates that the immunoconjugates of the present invention can be used to treat tumors that have intra-tumoral heterogeneous expression of ROR1.

[0195] The present *in vivo* studies also show that ADC-A was effective in treating drug-resistant cancers. We observed regressions in human tumor xenografts that were resistant to ibrutinib (the Jeko-1 MCL model) or to rituximab-CHOP immunochemotherapy (the Richter transformation model). Since ROR1 is a marker for advanced cancers and that prior

chemotherapy appears to increase ROR1 expression, our findings demonstrate the potential of the immunoconjugates of the present invention in treating advanced or aggressive cancers.

8. Further *in vivo* evaluation of ADCs

[0196] The *in vivo* efficacy of the ADCs, e.g., ADC-A, E, F, L, M, N, P, Q, and R may be further evaluated in a ROR1-positive, subcutaneous, human MCL xenograft model using Jeko-1 cells. The animals are dosed IV q4d with vehicle, 1 mg/kg ADC, or 5 mg/kg ADC. Tumor growth and body weights are measured every 2-3 days. Pharmacokinetic analysis of the ADCs of the present invention may be performed to determine standard pharmacokinetic parameters such as antibody C_{max} and half-life.

Example 9: Combination Therapy

[0197] The effects of combining ADC-A with other anti-proliferative agents were examined. The initial studies focused on the effects of ADC-A combined with an inhibitor of BTK (ibrutinib, ACP-196/acalabrutinib), Bcl-2 (ABT-199/venetoclax), mTOR (INK128), or PI3K (idelalisib). Additional studies examined the effects of combining ADC-A with two additional Bcl-2 inhibitors, termed Bcl-2i-1 and Bcl-2i-2. Cell lines were tested for both distinct DLBCL subtypes – germinal center B-cell (GCB) and activated B-cell (ABC). The median-effect analysis was used to determine synergism, antagonism, or additivity of inhibition of proliferation of various cell lines treated with ADC-A combined with the anti-proliferative agents. The Combination Index (CI) was determined using the Chou/Talalay equation. The IC₅₀ for each compound was determined in a 72 hour CellTiter-Glo® assay. For combination assays, drugs were used at equimolar ratios (i.e., at the ratio of their IC₅₀ values). CalcuSyn software (by Biosoft) was used for dose effect analysis. A Combination Index of less than 1.1 indicates the treatments are synergistic; 0.9 – 1.1 indicates the treatments are additive; and greater than 1.1 indicates that the treatments are antagonistic.

[0198] ADC-A displayed a synergistic effect with two different BTK inhibitors, ibrutinib (**FIG. 18A**) and ACP-196/acalabrutinib (**FIG. 18B**). The synergistic effect was more pronounced with acalabrutinib and with MCL cell lines. Representative data for ADC-A combined with ibrutinib and acalabrutinib on MCL cell line Jeko-1 are shown in **FIGS. 19A** and **19B**, respectively.

[0199] ADC-A also displayed a synergistic effect with Bcl-2 inhibitor ABT-199/venetoclax (**FIG. 20A**). The synergistic effect was pronounced in both MCL and DLBCL cell lines. The

activity of ADC-A combined with additional Bcl-2 inhibitors, Bcl2i-1 and Bcl2i-2, was examined on Jeko-1 (**FIG. 20B**) and Mino (**FIG. 20C**) cells (both are MCL cell types). ADC-A displayed a synergistic effect with both inhibitors on Jeko-1 cells and an additive effect with both inhibitors on Mino cells. Representative data for ADC-A combined with venetoclax on Jeko-1 are shown in **FIG. 21**.

[0200] ADC-A displayed a synergistic effect with mTOR1/2 inhibitor INK128/sapanisertib (**FIG. 22**). The synergistic effect was observed on both MCL and DLBCL cell lines.

Representative data for ADC-A combined with sapanisertib on Jeko-1 are shown in **FIG. 23**.

[0201] ADC-A displayed a synergistic effect with PI3K inhibitor CAL-101/idelalisib (**FIG. 24**). The synergistic effect was observed on both MCL and DLBCL cell lines. Representative data for ADC-A combined with idelalisib demonstrating synergistic effects on both subtypes of DLBCL are shown in **FIG. 25A** (TMD cells, DLBCL-ABC) and **FIG. 25B** (DOHH2 cells, DLBCL-GCB).

Example 10: Further Evaluation of Combination Therapy

[0202] The *in vivo* efficacy of the ADCs in combination with a Bcl-2 inhibitor may be further assessed in a ROR1-positive human MCL xenograft model using Jeko-1 cells or in a PDX model. Both the ADC and the Bcl-2 inhibitor are dosed at maximum tolerated and sub-optimal doses, alone and in combination as outlined below, in a repeat dose study. Tumor growth and body weights are measured every 2-3 days.

- ADC-A and Bcl-2 inhibitor MTD dosing
 - 5 mg/kg ADC-A, IV, q4d
 - 100 mg/kg venetoclax (ABT-199), weekly
- ADC-A and Bcl-2 inhibitor sub-optimal and combination dosing
 - 1 mg/kg ADC-A, IV, q4d
 - 2 mg/kg ADC-A, IV, q4d
 - 50 mg/kg ABT-199, PO, qd
 - 100 mg/kg ABT-199, PO, qd
 - 1 mg/kg ADC-A, IV, q4d + 50 mg/kg ABT-199, PO, qd
 - 2 mg/kg ADC-A, IV, q4d + 50 mg/kg ABT-199, PO, qd
 - 1 mg/kg ADC-A, IV, q4d + 100 mg/kg ABT-199, PO, qd

- 2 mg/kg ADC-A, IV, q4d + 100 mg/kg ABT-199, PO, qd

[0203] Pharmacokinetic analysis is performed to determine standard pharmacokinetic parameters such as antibody C_{max} and half-life.

Example 11: Phase 2 Clinical Study of Anti-ROR1-MMAE Immunoconjugates

[0204] The following describes a protocol for a prospective open label Phase 1b/2 clinical trial for anti ROR1-MMAE immunoconjugate therapy.

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histological diagnosis of CLL/SLL or MCL as documented in medical records
- CLL/SLL or MCL has been previously treated and has relapsed after or progressed during prior therapy
- Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 non-biopsied, non-irradiated lesion that measures ≥ 2.0 cm in the longest dimension [LD] and ≥ 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).
- Current medical need for therapy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer 1 week before the start of study therapy.
- All acute toxic effects of any prior antitumor therapy resolved to Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or neurotoxicity [Grade 1 or 2 permitted], or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions as noted below]).
- Adequate bone marrow function:
 - a) Absolute neutrophil count (ANC) $\geq 1.0 \times 10^9/L$ (Grade ≤ 2). b) Platelet count $\geq 50 \times 10^9/L$ (Grade ≤ 2). b) Hemoglobin ≥ 8.0 g/dL (Grade ≤ 2) maintained for ≥ 1 week from any prior transfusion.
- Note: Grade ≥ 3 neutropenia, thrombocytopenia, or anemia is permitted if the abnormality

is related to bone marrow involvement with hematological malignancy (as documented by bone marrow biopsy/aspirate obtained since the last prior therapy).

- Adequate hepatic profile:
 - Serum alanine aminotransferase (ALT) $\leq 3 \times$ upper limit of normal (ULN) (Grade ≤ 1).
 - Serum aspartate aminotransferase (AST) $\leq 3 \times$ ULN (Grade ≤ 1).
 - Serum bilirubin $\leq 1.5 \times$ ULN (Grade ≤ 1).
- Adequate renal function:
 - a) Estimated creatinine clearance (eClCR) > 45 mL/minute (with eClCR to be calculated by the Cockcroft-Gault formula), or b) Measured creatinine clearance > 45 mL/minute (as assessed with a 24-hour urine collection).
- Adequate coagulation profile:
 - Prothrombin time (PT) $\leq 1.5 \times$ ULN (Grade ≤ 1).
 - Activated partial thromboplastin time (aPTT) $\leq 1.5 \times$ ULN (Grade ≤ 1).
- Negative viral serology:
 - Negative human immunodeficiency virus (HIV) antibody.
 - Negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBC) antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (PCR) testing.
 - Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA) by quantitative PCR.
- For female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.
- In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.
- Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures (including all bone marrow biopsy/aspirations and radiographic studies), and study restrictions.

Exclusion Criteria:

- Known histological transformation to an aggressive lymphoma (ie, Richter

transformation). Note: Biopsy documentation of the absence or presence of transformation is not required.

- Known central nervous system malignancy. Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.
- History of another malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin; adequately treated carcinoma in situ without evidence of disease; adequately treated, papillary, noninvasive bladder cancer; other cancer that has been in complete remission for ≥ 2 years.
- Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade ≥ 3 hypertension (diastolic blood pressure ≥ 100 mmHg or systolic blood pressure ≥ 160 mmHg) despite antihypertensive therapy.
- Significant screening ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation/flutter, left bundle branch block, 2nd-degree atrioventricular (AV) block type II, 3rd-degree AV block, Grade ≥ 2 bradycardia, or corrected QT (QTc) >450 msec (for men) or >470 msec (for women).
- Gastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.
- Ongoing risk for bleeding due to active peptic ulcer disease; bleeding diathesis; or requirement for systemic anticoagulation with an antiplatelet drug (eg, aspirin, triflusil, clopidogrel, prasugrel, ticagrelor, ticlopidine, cilostazol, vorapaxar, dipyridamole); or with heparin, low-molecular-weight heparin or heparin fractions (eg, enoxaparin, dalteparin, fondaparinux) or oral anticoagulants (eg, apixaban, rivaroxaban, dabigatran etexilate, warfarin). Note: Use of heparin or thrombolytic agents for local maintenance or clearance of a central venous catheter is permitted.
- Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Subjects with

localized fungal infections of skin or nails are not precluded from participation.

- In subjects with prior hematopoietic progenitor cell transplantation, evidence of ongoing graft-versus-host disease (GVHD).
- Pregnancy or breastfeeding.
- Major surgery within 4 weeks before the start of study therapy.
- Prior solid organ transplantation.
- Prior anti-ROR1 therapy within 12 weeks prior to the start of study therapy.
- Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids. Note: At Screening, subjects may be using topical or inhaled corticosteroids. During study therapy, use of corticosteroids as prophylaxis for infusion reactions will be minimized. However, subjects may use systemic, enteric, topical or enteric corticosteroids as required for treatment-emergent conditions

Primary Outcome Measures:

- Phase 1b: Recommended dosing regimen (RDR) [Time Frame: From baseline to 52 weeks] Evaluation of cirmtuzumab dose-pharmacodynamic and pharmacokinetic-pharmacodynamic relationships, and safety.
- Phase 2: Complete Response (CR) rate [Time Frame: From randomization to discontinuation of treatment of all study subjects or 72 weeks after accrual of the final subject] Proportion of subjects achieving a CR in accordance with pre-established response criteria for lymphoma (Cheson, J Clin Oncol. 32(27):3059-68 (2014)).

Table 11 Exemplary Dosing Regimens

Arms	Assigned Interventions
Phase 1b - dose finding for ROR1-MMAE	Administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter
Phase 1b - dose expansion for ROR1-MMAE	Administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter
Phase 2 - safety and efficacy evaluation for ROR1-MMAE	Administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter

[0205] Dose finding phase will be conducted by parallel dose comparison at 1.0, 2.0, and 3.0 mg/kg.

[0206] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.

[0207] The amino acid sequences and nucleotide sequences described herein are listed in Table 12 below.

Table 12 List of Sequences

SIN	Description	SEQUENCE
1	Human ROR1 fragment	VATNGKEVVS STGVLFVKFG PC
2	Human ROR1 fragment	EVVSSTGVLF VKFGPC
3	Ab1 heavy chain	QVQLQESGPGLVKPSQTLSTCTVSGY AFTAYNIHWVRQAPGQGLEWM GSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLMTNMDPVDTATYYC ARGWYYFDYWGHTLTVSSASTKGPSVFPLAPSSKSTSGGTAAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHPKPSNTKVDKKVEPKSCDKTHCPCPAPELLGGPSVFLPPK PKDTLMISRTPETCVVVDVSHEDEVKFNWYVDGVEVHNAKTPREE QYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TPPPVLDSDGSFFLYSKLTVDKSRWQQGVFSCSVMHEALHNHYTQKSL SLSPGK
4	Ab1 light chain	DIVMTQTPLSLPVTPGEPEASCRASKSISKYLAWYQQKPGQAPRLLIYSG STLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPYTFGEGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC
5	Ab1 VH	QVQLQESGPGLVKPSQTLSTCTVSGY AFTAYNIHWVRQAPGQGLEWM GSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLMTNMDPVDTATYYC ARGWYYFDYWGHTLTVSS
6	Ab1 VL	DIVMTQTPLSLPVTPGEPEASCRASKSISKYLAWYQQKPGQAPRLLIYSG STLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPYTFGEGT

SIN	Description	SEQUENCE
		KVEIK
7	Ab1 HCDR1	GYAFTAYN
8	Ab1 HCDR2	FDPYDGGS
9	Ab1 HCDR3	GWYYFDY
10	Ab1 LCDR1	KSISKY
11	Ab1 LCDR2	SGS
12	Ab1 LCDR3	QQHDESPY
13	Ab1 VH frag.	SGYAFTAYNIHWVRQ
14	Ab1 VH frag.	GSFDPYDGGSSYNQKF
15	Ab1 VH frag.	YYCARGWYYFDYWGHGTLVTVSS
16	Ab1 VL frag.	CRASKSISKYLAWY
17	Ab1 VL frag.	LLIYSGSTLQSG
18	Ab1 VL frag.	CQQHDESPYTFGE GTKVEIK
19	Ab1 heavy chain coding sequence	AAGCTTACCGCCACCATGGGCTGGAGCTGTATCATCCTCTTCCCTGGTG GCGACCGCGACGGGTGTCCACTCCCAGGTGCAGCTCCAGGAGTCCGG CCCCGGGCTTGTGAAGCCGTACAAACCCCTGTCCCTGACGTGCACGG TCTCCGGCTACGCCCTCACGGCCTACAAACATAATTGGGTCCGGCAGG CGCCGGGCCAGGGCTGGAGTGGATGGGTTCTCGACCCGTACGAT GGCAGGGAGCTCGTACAACCAGAAGTTCAAAGACCGCCTGACGATCTC CAAGGACACCTCGAAAAACCAAGGTCGTCCCTGACCATGACCAACATGG ACCCGGTGGACACGGCGACCTACTATTGCGCCCGCGGCTGGTACTAC TTCGACTACTGGGCCACGGGACCCCTGGTCACCGTGTCTCCGCTTCG ACCAAGGGCCCCAGCGTCTTCCCCTCGCGCCCTCTCGAAGTCCACC TCGGCGGCACTGCCGCCCTGGGCTGCTGAGTCCTCGGGCTGTATTCACTCA GGAGGCCGGTGACCGTCTCGTGGAACAGCGGGGACTCACCTCCGGCG TGCACACCTTCCCGCCGTGCTGAGTCCTCGGGCTGTATTCACTCA GCTCGGTGTCACCGTCCCCTCGTCCGTGACCGCAGACGTACA TCTGCAACGTCAACCACAAGCCCTGAAACACCAAGGTGGACAAGAAG GTCGAGCCGAAGTCTCGGATAAGACCCACACCTGCCCGGTGCCCC GGCCCCCGAGCTCCTGGCGGTCCGTGTTCCCTCTTCCCGCCAA GCCCAAGGACACCCCTGATGATCAGCCGCACGCCCGAGGTGACCTGCG TCGTGTTGGACCGTCTCCCACGAGGATCCCAGGGTGAAGTTCAACTGG TACGTGGACGGGTGGAGGTCCACAACGCCAAGACAAAGCCGCGGG AAGAGCAGTACAACACTCGACCTACCGCGTCGTGACCGTGTGACGGTC CTCCACCAAGGACTGGCTGAACGGCAAGGAGTACAAATGCAAGGTGTC

SIN	Description	SEQUENCE
		CAACAAGGCCCTGCCCGCCCATCGAGAAGACCATCTCCAAGGCCA AGGGACAGCCCGCGAGCCGCAGGTCTACACGCTGCCTCCCTCCGG GACGAGCTACGAAGAACCAAGGTATCGCTCACCTGCCTCGTGAAGGG CTTCTACCCGAGCGACATGCCGTCGAGTGGGAGAGCAACGGCCAGC CCGAGAACAACTACAAAACCACGCCGCCGGTCCCTGACTCTGACGGG TCCTTCTCCTGTACTCCAAGCTGACCGTGGACAAGTCGCGGTGGCAG CAGGGGAACGTGTTCTCGTGCCTGACGAGGCGTTGCACAA CCACTACACCCAGAACGTCACTCTCCCTGAGCCCAGGCAAGTGATAAT CTAGAGTCGGGCGGCCGGC
20	Ab1 light chain coding sequence	AAGCTTACCGCCACCATGGGCTGGTCATGCATCATCCTGTTCCCTGGTC GCCACCGCGACGGGGTCCACAGTGATACTGTCATGACGCAGACGCC GCTGAGCCTCCCGGTGACGCCCGCGAGCCGCCAGCATCTCCTGCC GCGCTTCCAAGTCCATCTGAAGTACCTGGCGTGGTATCAGCAGAAC CCCAGGCCAGGCCCCGCGCCTGCTCATCTACTCTGGTCCACGCTCCAG TCGGGCATCCCGCCCCGGTTCTCGGGTTGGATACGGCACCGACTTC ACCTGACCATCAACAAACATCGAGAGCGAACGACGCCGTACTACTT CTGCCAGCAGCACGACGAGTCCCCGTACACCTCGCGAGGGGACCA AGGTCGAGATCAAGCGTACCGTGCAGCAGCTCAAGTCTGGCACCGCCTCGTCTGT CCCCCGTCCGACGAGCAGCTCAAGTCTGGCACCGCCTCGTCTGT CTCCTGAACAACACTTCTACCCAGGGAAAGCCAAGGTCCAGTGGAGGT GGACAACCGCGCTGCAGTCCGGGAATAGCCAGGAGTCGGTGACGGAG CAGGACTCCAAGGACTCCACGTACTCGCTCTCGTCCACCCCTGACCCCT TCCAAGGCGGACTACGAAAAGCACAAAGGTCTACGCCCTGCGAGGTGAC GCACCAAGGCTGTCCTCCCCAGTGACCAAGTCGTTCAACCGCGCG AGTGCTGATAATCTAGAGTCGGGCGGCCGGC
21	Ab1 VH coding sequence 1	AAGCTTACCGCCACCATGGGCTGGAGCTGTATCATCCTTCCCTGGTG GCGACCGCGACGGGTGTCCACTCCCAGTGACGCTCCAGGAGTCCGG CCCCGGGCTTGTGAAGCCGTACAAACCCCTGTCCTGACGTGCACGG TCTCCGGCTACGCCCTACGGCCTACAAACATACATTGGGTCGGCAGG CGCCGGGCCAGGGCTGGAGTGGATGGGTTCCCTCGACCCGTACGAT GGCGGGAGCTCGTACAACCAAGAACGAAAGTCAAAGACCGCCTGACGATCTC CAAGGACACCTCGAAAACCAAGGTGTCCTGACCATGACCAACATGG ACCCGGTGGACACGGCGACCTACTATTGCGCCCGCGGCTGGTACTAC TTCGACTACTGGGACCGGGACCCCTGGTACCGTGTCTTCC
22	Ab1 VL coding sequence 1	GATATCGTCATGACGCAGACGCCGCTGAGCCTCCGGTGACGCCGG CGAGCCCGCCAGCATCTCCTGCCCGCTTCCAAGTCCATCTGAAGTA CCTGGCGTGGTATCAGCAGAACGCCGCCAGGCCCGCGCTGCTCA TCTACTCTGGTCCACGCTCCAGTCGGCATCCCGCCCCGGTTCTCGG GTTGGGATACGGCACCGACTTCACCCCTGACCATCAACAAACATCGAG AGCGAACGACGCCGTACTACTCTGCCAGCAGCACGACGAGTCCCC GTACACCTCGCGAGGGACCAAGGTGAGATCAAG
23	Ab1 VH coding sequence 2	CAGGTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCTTCACA GACCCCTGTCCCTCACCTGCACTGTCTGGTATGCATTCACTGCCA CAACATACACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGG

SIN	Description	SEQUENCE
		TGGGTTCTTIGATCCTTACGATGGTGGTAGTAGTTACAACCAAGAAGT TCAAGGACAGACTCACCATCTCCAAGGACACCTCCAAAAACCAGGTG GTCCTTACAATGACCAACATGGACCCGTGGACACAGCCACGTATTA CTGTGCAAGAGGGTGGTACTACTTTGACTACTGGGGCACCGAACCC TGGTCACCGTCTCCTCA
24	Ab1 VL coding sequence 2	GATATTGTGATGACCCAGACTCCACTCTCCCTGCCCGTCACCCCTGGA GAGCCGGCCTCCATCTCCTGCAGGGCAAGTAAGAGCATTAGCAAATA TTTAGCCTGGTACCAAGCAGAAACCTGGCCAGGCTCCAGGCTCCTCAT CTATTCTGGATCCACTTGCAATCTGGATCCCACCTCGATTAGTGG CAGCGGGTATGGAACAGATTTACCCCTCACAATTAAATAACATAGAAT CTGAGGATGCTGCATATTACTTCTGTCAACAGCATGATGAATCCCCGT ACACGTTGGCGAGGGGACCAAGGTGGAAATCAA
25	D10 VH	QVQLKESGPGLVAPSQTLSITCTVSGFSLTSYGVHWVRQPPGKGLEWL VIWAGGFTNYSALKSRLSISKDNSKSQVLLKMTSLQTDAMYYCARR GSSYSMDYWGQGTSVIVSS
26	D10 VL	EIVLSQSPAITAASLGQKVTTCSASSNVSYIHWYQQRSGTSPRPWIYEISK LASGVPVRFSGSGSGTTSYSLTISSMEAEDAAIYYCQQWNYPLITFGSGTK LEIQ
27	D10 HCDR1	GFSLTSYG
28	D10 HCDR2	WAGGFT
29	D10 HCDR3	RGSSYSMDY
30	D10 LCDR1	SNVSYI
31	D10 LCDR2	EIS
32	D10 LCDR3	QQWNYP LI
33	D10 VH coding sequence	CAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACA GACTCTGTCCATCACTTGCAGTGTCTCTGGTTTCATTAAACCAGTTAT GGTGTACACTGGGTTGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCT GGGAGTAATATGGGCTGGTGGATTCAAATTATAATTCCGGCTCTCA AGTCCAGACTGAGCATCAGCAAAGACAACCTCAAGAGCCAAGTTCTC TTAAAAATGACCAGTCTGCAAACGTGATGACACAGCCATGTACTACTG TGCCAGGAGAGGTAGTTCTATTCTATGGACTATTGGGTCAAGGAA CCTCAGTCACCGTCTCCTCA
34	D10 VL coding sequence	GAAATTGTGCTCTCTCAGTCTCCAGCCATCACAGCTGCATCTCTGGGC CAAAAGGTACCCATCACCTGCAGTGCCAGTTCAAATGTAAGTTACAT CCACTGGTACCAAGCAGAGGTCAAGCACCTCCCCAGACCATGGATT ATGAAATATCCAAACTGGCTCTGGAGTCCCAGTTCGCTTCAGTGGCA GTGGGTCTGGGACCTCTTACTCTCTCACAAATCAGCAGCATGGAGGCTG

SIN	Description	SEQUENCE
		AAGATGCTGCCATTATTATTGTCAGCAGTGGATTATCCTCTTATCA CGTCGGCTCGGGGACAAAGTTGGAAATACAA
35	4A5 VH	EVKLVESGGGLVKPGGSLKLSKAASGFTFSSYAMSWVRQIPEKRLEWVA SISRGGTTYPDSVKGRFTISRDNVNILYLMQMSLRSEDTAMYYCGRYD YDGYYAMDYWGQGTSVTVSS
36	4A5 VL	DIKMTQSPSSMYASLGERVTITCKASPDINSYLSWFQQKPGKSPKTLIYRA NRLVDQVPSRFSGQGSGQDYSLTINSLEYEDMGIYYCLQYDEFPYTFGG GTKLEMK
37	4A5 HCDR1	GFTFSSYA
38	4A5 HCDR2	ISRGGTT
39	4A5 HCDR3	YDYDGYYAMDY
40	4A5 LCDR1	PDINSY
41	4A5 LCDR2	RAN
42	4A5 LCDR3	LQYDEFPY
43	4A5 VH coding sequence	GAAGTGAAACTGGTGGAGTCTGGGGAGGCTTAGTGAAGCCTGGAG GGTCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTCAGTAGCT ATGCCATGTCTGGGTTGCCAGATTCCAGAGAAAGAGGCTGGAGTGG GTCGCATCCATTAGTCGTGGTGGTACCACTACTATCCAGACAGTGTG AAGGGCCGATTACCATCTCCAGAGATAATGTCAGGAACATCCTGTA CCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACT GTGGAAGATATGATTACGACGGGTACTATGCAATGGACTACTGGGGT CAAGGAACCTCAGTCACCGTCTCCTCA
44	4A5 VL coding sequence	GACATCAAGATGACCCAGTCTCCATCTTCCATGTATGCATCTCTAGGA GAGAGAGTCACTATCACTTGCAAGGCAGTCCGGACATTAATAGCTA TTAACAGCTGGTCCAGCAGAAACCAGGGAAATCTCCTAACAGCCCTGA TCTATCGTCAAACAGATTGGTTGATGGGTCCCATCAAGGTTCAAGTGC GCGGTGGATCTGGCAAGATTATTCTCTCACCATCACAGCCTGGAG TATGAAGATAGGAAATTATTATTGTCTACAGTATGATGAATTCCG TACACGTTGGAGGGGGACCAAGCTGGAAATGAAAC
45	99961 VH	EIQLQQSGPVLVKPGASVKVSCKASGYAFTAYNIHWVRQSHGKRLEWIG SFDPYDGGSSYNQKFKDKATLTVDKSSTAYMHLNSLTSEDSAVYYCAR GWYYFDYWGHTTLTVSS
46	99961 VL	DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKGKTNKLIIYSG STLQSGIPSFRGSGSGTDFLTISLEPEDFAMYCYCQQHDESPYTFGEGT

SIN	Description	SEQUENCE
		KLEIKR
47	Ab4 heavy chain	QVQLQESGPGLVKPSQTLSTCTVSGYAFTAYNIHWIRQPPGKGLEWIGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLMTNMDPVDTATYYCARGWYYFDYWGHTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPETCVVVDVSHEDEVKFNWYVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
48	Ab4 VH	QVQLQESGPGLVKPSQTLSTCTVSGYAFTAYNIHWIRQPPGKGLEWIGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLMTNMDPVDTATYYCARGWYYFDYWGHTLTVSS
49	Ab4 light chain	DVVMQTQSPSLPVTLGQPASISCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
50	Ab4 VL	DVVMQTQSPSLPVTLGQPASISCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK
51	Ab4 heavy chain coding sequence	CAGGTCCAGCTGCAGGAGTCAGGTCCCGACTGGTCAAGCCGTCGCA GACGCTGCTCCCTCACCTGACCGTGTGGCTACGCCCTCACCGCCA CAACATCCACTGGATCCGTACGCCCTGGAAAGGGCCTCGAGTGGATCGGCAGCTCGACCCGTACGACGGCGGGTCGTCCTACAACCAGAAGTTCAAGGACCGCCTACCATCAGCAAGGACACCTCCAAGAACCAAGGT CGTCCTACCATGACCAACATGGACCCGTGGACACCACGCCACGTACTACTGCGCGGGCTGGTACTACTTCGACTACTGGGGCACGGCACCCTCGTCACGGCTCGTCGGCGAGCACCAAGGGTCCAGCGTCTTCCCCCTGGCCCCCTCCAGCAAGTCCACCTCGGGGGGACCGCCGCCCCTGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACCTCCGGCGCCCTACCCAGCGGGGTCCACACCTCCGGCGGTCCCTGCAGTCATCCGGTCTACTCCTTGAGCTCAGTCGTACCGTCCCAGCTCCTCCCTCGGAACCGCAGACCTACATCTGCAACGTCAACCACAAGCCGTCCAACACCAAGGTGACAAGAAGGTGGAGCCAAATCGTGCACAGAACCCCCACACCTGCCCGTGCCCCGCCGGAACTGCTCGGCCGCCTCGGTGTTCCCTGTTCCCCCGAAGGCCAAGGAACACCCCTCATGATCTCCCGCACCCCGAGGTCACCTGCGTGGTGGATGTCTCCCACGAGGACCCGAGGGTGAAGTTCAACTGGTACGTGGACGGGGTCGAGGGTGCACAACGCCAAGACCAAGCCCCGAGAGGAACAGTATAACTCGACGTAACGCGTGGTCAGCGTCTGACCGTGCTCCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGAGCAACAAAGGCCCTGCCCCCCCC

SIN	Description	SEQUENCE
		ATCGAGAAGACGATCTCCAAGCGAAGGGGAGCCGCGAGCCGC AGGTCTACACCTGCCGCCAGCCGGACGAGCTACGAAGAATCAG GTCTCGCTCACCTGCCTCGTAAGGGTTCTACCCGTCGGACATCGCG GTCGAATGGGAGTCGAACGGTCAGCCCCAGAATAACTACAAGACGA CCCCGCCGTCTGGACTCGGACGGCAGCTCTCCTGTACTCGAAGC TGACGGTCGACAAGTCGCGCTGGCAGCAGGGCAACGTCTCTCGTGC TCGGTGATGCACGAGGCCCTCCACAACCACTACACACAGAAGAGCCT CTCGCTTCGCCGGGCAAG
52	Ab4 VH coding sequence	CAGGTCCAGCTGCAGGAGTCAGGTCCCGACTGGTCAAGCCGTCGCA GACGCTGTCCCTCACCTGCACCGTGTGGCTACGCCTCACCGCTA CAACATCCACTGGATCCGTCAAGCCCCCTGGGAAGGGCCTCGAGTGG TCGGCAGCTTCGACCCGTACGACGGCAGGTCGTCCCTACAACCAGAAG TTCAAGGACCCCTACCATCAGCAAGGACACCTCAAGAACCAAGGT CGTCCTCACCATGACCAACATGGACCCGTGGACACCGCCACGTACT ACTGCGCGGGGCTGGTACTACTTCGACTACTGGGGCACGGCACC CTCGTCACGGTCTCGTGC
53	Ab4 light chain coding sequence	GACGTCGTATGACCCAGTCGCCCCCTCCCTGCCGGTTACCCGGC CAGCCCGCCTCCATCAGCTGCCGTGCCTCCAAGTCCATTCCAAGTAC CTGGCCTGGTACCAAGCAGAAGCCGGGAAGGCCCAAAGCTCCTCAT CTACTCCGGCTCCACCCCTCCAGAGCGGCATCCCCCCCCGCTTCAGCG CTCCGGCTACGGCACCGACTTCACCCCTACCATCAATAACATCGAGTC GGAGGACGCCCGTACTACTTCTGCCAGCAGCACGAGAATGCCGT ACACCTTCGGGGAGGGCACCAAGGTGGAGATCAAGAGGACGGTCGC CGGCCCTCCGTGTTCATCTTCCCCCTCGGACGAACAGCTGAAGTC CGGGACCGCCTCCGTCTGCCTCCTCAACAACTTCTACCCGCCGA GGCCAAGGTGCACTGGAGGTGACACCGCCTCCAGTCCGGCAACT CCCAGGAGTCGGTGACCGAGCAGGACTCGAAGGACAGTACCTACTCG CTGAGCTCCACACTGACGCTCTCGAAGGCCACTACGAGAACCAA GGTGTACGCATGCGAGGTGACCCACCAGGGCTGAGCTGCCGGTGA CTAAGTCGTTAACAGGGCGAATGC
54	Ab4 VL coding sequence	GACGTCGTATGACCCAGTCGCCCCCTCCCTGCCGGTTACCCGGC CAGCCCGCCTCCATCAGCTGCCGTGCCTCCAAGTCCATTCCAAGTAC CTGGCCTGGTACCAAGCAGAAGCCGGGAAGGCCCAAAGCTCCTCAT CTACTCCGGCTCCACCCCTCCAGAGCGGCATCCCCCCCCGCTTCAGCG CTCCGGCTACGGCACCGACTTCACCCCTACCATCAATAACATCGAGTC GGAGGACGCCCGTACTACTTCTGCCAGCAGCACGAGAATGCCGT ACACCTTCGGGGAGGGCACCAAGGTGGAGATCAAG
55	Linker peptide moiety sequence	GGFG
56	Linker peptide moiety sequence	ALAL
57	Linker peptide moiety	GFLG

SIN	Description	SEQUENCE
	sequence	
58	Glutamine tag	LLQGA
59	Sortase motif	LPxTG
60	Sortase motif	NPQTN
61	BirA tag	GFEIDKVWYDLDA
62	Human CH ₁ domain plus upper hinge region	ASTKGPSVPLAPSSKSTSGTAALGCLVKDYFPEPVTWNSGALTSGVHTFPALQSSGLYSLSSVTVPSQLGTQTYICNVNHKPSNTKVDKKVEPKSC
63	Human Kappa constant domain	RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
64	Humanized 4A5 scFv	DIQMTQSPSSLSASVGDRVTITCKASPDINSYLSWFQQRPGQSPRRIYRANRLVDGVPDRFSGSGSGTDFTLKISRVEAEDGVVYYCLQYDEFPYTFGQGTKVEIKGGGGSGSTSGSGKPGSGEGSTKGGGGSEVQLVQSGAEVKKPGESLRISCKSGSGFTSSYAMSWIRQSPSRGLEWLGSISRGGTTYYPDHSVKGRTISRDNAKNSLYLQMNSLRAEDTAVYCGRYDYDGYYAMDYWGQGTLTVSS
65	Ab1 scFv	DIVMTQTPLSLPVTPGEPAISCRASKSISKYLAWYQQKPGQAPRLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPTYTFGE GTKVEIKGGGGSGSTSGSGKPGSGEGSTKGGGGGSQVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQFKDRLTISKDTSKNQVVLMTNMDPVDTATYYCARGWYYFDYWGHGTLTVSS
66	Ab2 scFv	DVVMTQSPLSLPVTLGQPASISCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPTYTFGE GTKVEIKGGGGSGSTSGSGKPGSGEGSTKGGGGGSQVQLQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQFKDRLTISKDTSKNQVVLMTNMDPVDTATYYCARGWYYFDYWGHGTLTVSS
67	Ab3 scFv	DIVMTQTPLSLPVTPGEPAISCRASKSISKYLAWYQQKPGQAPRLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFCQQHDESPTYTFGE GTKVEIKGGGGSGSTSGSGKPGSGEGSTKGGGGGSQVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWIRQPPGKGLEWIGSFDPYDGGSSYNQFKDRLTISKDTSKNQVVLMTNMDPVDTATYYCARGWYYFDYWGHGTLTVSS

SIN	Description	SEQUENCE
		YCARGWYYFDYWHGTLTVSS
68	Ab4 scFv	DVVMQTQSPLSLPVTLGQPASISCRASKSISKYLAWYQQKPGKA PKLLIYSGSTLQSGIPPRFSGSGYGTDFLTINNIESEDAAYYFC QQHDESPYTFGEGTKVEIKGGGGSGSTSGSGKPGSGEGSTKGG GGGSQVQLQESGPGLVKPSQLSLTCTVSGYAFTAYNIHWIRQ PPGKGLEWIGSFDPYDGGSSYNQKFDRLTISKDTSKNQVVLT MTNMDPVDTATYYCARGWYYFDYWHGTLTVSS


*SIN: SEQ ID NO.

[0208] It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

[0209] The term “comprise” and variants of the term such as “comprises” or “comprising” are used herein to denote the inclusion of a stated integer or stated integers but not to exclude any other integer or any other integers, unless in the context or usage an exclusive interpretation of the term is required.


[0210] Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge.

[0211] Definitions of the specific embodiments of the invention as claimed herein follow. According to a first embodiment of the invention, there is provided an immunoconjugate of the formula:



wherein Ab is an antibody that binds to ROR1, and wherein the heavy chain complementarity determining regions of the antibody comprise the amino acid sequences of SEQ ID NOs: 7, 8 and 9, and wherein the light chain complementarity determining regions of the antibody comprise the amino acid sequences of SEQ ID NOs: 10, 11, and 12;

each occurrence of the group $[(\text{L})_m-(\text{D})]$ has the structure:



, wherein $\sim\sim\sim$ represents the site of attachment to the antibody; and

n is an integer from 1 to 8.

[0212] According to a second embodiment of the invention, there is provided a pharmaceutical composition comprising the immunoconjugate of the first embodiment and a pharmaceutically acceptable excipient.


[0213] According to a third embodiment of the invention, there is provided a method of treating an ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of the first embodiment.

[0214] According to a fourth embodiment of the invention, there is provided the use of the immunoconjugate of the first embodiment or the pharmaceutical composition the second embodiment in the preparation of a medicament for treating a ROR1-expressing cancer in a patient in need thereof.

[0215] According to a fifth embodiment of the invention, there is provided a method of making the immunoconjugate of the first embodiment, comprising:
providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and
conjugating monomethyl auristatin E (MMAE) to the antibody;
wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.


CLAIMS

1. An immunoconjugate of the formula:



wherein Ab is an antibody that binds to ROR1, and wherein the heavy chain complementarity determining regions of the antibody comprise the amino acid sequences of SEQ ID NOS: 7, 8 and 9, and wherein the light chain complementarity determining regions of the antibody comprise the amino acid sequences of SEQ ID NOS: 10, 11, and 12;

each occurrence of the group $-(\text{L})_m-(\text{D})$ has the structure:



wherein $\sim\sim$ represents the site of attachment to the antibody; and

n is an integer from 1 to 8.

2. The immunoconjugate of claim 1, wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOS: 3 and 4, respectively.
3. The immunoconjugate of claim 2, wherein n is an integer from 1 to 5.
4. The immunoconjugate of claim 3, wherein n is 4.
5. The immunoconjugate of claim 1, wherein the V_H and V_L of the antibody comprise the amino acid sequences of SEQ ID NOS: 5 and 6, respectively.
6. A pharmaceutical composition comprising the immunoconjugate of any one of claims 1 to 5 and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 6, further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.
8. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of any one of claims 1 to 5 or the pharmaceutical composition of claim 6 or claim 7.
9. Use of the immunoconjugate of any one of claims 1 to 5 or the pharmaceutical composition of claim 6 or claim 7 in the preparation of a medicament for treating a ROR1-expressing cancer in a patient in need thereof.
10. A method of making the immunoconjugate of claim 1, comprising:
 - providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and
 - conjugating monomethyl auristatin E (MMAE) to the antibody;
 - wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

VelosBio Inc.

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON






FIG. 2A**FIG. 2B**

FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6







FIG. 7A**FIG. 7B****FIG. 7C**

FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D





FIG. 8E

BT549

**FIG. 8F**

TOV112D






FIG. 8G**FIG. 8H**


FIG. 8I

FIG. 9




FIG. 10




FIG. 11




FIG. 12





FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B







FIG. 20A**FIG. 20B****FIG. 20C**

FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25A





FIG. 25B



024651_W0002_SL.txt
SEQUENCE LISTING

<110> VELOSBI0 INC.

<120> ROR1 ANTIBODY IMMUNOCONJUGATES

<130> 024651.W0002

<140>

<141>

<150> 62/524,388

<151> 2017-06-23

<150> 62/524,386

<151> 2017-06-23

<150> 62/524,382

<151> 2017-06-23

<160> 68

<170> PatentIn version 3.5

<210> 1

<211> 22

<212> PRT

<213> Homo sapiens

<400> 1

Val Ala Thr Asn Gly Lys Glu Val Val Ser Ser Thr Gly Val Leu Phe
1 5 10 15

Val Lys Phe Gly Pro Cys
20

<210> 2

<211> 16

<212> PRT

<213> Homo sapiens

<400> 2

Glu Val Val Ser Ser Thr Gly Val Leu Phe Val Lys Phe Gly Pro Cys
1 5 10 15

<210> 3

<211> 446

<212> PRT

<213> Artificial Sequence

024651_W0002_SL.txt

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 3

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ala Phe Thr Ala Tyr
20 25 30

Asn Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val
65 70 75 80

Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly Thr Leu Val
100 105 110

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
130 135 140

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145 150 155 160

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
165 170 175

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu

024651_W0002_SL.txt

180

185

190

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
195 200 205

Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
245 250 255

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
260 265 270

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
275 280 285

Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
290 295 300

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305 310 315 320

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
325 330 335

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
340 345 350

Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
370 375 380

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp

385

390

395

400

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
405 410 415

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
420 425 430

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 4
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 4
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

024651_W0002_SL.txt

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> 5
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 5
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ala Phe Thr Ala Tyr
20 25 30

Asn Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

024651_W0002_SL.txt

Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val
65 70 75 80

Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 6
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 6
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

024651_W0002_SL.txt

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys
100 105

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 7
Gly Tyr Ala Phe Thr Ala Tyr Asn
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 8
Phe Asp Pro Tyr Asp Gly Gly Ser
1 5

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 9
Gly Trp Tyr Tyr Phe Asp Tyr
1 5

024651_W0002_SL.txt

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 10
Lys Ser Ile Ser Lys Tyr
1 5

<210> 11
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 11
Ser Gly Ser
1

<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 12
Gln Gln His Asp Glu Ser Pro Tyr
1 5

<210> 13
<211> 15
<212> PRT
<213> Artificial Sequence

<220>

024651_W0002_SL.txt

<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 13
Ser Gly Tyr Ala Phe Thr Ala Tyr Asn Ile His Trp Val Arg Gln
1 5 10 15

<210> 14
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 14
Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
1 5 10 15

<210> 15
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 15
Tyr Tyr Cys Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly
1 5 10 15

Thr Leu Val Thr Val Ser Ser
20

<210> 16
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

024651_W0002_SL.txt

<400> 16
Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala Trp Tyr
1 5 10

<210> 17
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 17
Leu Leu Ile Tyr Ser Gly Ser Thr Leu Gln Ser Gly
1 5 10

<210> 18
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 18
Cys Gln Gln His Asp Glu Ser Pro Tyr Thr Phe Gly Glu Gly Thr Lys
1 5 10 15

Val Glu Ile Lys
20

<210> 19
<211> 1438
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 19
aagcttaccg ccaccatggg ctggagctgt atcatcctct tcctggtggc gaccgcgacg 60

024651_W0002_SL.txt

ggtgtccact cccaggtgca gctccaggag tccggcccg ggcttgtcaa gccgtcacaa	120
accctgtccc tgacgtgcac ggtctccggc tacgccttca cggcctacaa catacattgg	180
gtccggcagg cgccgggcca ggggctggag tggatgggtt cttcgaccc gtacgatggc	240
gggagctcgt acaaccagaa gttcaaagac cgcctgacga tctccaagga cacctcgaaa	300
aaccaggctcg tcctgaccat gaccaacatg gacccggtgg acacggcgac ctactattgc	360
gcccggcggct ggtactactt cgactactgg ggccacggga ccctggtcac cgtgtcttcc	420
gcttcgacca agggcccccag cgtcttcccg ctcgcgcct cctcgaagtc cacctcggc	480
ggcactgccc ccctgggctg cctggtcaag gactacttcc cggagccggt gaccgtctcg	540
tggaacagcg gggcactcac ctccggcgtg cacacccctcc cggccgtgct gcagtcctcg	600
gggctgtatt cactcagctc ggtcgtcacc gtccctcgt cgtccctcgg cacgcagacg	660
tacatctgca acgtcaacca caagccctcg aacaccaagg tggacaagaa ggtcgagccg	720
aagtccctgcg ataagaccca caccctcccc ccgtgcccgg ccccccggact cctgggcccgt	780
ccgtccgtgt tcctcttccc gccaagccc aaggacaccc tggatgtatcg ccgcacgccc	840
gaggtgacct gcgtcgtcgt ggacgtctcc cacgaggatc ccgaggtgaa gttcaactgg	900
tacgtggacg gggtgaggtt ccacaacgccc aagacaaaggc cgccggaaaga gcagttacaac	960
tcgacccatcc gcgtcgtcag cgtcgtcacc gtcctccacc aggactggct gaacggcaag	1020
gagtacaaat gcaagggtgtc caacaaggcc ctgcccgcgc ccatcgagaa gaccatctcc	1080
aaggccaaagg gacagcccg cgagcccgag gtctacacgc tgcctccctc ccgggacgag	1140
ctcacgaaga accaggtatc gtcacactgc ctcgtgaagg gcttctaccc gagcgacatc	1200
gccgtcgagt gggagagcaa cggccagccc gagaacaact acaaaaaccac gccgcccgtc	1260
ctcgactctg acgggtcctt cttcctgtac tccaagctga ccgtggacaa gtcgcgggtgg	1320
cagcagggga acgtgttctc gtgcgtggc atgcacgagg cgttgcacaa ccactacacc	1380
cagaagtca ctcctgag cccggcaag tgataatcta gagtcggggc ggccggcc	1438

<210> 20
<211> 742
<212> DNA
<213> Artificial Sequence

024651_W0002_SL.txt

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 20
aagcttaccg ccaccatggg ctggtcatgc atcatcctgt tcctggtcgc caccgcgacg 60
ggggtccaca gtgatatacg catgacgcag acgcccgtga gcctcccggt gacgcccggc 120
gagcccgcca gcatctcctg ccgcgttcc aagtccatct cgaagtacct ggcgtggtat 180
cagcagaagc ccggccaggc cccgcgcctg ctcatctact ctggttccac gctccagtcg 240
ggcatccgc cccgggttctc gggttcgga tacggcaccg acttcaccct gaccatcaac 300
aacatcgaga gcgaagacgc ggcgtactac ttctgccagc agcacgacga gtccccgtac 360
accttcggcg aggggaccaa ggtcgagatc aagcgtaccg tcgcggcacc gagcgtttc 420
atcttcccc cgtccgacga gcagctcaag tctggcaccg cctcggtcgt ctgtctcctg 480
aacaacttct accccaggga agccaaggtc cagtggagg tggacaacgc gctgcagtcc 540
ggaaatagcc aggagtcggt gacggagcag gactccaagg actccacgta ctcgctctcg 600
tccaccctga ccctctccaa ggcggactac gaaaagcaca aggtctacgc ctgcgaggtg 660
acgcaccaag gcctgtcctc cccagtgacc aagtcgttca accgcggcga gtgctgataa 720
tctagagtcg gggcggccgg cc 742

<210> 21
<211> 420
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 21
aagcttaccg ccaccatggg ctggagctgt atcatcctct tcctggtggc gaccgcgacg 60
ggtgtccact cccaggtgca gctccaggag tccggcccg ggcttgtgaa gccgtcacaa 120
accctgtccc tgacgtgcac ggtctccggc tacgccttca cggcctacaa catacattgg 180
gtccggcagg cgccgggcca ggggctggag tggatgggtt cttcgaccc gtacgatggc 240

024651_W0002_SL.txt

gggagctcgtaacaaccagaa gttcaaagac cgccctgacgatctccaagga cacctcgaaa 300
aaccaggtcg tcctgaccat gaccaacatg gaccgggtgg acacggcgac ctactattgc 360
gcccgcggct ggtactactt cgactactgg ggccacggga ccctggtcac cgtgtcttcc 420

<210> 22
<211> 321
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 22
gatatcgta tgacgcagac gcccgtgagc ctcccggtga cgcccgccgaa gcccggccagc 60
atctcctgcc gcgcttccaa gtccatctcg aagtacctgg cgtggtatca gcagaagccc 120
ggccaggccc cgccgcctgct catctactct ggttccacgc tccagtcggg catccgccc 180
cggttctcgg gttcgggata cggcaccgac ttcaccctga ccatcaacaa catcgagagc 240
gaagacgcgg cgtactactt ctgccagcag cacgacgagt ccccgtaacac cttcggcgag 300
gggaccaagg tcgagatcaa g 321

<210> 23
<211> 348
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 23
caggtgcagc tgcaggagtc gggcccagga ctggtaagc cttcacagac cctgtccctc 60
acctgcactg tctctggta tgcattcaact gcctacaaca tacactgggt ggcacaggcc 120
cctggacaag ggcttgagtg gatgggtct tttgatcctt acgatggtg tagtagttac 180
aaccagaagt tcaaggacag actcaccatc tccaaggaca cctccaaaaa ccaggtggtc 240
cttacaatga ccaacatgga ccctgtggac acagccacgt attactgtgc aagagggtgg 300

024651_W0002_SL.txt

tactactttg actactgggg ccacggaacc ctggtcaccg ttcctca 348

<210> 24
<211> 321
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 24
gatattgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca gggcaagtaa gagcattagc aaatatttag cctggcacca gcagaaacct 120
ggccaggctc ccaggctcct catctattct ggatccactt tgcaatctgg gatcccacct 180
cgattcagtg gcagcgggta tggAACAGAT tttaccctca caattaataa catagaatct 240
gaggatgctg catattactt ctgtcaacag catgatgaat ccccgatcac gttcggcgag 300
gggaccaagg tggAAATCAA a 321

<210> 25
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 25
Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
1 5 10 15

Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30

Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

Gly Val Ile Trp Ala Gly Gly Phe Thr Asn Tyr Asn Ser Ala Leu Lys

50

55

60

Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Leu Leu
65 70 75 80

Lys Met Thr Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95

Arg Arg Gly Ser Ser Tyr Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser
100 105 110

Val Ile Val Ser Ser
115

<210> 26

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 26

Glu Ile Val Leu Ser Gln Ser Pro Ala Ile Thr Ala Ala Ser Leu Gly
1 5 10 15

Gln Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Asn Val Ser Tyr Ile
20 25 30

His Trp Tyr Gln Gln Arg Ser Gly Thr Ser Pro Arg Pro Trp Ile Tyr
35 40 45

Glu Ile Ser Lys Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Ile Tyr Tyr Cys Gln Gln Trp Asn Tyr Pro Leu Ile Thr
85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Gln
100 105

<210> 27
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 27
Gly Phe Ser Leu Thr Ser Tyr Gly
1 5

<210> 28
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 28
Trp Ala Gly Gly Phe Thr
1 5

<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 29
Arg Gly Ser Ser Tyr Ser Met Asp Tyr
1 5

<210> 30

024651_W0002_SL.txt

<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 30
Ser Asn Val Ser Tyr Ile
1 5

<210> 31
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 31
Glu Ile Ser
1

<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 32
Gln Gln Trp Asn Tyr Pro Leu Ile
1 5

<210> 33
<211> 351
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic

024651_W0002_SL.txt

polynucleotide"

<400> 33
caggtgcagc tgaaggagtc aggacctggc ctgggtggcgc cctcacagac tctgtccatc 60
acttgcactg tctctgggtt ttcattaacc agttatggtg tacactgggt tcgcccagcct 120
ccagggaaagg gtctggagtg gctgggagta atatgggctg gtggattcac aaattataat 180
tcggctctca agtccagact gagcatcagc aaagacaact ccaagagcca agttctctta 240
aaaatgacca gtctgcaaac tgatgacaca gccatgtact actgtgccag gagaggttagt 300
tcctattcta tggactattg gggtaagga acctcagtca ccgtctcctc a 351

<210> 34
<211> 318
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"

<400> 34
gaaattgtgc tctctcagtc tccagccatc acagctgcat ctctgggcca aaaggtcacc 60
atcacctgca gtgccagttc aaatgttaagt tacatccact ggtaccagca gaggtcaggc 120
acctccccca gaccatggat ttatgaaata tccaaactgg cttctggagt cccagttcgc 180
ttcagtgccca gtgggtctgg gacctttac tctctcacaa tcagcagcat ggaggctgaa 240
gatgctgcca tttattattg tcagcagtgg aattatcctc ttatcacgtt cggctcgaaa 300
acaaagttgg aaatacaa 318

<210> 35
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 35
Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1

5

10

15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ile Pro Glu Lys Arg Leu Glu Trp Val
35 40 45

Ala Ser Ile Ser Arg Gly Gly Thr Thr Tyr Tyr Pro Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile Leu Tyr Leu
65 70 75 80

Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Gly
85 90 95

Arg Tyr Asp Tyr Asp Gly Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 36
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 36
Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly
1 5 10 15

Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Pro Asp Ile Asn Ser Tyr
20 25 30

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile
35 40 45

024651_W0002_SL.txt

Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Gly Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Asn Ser Leu Glu Tyr
65 70 75 80

Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Met Lys
100 105

<210> 37

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 37

Gly Phe Thr Phe Ser Ser Tyr Ala
1 5

<210> 38

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 38

Ile Ser Arg Gly Gly Thr Thr
1 5

<210> 39

<211> 11

<212> PRT

<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 39
Tyr Asp Tyr Asp Gly Tyr Tyr Ala Met Asp Tyr
1 5 10

<210> 40
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 40
Pro Asp Ile Asn Ser Tyr
1 5

<210> 41
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 41
Arg Ala Asn
1

<210> 42
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 42

024651_W0002_SL.txt

Leu Gln Tyr Asp Glu Phe Pro Tyr Thr

1 5

<210> 43

<211> 357

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"

<400> 43

gaagtgaaac tggggaggc ttggggaggc ttggggaggc cttgggggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agctatgcca tgtcttgggt tcgcccatt 120

ccagagaaga ggctggaggc ggtcgcatcc attagtcgtg gtggtaccac ctactatcca 180

gacagtgtga agggccgatt caccatctcc agagataatg tcaggaacat cctgtacctg 240

caaattgagca gtctgaggc tgaggacacg gccatgtatt actgtggaag atatgattac 300

gacgggtact atgcaatgga ctactgggtt caaggaacct cagtcaccgt ctcctca 357

<210> 44

<211> 322

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"

<400> 44

gacatcaaga tgacccagtc tccatcttcc atgtatgcat ctctaggaga gagagtca 60

atcacttgca aggcgagtcc ggacattaat agctattaa gctggttcca gcagaaacca 120

gggaaatctc ctaagaccct gatctatcgt gcaaacagat tgggtgatgg ggtcccatca 180

aggttcagtg gcggtggatc tggcaagat tattctctca ccatcaacag cctggagtat 240

gaagatatgg gaatttatta ttgtctacag tatgtatgaat ttccgtacac gttcggaggg 300

gggaccaagc tggaaatgaa ac 322

024651_W0002_SL.txt

<210> 45
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 45
Glu Ile Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ala Tyr
20 25 30

Asn Ile His Trp Val Arg Gln Ser His Gly Lys Arg Leu Glu Trp Ile
35 40 45

Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly Thr Thr Leu
100 105 110

Thr Val Ser Ser
115

<210> 46
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

024651_W0002_SL.txt

<400> 46

Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly
1 5 10 15

Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Arg Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 47

<211> 446

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 47

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ala Phe Thr Ala Tyr
20 25 30

Asn Ile His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

024651_W0002_SL.txt

Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val
65 70 75 80

Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly Thr Leu Val
100 105 110

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
130 135 140

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145 150 155 160

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
165 170 175

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
180 185 190

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
195 200 205

Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
245 250 255

024651_W0002_SL.txt

Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
260 265 270

Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
275 280 285

Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
290 295 300

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305 310 315 320

Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
325 330 335

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
340 345 350

Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
370 375 380

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385 390 395 400

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
405 410 415

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
420 425 430

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 48

<211> 116

<212> PRT

024651_W0002_SL.txt

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 48

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ala Phe Thr Ala Tyr
20 25 30

Asn Ile His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Ser Phe Asp Pro Tyr Asp Gly Gly Ser Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val
65 70 75 80

Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr Trp Gly His Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 49

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 49

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly

1

5

10

15

Gln Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys

210

<210> 50
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 50
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys
100 105

<210> 51
<211> 1338
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

024651_W0002_SL.txt

<400> 51

caggtccagc tgcaggagtc aggtcccgga ctggtaaagc cgtcgac gctgtccctc	60
acctgcaccg tgtcgggcta cgccttcacc gcctacaaca tccactggat ccgtcagccc	120
cctgggaagg gcctcgagtg gatcgac gttcgaccgt acgacggcgg gtcgtcctac	180
aaccagaagt tcaaggaccg cctcaccatc agcaaggaca cctccaagaa ccaggtcgac	240
ctcaccatga ccaacatgga ccccggtggac accgcccacgt actactgcgc gcggggctgg	300
tactactcg actactgggg gcacggcacc ctcgtcacgg tctcgtcggc gagcaccaag	360
ggtccgagcg tcttccccct ggccccctcc agcaagtcca cctcgggggg caccgcccgc	420
ctgggctgcc tggtaagga ctacttcccc gagcccgta ccgtgagctg gaactccggc	480
gccctcacca gcggggtcca cacccctccg gcgggtcctgc agtcatccgg tctctactcc	540
ttgagctcag tcgtcacccgt cccgagctcc tccctcgaa cgcagaccta catctgcaac	600
gtcaaccaca agccgtccaa caccaaggac gacaagaagg tggagccaa atcgtgcac	660
aagaccaca cctgcccccc gtggcccgcc ccggaaactgc tcggcggccc ctgggtttc	720
ctgttccccc cgaagccaa ggacaccctc atgatctccc gcaccccccga ggtcacctgc	780
gtgggtggatgg atgtctccca cgaggacccc gaggtgaagt tcaactggta cgtggacggg	840
gtcgagggtgc acaacgccaa gaccaagccc cgagaggaac agtataactc gacgtaccgc	900
gtggtcagcg tcctgaccgt gctccaccag gactggctga acggcaagga gtacaagtgc	960
aaggtagca acaaggccct gcccggccccc atcgagaaga cgatctccaa ggcgaagggg	1020
cagccgcgcg agccgcaggt ctacaccctg ccgcccagcc gggacgagct cacgaagaat	1080
caggtctcgc tcacctgcct cgtcaagggt ttctaccgt cggacatcgc ggtcgaatgg	1140
gagtcgaacg gtcagccga gaataactac aagacgaccc cggccgtcct ggactcggac	1200
ggcagcttct tcctgtactc gaagctgacg gtcgacaagt cgcgtggca gcagggcaac	1260
gtcttctcgat gctcggtgat gcacgaggcc ctccacaacc actacacaca gaagagcctc	1320
tcgcttcgc cggcaag	1338

<210> 52

<211> 348

<212> DNA

<213> Artificial Sequence

024651_W0002_SL.txt

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 52
caggtccagc tgcaggagtc aggtcccgga ctggtaagc cgtcgcagac gctgtccctc 60
acctgcaccc tgtcgggcta cgccttcacc gcctacaaca tccactggat ccgtcagccc 120
cctgggaagg gcctcgagtg gatcgccagc ttcgacccgt acgacggcgg gtcgtcctac 180
aaccagaagt tcaaggaccg cctcaccatc agcaaggaca cctccaagaa ccaggtcg 240
ctcaccatga ccaacatgga cccctggac accgccacgt actactgcgc gcggggctgg 300
tactacttcg actactgggg gcacggcacc ctcgtcacgg tctcgtcg 348

<210> 53
<211> 642
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 53
gacgtcgtga tgacccagtc gcccctctcc ctgcccgtta ccctgggcca gcccgcctcc 60
atcagctgcc gtgcctccaa gtccatttcc aagtacctgg cctggtagcca gcagaagccg 120
ggaaaggccc caaagctcct catctactcc ggctccaccc tccagagcgg catccccccc 180
cgcttcagcg gctccggcta cggcaccgac ttcaccctca ccatcaataa catcgagtcg 240
gaggacgccc cgtactactt ctgccagcag cacgacaaat cggcgatcac cttcggggag 300
ggcaccaagg tggagatcaa gaggacggtc gccgcgcct ccgtgttcat cttccccccc 360
tcggacgaac agctgaagtc cgggaccgccc tccgtcgct gcctcctcaa caacttctac 420
ccgcgcgagg ccaaggtgca gtggaaagggtc gacaacgcgc tccagtcgg caactcccag 480
gagtcgggtga ccgagcagga ctcgaaggac agtacctact cgctgagctc cacactgacg 540
ctctcgaagg ccgactacga gaagcacaag gtgtacgcat gcgaggtgac ccaccagggg 600
ctgagctcgc cggtgactaa gtcgttcaac aggggcgaat gc 642

024651_W0002_SL.txt

<210> 54
<211> 321
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 54
gacgtcgtga tgacccagtc gccccctctcc ctgccggtta ccctgggcca gccccgcctcc 60
atcagctgcc gtgcctccaa gtccatttcc aagtacctgg cctggtagcca gcagaagccg 120
gggaaggccc caaagctcct catctactcc ggctccaccc tccagagcgg catccccccc 180
cgcttcagcg gctccggcta cggcaccgac ttcaccctca ccatcaataa catcgagtcg 240
gaggacgccc cgtactactt ctgccagcag cacgacgaat cgccgtacac cttcggggag 300
ggcaccaagg tggagatcaa g 321

<210> 55
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 55
Gly Gly Phe Gly
1

<210> 56
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 56

Ala Leu Ala Leu

1

<210> 57
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 57
Gly Phe Leu Gly
1

<210> 58
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic peptide"

<400> 58
Leu Leu Gln Gly Ala
1 5

<210> 59
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: sortase motif"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<400> 59
Leu Pro Xaa Thr Gly

1 5

<210> 60
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown:
sortase motif"

<400> 60
Asn Pro Gln Thr Asn
1 5

<210> 61
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<400> 61
Gly Phe Glu Ile Asp Lys Val Trp Tyr Asp Leu Asp Ala
1 5 10

<210> 62
<211> 103
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 62
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

024651_W0002_SL.txt

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Lys Val Glu Pro Lys Ser Cys
100

<210> 63

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 63

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
Page 35

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 64
<211> 254
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 64
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Pro Asp Ile Asn Ser Tyr
20 25 30

Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile
35 40 45

Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Asp Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala
65 70 75 80

Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ser
100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
115 120 125

Lys Gly Gly Gly Gly Ser Glu Val Gln Leu Val Gln Ser Gly Ala
130 135 140

024651_W0002_SL.txt

Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser
145 150 155 160

Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Ile Arg Gln Ser Pro
165 170 175

Ser Arg Gly Leu Glu Trp Leu Gly Ser Ile Ser Arg Gly Gly Thr Thr
180 185 190

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
195 200 205

Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
210 215 220

Thr Ala Val Tyr Tyr Cys Gly Arg Tyr Asp Tyr Asp Gly Tyr Tyr Ala
225 230 235 240

Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 65
<211> 251
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 65
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

024651_W0002_SL.txt

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ser
100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
115 120 125

Lys Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro
130 135 140

Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser
145 150 155 160

Gly Tyr Ala Phe Thr Ala Tyr Asn Ile His Trp Val Arg Gln Ala Pro
165 170 175

Gly Gln Gly Leu Glu Trp Met Gly Ser Phe Asp Pro Tyr Asp Gly Gly
180 185 190

Ser Ser Tyr Asn Gln Lys Phe Lys Asp Arg Leu Thr Ile Ser Lys Asp
195 200 205

Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val
210 215 220

Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr
225 230 235 240

Trp Gly His Gly Thr Leu Val Thr Val Ser Ser
245 250

024651_W0002_SL.txt

<210> 66
<211> 251
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 66
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ser
100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
115 120 125

Lys Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro
130 135 140

Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser
145 150 155 160

024651_W0002_SL.txt

Gly Tyr Ala Phe Thr Ala Tyr Asn Ile His Trp Val Arg Gln Ala Pro
165 170 175

Gly Gln Gly Leu Glu Trp Met Gly Ser Phe Asp Pro Tyr Asp Gly Gly
180 185 190

Ser Ser Tyr Asn Gln Lys Phe Lys Asp Arg Leu Thr Ile Ser Lys Asp
195 200 205

Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val
210 215 220

Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr
225 230 235 240

Trp Gly His Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 67

<211> 251

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 67

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser

024651_W0002_SL.txt

65

70

75

80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ser
100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
115 120 125

Lys Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro
130 135 140

Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser
145 150 155 160

Gly Tyr Ala Phe Thr Ala Tyr Asn Ile His Trp Ile Arg Gln Pro Pro
165 170 175

Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Asp Pro Tyr Asp Gly Gly
180 185 190

Ser Ser Tyr Asn Gln Lys Phe Lys Asp Arg Leu Thr Ile Ser Lys Asp
195 200 205

Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val
210 215 220

Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr
225 230 235 240

Trp Gly His Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 68

<211> 251

<212> PRT

<213> Artificial Sequence

024651_W0002_SL.txt

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 68

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Pro Arg Phe Ser Gly
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65 70 75 80

Glu Asp Ala Ala Tyr Tyr Phe Cys Gln Gln His Asp Glu Ser Pro Tyr
85 90 95

Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ser
100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
115 120 125

Lys Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro
130 135 140

Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser
145 150 155 160

Gly Tyr Ala Phe Thr Ala Tyr Asn Ile His Trp Ile Arg Gln Pro Pro
165 170 175

Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Asp Pro Tyr Asp Gly Gly
180 185 190

024651_W0002_SL.txt

Ser Ser Tyr Asn Gln Lys Phe Lys Asp Arg Leu Thr Ile Ser Lys Asp
195 200 205

Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val
210 215 220

Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Trp Tyr Tyr Phe Asp Tyr
225 230 235 240

Trp Gly His Gly Thr Leu Val Thr Val Ser Ser
245 250